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Abstract 
Raman spectroscopy is a technique that utilises inelastic scattering processes to provide a 
biochemical fingerprint that has been shown to successfully discriminate oesophageal 
pathologies. The aim of this study was to develop Raman spectroscopy as a clinical tool; 
both in vivo for ‘targeted biopsy’, and in ex vivo for ‘automated histopathology’.   
 
Two different Raman probes were evaluated and compared and tissue classification models 
generated ex vivo. A preliminary classification model of a novel single collection fibre 
probe demonstrated potential for the probe design. Both probes were shown to discriminate 
three different oesophageal pathology groups. A cross-validated tissue classification model 
(88 samples) discriminated normal, Barrett’s and neoplasia with an overall accuracy of 
86.5% with a sensitivity of 83.3-89.5% and specificity of 89.2-97.1%. A novel rapid 
Raman mapping technique was evaluated. It was shown that sufficient biochemical 
information for pathology diagnosis could be extracted from low signal to noise ratio data 
using multivariate analysis providing the dataset was sufficiently large, thus demonstrating 
the feasibility of automated histopathology in a clinically realistic time frame. Furthermore, 
it was demonstrated that high spatial resolution imaging was not necessarily required for 
automated histopathology using novel interpretation of multivariate techniques. A tissue 
classification model generated from two rapid Raman maps containing separated substrate, 
normal, HGD, luminescence and fibrous connective tissue with an overall training 
performance of 97.5%  Problems limiting clinical implementation of Raman techniques 
were investigated and methods of overcoming devised. 
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Chapter 1 Introduction 
This thesis is concerned with the potential medical applications of Raman spectroscopy 
for pathology diagnosis, both in vivo, with the development and evaluation of Raman 
probes for endoscopic use and also ex vivo, for potential automated histopathology. The 
work follows on from previous work carried out within the Biophotonics Research Unit 
at Gloucestershire Royal NHS Foundation Trust.1,2 
 
The thesis structure is set out such that a general overview of the clinical need is 
provided, focusing on the detection of oesophageal adenocarcinoma and 
premalignancies. This is followed by a review of optical technologies for pathology 
diagnosis and other competing technologies before introducing both Raman as the 
methodology of choice for both potential in vivo ‘optical biopsy’ using Raman probes 
and ex vivo ‘automated histopathology’ using Raman mapping. A review of the literature 
is included with applications in other fields and other disease sites. The methodology 
and results are split according to the in vivo and ex vivo studies, with a subsequent 
chapter covering general application issues common to both technologies. Following this 
is future work and a summary of conclusions.  
 
This chapter introduces oesophageal cancer in general, the techniques currently used for 
diagnosing oesophageal cancer, the shortcomings of current techniques and how these 
can be overcome using novel optical technology which can detect early cancer. The 
chapter concludes with the aims of this research project.  
1.1 Clinical motivation 
1.1.1 Incidence of oesophageal cancer 
The number of cases of oesophageal cancer is increasing (see Figure 1-1) whilst the 
prognosis for these patients remains poor.  The reasons for this increase can not be 
pinpointed, although possible causes include genetic predisposition, dietary or 
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environmental changes. The oesophagus is lined with epithelial cells, of importance 
since 85-90% of all cancers originate in the epithelia. 3,4 Treatment of epithelial cancers 
(referred to as carcinomas), is easier and more successful when diagnosed at pre-
invasive stages (before the cells penetrate the basement membrane),3 using a range of 
possible techniques such as those discussed in Section 1.1.2.3.  However, due to the 
nature of the disease, in many cases, the patient does not present until symptomatic, i.e. 
exhibiting dysphagia, which due to the elastic nature of the oesophagus, is only induced 
upon ~75% circumferential obstruction, at which point the cancer is usually advanced 
and often invasive.5 At this late stage the outcome is poor. Five year survival figures 
range from 2-25%,8 with Cancer Research UK quoting a figure of <10% (Figure 1-2).6 
The long term survival of patients with oesophageal cancer improves with early 
detection.  
 
 
Figure 1-1 : Age-standardised incidence rates of oesophageal cancer7 
In 2002 there were over 462,000 new cases of oesophageal cancer,8 with over 7,400 
cases in the UK in 2006.9  Oesophageal cancer is more common in men than women8 
(see Figure 1-1). There are two types of oesophageal cancer. Squamous cell carcinomas 
(SCC) and adenocarcinomas (adeno). SCC originates in the squamous epithelial surface 
(with a pre cursor stage - squamous cell dysplasia), with risk factors associated to 
smoking and Helicobactor pylori infection.5 This thesis concentrates on the second type 
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of cancer adenocarcinomas, which originate in the glandular or columnar epithelium. 
Adenocarcinoma, are of particular concern in the Western world since incidence of 
adenocarcinoma has increased to a level above that of SCC,5 furthermore, the incidence 
of SCC has remained stable.7  
 
Amongst other risk factors, there is a medical condition for which the chance of 
developing oesophageal cancer is increased called Barrett’s oesophagus (BO), a 
condition caused by gastric acid reflux, where stomach and bile acids are regurgitated 
into the oesophagus causing irritation and inflammation, and eventually a metaplastic 
change.8,10  BO is discussed further in Section 1.1.1.1.  
 
 
Figure 1-2: Five-year age-standardised relative survival (%), adults diagnosed 1996-1999, 
England and Wales by sex and site (Cancer Research UK, 20066) 
1.1.1.1 Barrett’s oesophagus (BO) 
If an epithelial cell has been damaged the probability of malignant transformation is 
more likely. One example of this is where a cancer is formed on the basis of metaplasia, 
(pathological condition in which the normal mucosa is replaced by another type of 
mucosa) as in the case of Barrett’s Oesophagus (BO), or often referred to as columnar-
 - 4 - 
line oesophagus (CLO). This is a condition in which acid reflux causes the lining of the 
oesophagus to undergo cellular changes characterised by the replacement of normal 
squamous epithelium by simple columnar epithelia as found in intestinal mucosa. This is 
referred to as a metaplastic change and is demonstrated in Figure 1-3, comparing normal 
and Barrett’s oesophageal endoscope images. There are three different cell types 
associated with BO – fundic type mucosa (FM), cardiac mucosa (CM - junctional type 
mucosa) and intestinal metaplasia (IM - columnar epithelium with goblet cells).11,12 
 
There is an increased risk of developing cancer of the oesophagus for patients with 
Barrett's oesophagus.11 Carcinogenesis is not fully understood but is thought to follow 
the chain of intestinal metaplasia, low grade dysplasia (LGD), high grade dysplasia 
(HGD) leading to invasive cancer.13,14,15 
 
Figure 1-3: Endoscopic images of the oesophagus showing normal (left) and BO (right)16 
1.1.1.2 Dysplasia 
Dysplasia is a neoplastic epithelial change, which by the original definition by Riddell et 
al.17, must be confined by the basement membrane of the originating gland.11,14,18 The 
difference between normal and dysplastic cells is illustrated in Figure 1-4. Dysplastic 
cells are characterised by the following points:3  
• Vary greatly in size and shape (pleomorphism), usually abnormally large  
• Darkly stained nuclei (due to excessive chromatin)  
• Abnormal mitosis may be observed 
• Overall cell disorganisation 
• Loss of cell maturation 
 
Dysplasia is generally split into two categories, low and high grade dysplasia (LGD and 
HGD). For LGD, the changes are mild, with preservation of glandular structures/crypts. 
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Considering HGD, the cytological changes mentioned above are more severe, in 
particular more nuclear pleomorphism and hyperchroism compared to LGD.11 These 
changes can be seen compared to BO in Figure 1-4. 
 
Dysplastic cells are often described as having malignant potential since they always 
precede cancer, but do not always result in cancer. Goldblum refers to high grade 
dysplasia as a pre-invasive lesion of adenocarcinoma.11  This increased risk of 
developing adenocarcinoma in patients with BO is reported as being in the range of 30% 
-120%.3,19  There has been an increase in the number of patients diagnosed with BO and 
Barrett’s dysplasia, but this may be explained by the increase in the number of patients 
undergoing endoscopy procedures and increased recognition of the condition. 
 
 
Figure 1-4: H&E comparison between a) Barrett’s (IM with goblet cells), b) LGD and c) 
HGD14 
Surveillance of dysplasia is considered as a vital step towards the prevention of cancer. 
However, surveillance using the biopsy techniques described below is hindered by the 
fact that dysplastic regions may be invisible to the practicing endoscopist.3 As a result, 
there is significant risk that these areas can potentially be missed during random biopsy.  
 
If oesophageal cancer or a pre-cancerous condition is diagnosed, the appropriate 
treatment can then be given. These treatment options are discussed in Section 1.1.2.3.   
 
The histopathological analysis technique is currently the gold standard for diagnosing 
oesophageal cancer, although it has some drawbacks. These are discussed below. 
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1.1.2 Current diagnostic techniques  
1.1.2.1 Diagnosis and surveillance using endoscopic biopsy 
When a patient presents with symptoms they will undergo an endoscopic examination. A 
biopsy (usually several) is taken, sectioned, stained with haematoxylin and eosin (H&E) 
and then analysed in histopathology. 
 
Currently, patients within certain risk categories, such as BO also undergo routine 
endoscopic surveillance in which biopsies are taken following a set protocol, such as the 
Seattle protocol in which quadrant biopsies are taken at 2 cm intervals over the length of 
the Barrett’s region.20,21 This biopsy process is invasive and there is a risk of infection 
and perforation at the biopsy site. However, it is reported that less than 10% of patients 
undergoing surveillance are actually diagnosed with cancer.22 As a result there is debate 
as to the cost effectiveness of these surveillance programs but this is beyond the scope of 
this thesis. BO is confirmed by a biopsy which shows intestinal metaplasia (IM), 
characterised by goblet cells (also referred to as specialised mucosa).14  
 
1.1.2.2 Disadvantages of endoscopic biopsy for diagnosing of oesophageal cancer 
Since the biopsy samples need to be sent to histopathology for analysis, there is a delay 
associated with obtaining the diagnosis. This can be exacerbated by the fact that the 
pathologists are often required to analyse a large number of samples due to surveillance 
programs, many of which will not contain any neoplastic change.23 Figure 1-5 shows the 
number of biopsy samples taken from one patient in a single endoscopy session. 
 
Figure 1-5 : Photograph showing the number of biopsies taken from one patient in a single 
endoscopy session 
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There is also a degree of uncertainty associated with the results since there are not strict 
boundaries between cell differentiation and despite comprehensive training for the 
histopathologist there is an element of subjectivity associated with the diagnosis. Studies 
have been done to assess inter and intra observer agreement, which is reportedly as low 
as 50% in some cases.18 Similar results have also been demonstrated by Montgomery et 
al. who compared the opinions of twelve pathologists and Kendall et al. comparing the 
opinion of three expert pathologists, both using Kappa statistics to analyse the results.1,24  
 
Furthermore, since the biopsy samples taken are small with respect to the size of the area 
under surveillance, there is a chance that the biopsy may miss an area of local disease 
even if a rigorous biopsy protocol is followed.25 The biopsies are taken using endoscopic 
guidance, in which a live image of the oesophagus is viewed via the endoscope camera.  
Dysplastic changes may remain undiagnosed if they are not visible to the practicing 
endoscopist. Some protocols suggest the use of jumbo biopsy forceps to obtain larger 
samples, but these are still thought to miss unsuspected cancer in BO.25  In one report by 
Dar et al., in which patients with HGD were treated with a prophylactic 
oesophagectomy, 43-57% of patients were found to have undetected adenocarcinoma26 
showing that there is a need for better techniques for early diagnosis.   
 
Ultrasound, magnification endoscopy, chromoendoscopy (a spray of Lugol’s solution, 
which highlights glycogen depletion27 and enhances visualisation of Barrett’s28 and 
inflammation) and narrow band imaging (NBI, in which improved contrast is achieved 
using filters are used to increase the relative amount of blue light in the image to 
emphasise superficial structures and blood vessels) are also used for diagnosis. The 
former has been reviewed by Kaffes et al. 29 and more recently Lennon et al.30 and 
details of the latter techniques can be found in a recent review of imaging techniques for 
neoplastic changes in the oesophagus by Curvers et al.31 They comment that these 
techniques are hindered by operator dependence, as found with the above mentioned 
histopathology.31  
 
Alternative and adjunct methods of diagnosis are being explored. One technique 
investigated by Lao-Sirieix et al., uses a sponge capsule which is swallowed and 
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retracted and samples the oesophageal epithelial surface as it is retracted32. However, the 
technique would still require cytology diagnosis, which again has the disadvantages of 
pathology diagnosis as described previously.  
  
Optical diagnostic techniques such as Raman spectroscopy (RS), optical coherence 
tomography (OCT) and fluorescence are currently being investigated and have been 
shown to have potential for diagnosing many different medical conditions, in particular 
early cancer which will enable earlier diagnosis and hence more successful treatment. 
These techniques utilise lasers and other light sources to construct detailed images and 
obtain spectral information which can be used to determine the structure and 
biochemical makeup of the sample.  Complex analytical techniques can be used to 
extract diagnostic information and hopefully remove the element of subjectivity 
associated with the diagnosis. The details of these techniques are discussed later in 
Section 1.2.  
 
The majority of the work carried out using these optical techniques is being done ex 
vivo, in a laboratory based environment in which the techniques are compared to the 
current ‘gold standard’ histopathology result. These techniques could potentially 
complement the histopathology facilities, acting as a screening process to remove 
normal samples, thus reducing the workload on an overworked department or providing 
a virtual second opinion. The most significant application, however, would be the use of 
these techniques in a real clinical situation, in vivo. Currently, only a few studies have 
been carried out in vivo.  This is mainly due to limitations of the equipment required, but 
as technological advances are made then the in vivo work is becoming possible. If the 
technology can be adapted in such a way as to make in vivo diagnosis possible, then the 
possible clinical impact would be significant. The reasons for this are summarized 
below. 
 
1. Reproducible objective results 
2. Biochemical basis rather than morphology 
3. Immediate diagnosis 
4. Immediate treatment if required 
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5. Relatively non-invasive (potential for optical biopsy without tissue excision) 
6. Potential to reduce costs 
 
1.1.2.3 Treatment options 
The treatment option will depend on the stage of disease, which is determined by the 
gold standard histopathology diagnosis, which as described previously is not a perfect 
gold standard. This serves as a reminder of the importance of the diagnostic decision and 
the need for improvements in diagnosis which can potentially be provided by optical 
techniques.  
 
Palliative treatments of advanced cancer include stent insertion, laser ablation, and also 
chemo-radiotherapy.33 Laser ablation can also be effective for the eradication of 
dysplasia although there is potentially a risk of perforation.34,35  
 
For radical treatment, oesophagectomy (the complete removal of the oesophagus) has a 
high associated morbidity and mortality. However, it is still reported as being the gold 
standard treatment for HGD in patients with BO.36 This is in part due to the high number 
of patients which are found to have invasive cancer retrospectively.26,27 Chemotherapy 
and radiotherapy have a role in reducing the size of bulky tumours, which in turn makes 
complete resection easier.33   
 
For dysplasia37 and nodules, photodynamic therapy (PDT), endoscopic mucosal 
resection (EMR) and oesophagectomy are treatment options, as described by Barr et 
al.13 An EMR is an endoscopic procedure which involves suction of the mucosa into a 
plastic cap which is then removed using a hot wire loop. It is being used increasingly to 
remove localised lesions.20,38 For further details of treatment options, the reader is 
referred to the following reference.39  Photodynamic therapy involves the administration 
of a drug (either topically or intravenously) which is activated by light, called a 
photosensitiser. The photosensitiser is excited to a metastable triple state, which 
produces highly unstable and reactive singlet oxygen as it returns to the ground state. 
The photosensitiser is preferentially retained by tumour cells (ratio of 2-3:1),13 and 
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consequently the technique can be used to selectively target and destroy cells, although 
there is obviously a degree of damage to normal cells as well.  PDT has also been shown 
to be a successful method of treating dysplasia.35 PDT has also been shown to be a 
successful method of eradicating small tumours in patients for whom surgery is 
considered too risky.40  
 
It is evident that the treatment options become less drastic and more successful for 
earlier lesions. This reiterates the need for earlier diagnosis using techniques such as 
optical spectroscopy. Prediction of progression to cancer would be a further potential 
benefit.  
 
1.1.2.4 Genetic biomarkers 
Genetic instability is one of the characteristics of malignant progression and genetic 
biomarkers are an active area of research.  The details of this are beyond the scope of 
this report, but further details can be found in the following references.41,42 
 
A biomarker is defined as a characteristic that is measured/evaluated that is indicative of 
a given pathology process or therapeutic response.41 Considering malignant progression, 
a biomarker would be required to be detectable at the premalignant stage and 
subsequently vary throughout the neoplastic transformation. Several tissue biomarkers 
have been evaluated, the main example being p53, a protein that controls transcription of 
other proteins responsible for regulating cell proliferation.43 Further biomarkers are 
under investigation.44 Tissue biomarkers can potentially provide information regarding 
the risk of progression, and although there are some studies which report correlation 
with carcinogenesis, the genetic pathway is so complex that it is difficult to isolate 
specific mutations or protein expressions and to date they are generally unreliable.45  
 
To summarise, there are inadequacies with current diagnostic methods and suggested 
alternatives such as novel endoscopic imaging techniques and genetic biomarkers have 
not delivered to date and alternative reproducible and objective methods of diagnosis are 
required.  
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1.2 Introduction to optical diagnostic techniques 
Optical diagnostic techniques have shown considerable promise as alternatives and 
adjuncts to current diagnostic techniques.  
1.2.1 Interactions between light and tissue 
When optical radiation interacts with matter different effects occur, including reflection, 
scatter (elastic scattering and inelastic scattering), absorption and autofluorescence. 
These effects, illustrated in Figure 1-6 are utilised in the following optical diagnostic 
techniques. 
 
Figure 1-6: Illustration of different interactions of light with tissue  
1.2.2 Light scattering spectroscopy (LSS) 
This is a technique which utilises backscattered photons which have the same 
wavelength (elastically scattered) as the incident light to obtain morphological 
information about a tissue sample. Singly scattered photons provide information relating 
to the surface (epithelial) morphology, whilst multiple scattered photons (diffuse 
reflectance) provide morphological information regarding deeper stromal tissue. The 
technique is capable of detecting precancerous changes such as “nuclear size” and 
“degree of pleomorphism” (cellular atypia).20,46 Morphological changes associated with 
dysplastic changes have been detected in several studies.20,47,48,49  Recently, Dhar et al. 
have reported a larger study of 45 patients (483 spectra from 138 sites) with PCA-fed 
LDA classification of normal hyperplastic and dysplastic polyps and adenocarcinoma 
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with good sensitivity and specificity (77-85%).50 Similar promising results have been 
reported by Lovat et al. in a cross validated multivariate model.51  
 
The disadvantage of LSS is that it only probes the morphology of the tissue and not the 
biochemical changes, and also there is a limited sampling volume. However, the 
technology is simple and inexpensive making it a possible tool for in vivo diagnosis, or 
multimodal techniques.    
1.2.3 Raman spectroscopy 
The Raman effect was first described in 1928 was discovered by Chandrasekhara 
Venkata Raman, for which he was awarded the Nobel Prize in 1930.52 The Raman 
effect, is an inelastic scattering process in which there is an energy exchange between 
light and matter which occurs when incident light causes molecular bonds to vibrate. 
Raman scattering is a relatively inefficient process with approximately one in a million 
scattered photons undergoing Raman scatter in tissue at visible wavelengths.53 
 
The spectrum of scattered light (a plot of the scattered light intensity against the change 
in frequency with respect to the incident light) can be used to investigate matter since the 
characteristic peaks caused by the molecular vibrations are specific to each molecular 
species so the spectrum effectively provides a biochemical fingerprint. Examples of 
different biochemical constituents in tissue can be seen in Figure 1-7.  
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Figure 1-7: Raman spectra from biochemical standards acquired using a 785 nm excitation 
and x50 Leica objective, 10 s acquisition time – a) Histone - is a protein constituent of 
chromatin (DNA, RNA and protein which form chromosomes), b)collagen – fibrous protein 
which forms the extra-cellular matrix of connective tissue c) d)deoxyribonucleic acid (DNA), 
d) phosphotidylcholine (a phospholipid) - one of the major constituents of cell membranes, 
consisting of a glycerol molecule with a phosphate and nitrogen molecule attached to the third 
hydroxyl group e) glycogen, the major energy (carbohydrate) storage form in the body, is a 
branched polysaccharide (with glucose subunit), f) actin – a contractile protein is a 
constituent of microfilaments which are the main constituent of the cytoskeleton3  
 
As mentioned previously, the peaks are characteristic of different molecular vibrations 
and these are labelled in the figure and can be assigned to different molecular bonds and 
more generally to biochemical constituents. These can be found in most biochemical 
constituents of tissue in varying concentrations. Some of the Raman peaks associated 
with the main constituents in tissue are listed below in Table 1-1.  A more 
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comprehensive list can be seen in Appendix A. Furthermore, since the relative 
contributions of these peaks within the spectrum are proportional to the abundance of 
that constituent, 54 the entire spectrum can be utilised to obtain quantitative information 
making Raman spectroscopy potentially a powerful tool for diagnosis and tissue 
analysis. 
  
Table 1-1: Typical biochemical constituents in oesophageal tissue and associated Raman 
peaks assignments from the literature and biochemical standards measured from Sigma 
Aldrich (above)*  
 cm-1  
Glycogen 481-489, 576, 853-856, 937, 1046-1048, 1083-1092, 1123, 1256, 1377-
1382, 1455 
Protein 760, 876, 937, 1001, 1034, 1240, 1329, 1458, 1655 
DNA 624, 682, 770-795, 925, 1016,  1095, 1250, 1332, 1577 
Phenyl ring (breathing mode) 
O-P-O (DNA backbone) 
1001 
785, 1090 
CH2 twisting 1299-1320 
CH2, CH3 bending (Amide III) 1450 
C=C stretch (Amide I) 1653-1658 
*Peak assigments obtained from the literature and measurements above 55,56,57,58 
 
Raman can be used via fibre optics for in vivo applications54 and also ex vivo in mapping 
studies, providing imaging of tissue sections.59 As Raman spectroscopy is the main 
modality utilised within this study further details of instrumentation for Raman 
spectroscopy and a review of the literature are discussed in Chapter 2.   
 
There are also other applications of Raman spectroscopy techniques including Coherent 
anti-Stokes Raman scattering (CARS) spectroscopy,60 which can be used for accurate 
optical sectioning, and surface enhanced Raman scattering (SERS)61 spectroscopy 
utilises the local electric field (surface plasmon) between noble metal particles to 
enhance Raman signal to an extent where the technique is capable of detecting single 
molecules.62 Currently the techniques are limited to research applications, although there 
is the potential for fluorescence labelled dyes used in so called resonant SERS or 
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SERRS which could potentially have an application of genotyping in vivo or for 
histopathology.63,64,65 
 
As described previously, light is scattered within turbid media. From each scattering 
event there is a possibility of Raman scatter. This has led to the development of 
techniques for obtaining Raman molecular information from deep within tissue. Depth 
resolution is achieved using both lateral spatial offset between excitation and detection 
(Spatially Offset Raman Spectroscopy (SORS)) and time gating of the collection of 
Raman scattered photons (Kerr gated Raman Spectroscopy).66,67 These techniques have 
been applied ex vivo to detect deep calcifications in a breast tissue phantom,68,69 and to 
detect subsurface bone.70   
1.2.4 Infrared (IR) absorption spectroscopy 
Infrared absorption spectroscopy is a technique which is commonly used as a research 
tool for biochemical investigations for biomedical applications.71,72 Mid-infrared 
spectroscopy is a similar spectroscopic technique to Raman, but the technique utilises 
absorption of mid-IR radiation (not from a monochromatic source as with Raman) rather 
than scattering to probe vibrational molecular information. Mid-IR absorption 
spectroscopy is complimentary to Raman since each are sensitive to different functional 
groups with IR being more sensitive to polar bonds including C=O, C-O, O-H and C-H.  
 
Detection methods do not need to be as sensitive as Raman since the signal is greater 
than Raman scatter and signal to noise ratio of spectra is greater, but in general there are 
fewer spectral peaks compared to Raman.73 Imaging methods are also much more rapid 
than Raman mapping techniques. Mid-IR absorption spectroscopy, is however, hindered 
by water absorption which prevents (or limits) in vivo applications.  
 
Considering applications on oesophageal tissue, Wang et al. have carried out studies of 
oesophageal tissues including comparison of normal and cancerous tissue,74 as have 
Maziak et al. in a more recent study.75 In the latter study, Maziak et al. reported 
biochemical differences in normal compared to malignant oesophageal tissue including 
increased nuclear to cytoplasmic ratio, a relative increase and decrease in DNA and 
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RNA respectively and a relative decrease in glycogen, all of which are consistent with 
expected biochemical changes.3,5 More subtle biochemical changes including the 
structural protein changes (which results in subtle changes in the peak position/shape) 
and accumulation of triglycerides were also noted.  
 
More recently, Wang et al. have also published a larger and more detailed FTIR study 
(using ATR) of premalignant (dysplastic) oesophageal tissues using partial least squares 
to estimate changes in biochemical constituents and LDA for tissue classification.76 In 
this study they reported that dysplastic mucosa could be detected with an overall 
accuracy of 89% (sensitivity 92% and specificity 80%).    
 
FTIR imaging is an established technique and there have been many applications using 
FTIR to detect cancer in other tissues including the skin,77,78 cervix,79  prostate,80,81 
brain82,83 and breast.84 
1.2.5 Autofluorescence 
Fluorescence occurs when fluorophores in tissue are excited upon the irradiation of short 
wavelength light (often blue or UV). The wavelength of the emitted fluorescence is 
greater than that of the incident light. Since different tissues have varying biochemical 
constituents, different tissue types contain different naturally occurring fluorophores and 
this concept was first used for cancer detection by Alfano et al. in 1984.85 Since then 
fluorescence has been widely used for both spectroscopic and imaging applications.86 
 
Panjehpour et al. reported application of fluorescence spectroscopy for detecting cancer 
in the oesophagus, and initial results (from 26 cancer and 108 normal spectra) were 
promising and resulted in a model with a sensitivity and specificity of 100% and 98% 
respectively.87 Subsequent studies have all been hindered by false-positives.88,89 
Similarly, fluorescence imaging is also hindered by false positives.31,90 
1.2.5.1 Induced Fluorescence 
Photosensitisers (refer to Section 1.1.2.3), such as 5-aminolevulinic acid (ALA) can be 
administered to the patient, either locally (in the form of a spray or topical cream) or 
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systemically. These are found to localise in areas of rapid cell division, such as 
dysplastic regions and cancers, which can provide enhanced fluorescent signal in these 
areas. In one study of 47 patients, a difference was noted in the sensitivity and 
specificity between the two methods, although there were small numbers of patients in 
each group, with an increased sensitivity to the recognition of dysplastic lesions using 
systemic administration (80-100%) compared to only 60% when a photosensitising 
spray was applied.91 A specificity of 70% was reported for the photosensitising spray, 
whilst poor specificity (26% and 56%) was reported for the systemic photosensitiser, 
which has been attributed to the presence of inflammatory cells. 
1.2.6 Optical coherence tomography (OCT) 
OCT is a technique analogous to ultrasound, but using light, to produce real time, high 
resolution (10-25microns) cross sectional images first presented by Fercher in 1990,92 
and subsequently published by Hitzenberger,93 and a fibre optic based system by Huang 
et al.94. Biological examples of OCT are discussed in the review by Wong Kee Song.90 
OCT can be used to look at the morphology of tissue samples and has been used for in 
vivo imaging. This has become routine in ophthalmology applications, but is still 
experimental elsewhere. OCT is sensitive to small differences in tissue refractive index 
(RI). It may be possible to obtain a diagnosis from the image alone, although, this 
process, unless computer automated, will be subjective, however, it has the potential for 
in vivo95 and even time gated use.96 OCT has also been used in combination with other 
techniques such as Raman to provide a multimodal approach for diagnosis as described 
in Section 1.2.7.  
 
Many groups have investigated the use of OCT in the oesophagus.95,97 It is reported that 
BO can be detected, however, there have been problems detecting dysplasia.90,95 More 
recently, intramucosal carcinoma and HGD have been distinguished from LGD and IM 
by Evans et al. with a sensitivity and specificity of 83% and 75%, respectively.98 OCT is 
hindered by the fact that image analysis is subjective, and in a discussion of OCT for 
detecting dysplasia, Poneros concludes that further work is needed and eventually 
computer automation will be required.99 Automation of OCT image analysis is one 
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possibility.100 Further details of the advancing field of OCT can be found in many 
review articles.101  
1.2.7 Multimodal optical diagnosis 
As mentioned previously, these various techniques can be combined to provide a 
multimodal technique.  
 
Several groups have applied this multimodal approach to diagnosis in the upper 
gastrointestinal tract, for example, near infrared (NIR) auto-fluorescence and LSS were 
recently combined to identify dysplastic oesophageal lesions by Leiber et al., in an ex 
vivo study on biopsy samples harvested from 20 patients. In this study, a classification 
model was developed to discriminate between low risk (Barrett’s mucosa without 
dysplasia and other benign samples) and high risk (LGD, HGD, squamous cell 
carcinoma (SCC) and adenocarcinoma) with a sensitivity and specificity of 86% and 
96% respectively.102  
 
Considering Raman in particular, Huang et al., illustrated that the most effective 
diagnostic algorithms were those developed using a combination of Raman and NIR 
autofluorescence spectroscopy.103 Patil et al. used OCT guided Raman for measuring 
breast tissue ex vivo and skin in vivo.104  
1.2.7.1 Summary of optical diagnostic techniques 
Optical spectroscopic techniques provide the most suitable solution to one of the 
limiting factors of histology, since the spectroscopic information lends itself to computer 
automation using tissue classification models. Other techniques such as OCT and 
autofluorescence imaging are still vulnerable to subjectivity and inter and intra operator 
variability. To summarise, the above mentioned spectroscopic techniques each have 
advantages and disadvantages:  
 
• LSS is simple, but provides only morphological information.  
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• Raman can provide detailed biochemical information, providing high molecular 
specificity, but interactions are weak. However, recent technological advances 
have meant this is no longer such a limiting factor. 
• FTIR is an established spectroscopic technique for probing biochemical changes 
in tissue sections, but it is limited by water absorption and as a result is not 
suitable for in vivo use.  
• Fluorescence spectroscopy (and imaging) may be useful for targeting biopsy but 
is hindered by false positives.  
• OCT results are promising, but it is likely to have a place for image guided 
targeting rather than definitive diagnosis.  
 
Automated diagnosis based on biochemistry rather than morphology is advantageous 
and furthermore, biochemical changes are likely to occur prior to morphological changes 
which provide the opportunity of detecting disease before it is visible to the eye. It is 
also suggested that standard H&E diagnosis underestimates the extent of intestinal 
features in BO,105 which may potentially be visible/detected using optical techniques. 
Considering the sampling volumes, Raman also samples the surface epithelial layer 
which lends itself to detecting precancerous changes in the surface epithelium in vivo. 
As mentioned previously, IR spectroscopy is limited by water absorption, and as a result 
sample thickness is limited to ~10 µm. Wani et al. identified Raman spectroscopy as a 
potential modality for overcoming problems associated with ‘blind biopsy’.15 Overall, 
Raman appears to be the modality of choice since the technique can be used both in vivo 
for optical biopsy and also ex vivo for imaging.   
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Figure 1-8: Illustration of the sampling depths of different optical diagnostic techniques 
(adapted  from21) 
1.3 Project aims and objectives 
The study outlined in this thesis has concentrated on evaluating Raman spectroscopy as 
a potential tool for pathology diagnosis both as an optical tool for targeted biopsy in vivo 
and also as a laboratory aid to the histopathologist. The research addresses key areas 
which will hopefully move Raman diagnostic techniques towards implementation in the 
clinical environment. The process of carcinogenesis of oesophageal adenocarcinoma is 
used as a typical example of an epithelial cancer.  There are three aims of the study: 
 
1) To evaluate and develop Raman probes for potential in vivo pathology diagnosis - 
referred to as ‘Raman targeted biopsy’ 
• To evaluate the current leading fibre optic (which is no longer available 
commercially) Raman probe by generating a large tissue classification model ex 
vivo (Section 5.3-5.5). 
• To compare novel probe designs to the current leading Raman probe using tissue 
equivalent phantoms, calibration standards and tissue classification models 
(Sections 5.2 and 5.7). 
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2) To evaluate the potential application of rapid Raman mapping techniques as a 
potential adjunct to the histopathologist by providing automated Raman histopathology 
• To evaluate a novel rapid Raman mapping technique for imaging biological tissue 
sections and compare to previous technology (Section 6.1- 6.2). 
• To investigate the feasibility of clinical implementation of rapid Raman mapping 
by investigating overall mapping times and mapping parameters (Section 6.4). 
• To evaluate the application of rapid Raman mapping technique as a potential 
research tool for the elucidation of biochemical changes associated with 
carcinogenesis (Section 6.5).   
 
3) To evaluate and overcome factors which limit implementation of Raman diagnostic 
techniques (optical biopsy and automated histopathology) into the clinical environment 
 
This work was undertaken within the Biophotonics Research Unit based at 
Gloucestershire Royal NHS Foundation Trust, UK under the supervision of Dr. N. 
Stone, Dr. C. Kendall, Prof. H. Barr.  
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Chapter 2 Raman Spectroscopy 
2.1 Raman theory 
Raman spectroscopy is a technique used to study vibrational and rotational modes in a 
system. It is based on the inelastic scattering, or Raman scattering of monochromatic 
light, resulting in the energy of the scattered photons gaining or losing energy (to or 
from the interacting molecules). This gives information regarding the system under 
investigation and enables biochemical changes within the tissue to be probed.  
 
When a sample is illuminated with a laser beam, several processes take place, as 
mentioned previously, including elastic (Rayleigh) and inelastic (Raman) scatter. The 
Rayleigh scattered light is filtered out (laser line filter), and the remaining light is 
dispersed onto a detector, most commonly a charge coupled device (CCD).  
 
Raman scattering is very weak, typically 10-6 of the elastically scattered light. The 
intensity of the Raman scattered light is proportional to the intensity of the input light 
(Iin), the density of the Raman scattering molecules (ρ), the sampling volume (V) and the 
Raman cross-section (σ), according to Equation 2-1.  
 
Iout ∝ Iin ρ V σ 
Equation 2-1 
 
The Raman cross-section describes how likely it is that a photon will interact due to 
local electric fields. It is wavelength dependent. The density of the sample describes the 
concentration of scattering molecules within the sampling volume. A photon interaction 
is more likely for higher concentrations.  
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The Raman shift is given by the difference in energy of the incident and scattered 
photons (related to the frequency according to Energy=hν, where h is Planck’s constant 
and ν is frequency) respectively. The Raman shift is often described in terms of 
wavenumber (cm-1).  
 
The vibrational energy is eventually dissipated as heat, although this is not measurable 
within the sample.  
2.1.1 Classical Raman model 
The intensity of Raman bands can be described using a simple classical model. An 
induced dipole moment, P is proportional to the external electric field, E. The constant 
of proportionality, α, is called the polarizability and describes how easily the electronic 
cloud around a molecule can be distorted.  
 
P=αE 
Equation 2-2 
 
The induced dipole will emit elastically scattered light at the same frequency as the 
incident light. However, specific vibrations within some molecules can alter the 
polarizability of a molecule during the vibration (described by the polarizability 
derivative δα/δQ, where Q is the normal coordinate of the vibration). Raman scattering 
can only occur by an internal conversion of energy in the molecules during this process. 
It follows, that the selection rule for a Raman active vibration, is that there must be a 
change in the polarizability, i.e. δα/δQ≠0. The Raman selection rule is analogous to that 
of an infrared-active vibration which states that during vibration there must be a net 
change in the permanent dipole. If a molecule is symmetric then it follows that there will 
not be a net change in the permanent dipole and hence symmetric molecules will be 
silent in the infrared region. 
 
Raman scattered photons may be of lower or higher energy than the incident photon and 
this is referred to as Stokes and anti-Stokes scatter respectively, as illustrated in Figure 
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2-1. This depends on the temperature, since anti-Stokes scatter occurs when the initial 
state of molecule is excited (either thermally or by other means). At room temperature, 
anti-Stokes scatter is weak with respect to Stokes scatter.   
 
Figure 2-1: Illustration of the Stokes and anti-Stokes shift in wavelength (λ) compared to the 
excitation wavelength 
If the vibration greatly affects the polarizability then the polarizability derivative will be 
large and the intensity of the Raman band will be high and vice versa. For example, in a 
highly polar bond such as O-H, induced polarisation due to an external electric field will 
be less than the larger electron cloud of the C=C double bond which is evenly distributed 
and easily distorted. The intensity of the Raman scatter also increases with the fourth 
power of the incident radiation frequency and as discussed later, this affects the choice 
of wavelength selected. However, the benefits of using a shorter wavelength are 
counteracted by possible damage to the sample, penetration depth and also fluorescence 
effects.  
 
2.1.2 Quantum mechanical model 
Whilst the classical explanation views the scattering process as a perturbation of the 
molecule’s electric field, in the quantum mechanical model the scattering is described by 
the excitation to a virtual energy state followed almost immediately by de-excitation and 
a change in vibrational energy with a timescale in the order of picoseconds. The 
molecule can only gain or lose energy equal to the energy difference between two 
allowed energy states. Elastic and Raman scatter are illustrated in Figure 2-2. In the case 
λ 
Laser light 
(excitation) 
Stokes shift  Anti-Stokes shift 
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of elastic scatter, the scattered photon has the same energy as the incident photon and 
returns to the original energy state. In the case of Raman scatter, the scattered photon has 
more or less energy than the incident photon, referred to as anti-Stokes and Stokes 
scatter respectively.  
 
elastic scatter 
Stokes 
Raman 
 
Anti- Stokes 
Raman 
Virtual states 
Vibrational states 
 
Figure 2-2: Quantum mechanical illustration of elastic and Raman scatter 
2.2 History of the medical applications of Raman spectroscopy 
The first interpretable biological application of Raman spectroscopy was performed by 
Lord et al. on a native protein in 1970,106 using a He-Ne (633nm) laser. However, the 
use of light in the visible spectrum is limited because of the high fluorescence 
background from biological tissues. Some complex tissue matrices exhibit low 
fluorescence and visible excitation was still feasible, for example in the eye.107 Despite 
background subtraction techniques, the fluorescence is the limiting factor in the visible 
region. For excitation in UV region, the fluorescence occurs at wavelengths beyond the 
Raman fingerprint region and furthermore, an increase in the signal due to resonance 
within the electronic transitions. However, there are problems associated with 
mutagenesis of biological tissue samples and the penetration depth is very small (µm).  
Over time there was a trend toward the near-infrared (NIR) region since there is a 
significant reduction in fluorescence and an increased penetration depth as discussed in a 
review by Hanlon et al.54 Furthermore, Stone demonstrated 830 nm was optimum for 
Raman spectroscopic investigations of oesophageal tissues. 108  
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The use of Raman confocal microscopy systems to obtain increased spatial resolution 
(only for a small well defined volume) has been investigated for examples on 
deoxyribonucleic acid (DNA) in chromosomes.109 For more detail on confocal Raman 
microscopy, the reader is referred to Turrel et al.110 Confocal microscopy has also been 
used to study subtle changes in cholesterol, phospholipids and proteins in complex 
tissues such as the lens cataracts.111 
 
Initially studies using Raman employed Fourier transform (FT) spectrometers. In 
general, these were used in conjunction with Nd:YAG laser excitation (1064nm) and 
cooled InGaAs detectors. FT Raman systems use interferometric methods to collect all 
wavelengths simultaneously, also allowing a greater light collection. Early use revealed 
spectral peaks that were previously masked by the large fluorescence background.112 
Initial work applying Raman spectroscopy to investigate the biochemical changes 
associated with carcinogenesis in gynaecological lesions showed that diseased tissue 
could be distinguished from normal.113 Other applications in the field of cancer 
diagnosis included brain tumours114 and skin lesions.115,116 However, the detectors used 
were noisy and required long spectral acquisition times (30-60minutes) Also, the laser 
powers required (0.5-1W) exceed maximum permissible exposure (MPE) limits for the 
eye and skin.   
 
The development of low noise charge coupled device (CCD) detector technology, the 
use of dispersion rather than interference methods,117,118 and the advent of small, 
efficient semiconductor laser sources have all contributed to the rapid advances in 
Raman  spectroscopy.  
 
The advent of edge and notch filters are one of the most important additions to the 
modern Raman spectrometer since they efficiently reject elastically scattered and stray 
light and have enabled more compact spectrometer designs.117  
 
Studies have shown that working in the NIR region, and in particular the 800-830nm 
region, minimises florescence whilst utilizing the CCD to its full potential.3,54,108,119 The 
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fluorescence continues to reduce at greater wavelengths, but this is counteracted by the 
fact that the efficiency of the CCD detector falls sharply with increased wavelength.3   
 
Figure 2-3: Raman spectra acquired using green (532 nm), red (633 nm) and NIR (785 nm) 
excitation. The fluorescence background masks the Raman peak in the red and green spectra 
whilst it is clearly visible in the NIR spectra. Note that the NIR wavelength is represented by 
the blue spectrum.120   
There have been many biological applications of Raman spectroscopy for different pre-
cancer and cancers including the oesophagus,1,2,108,121,122,123,124 cervix,125,126 prostate,127 
bladder,128,155 brain,114,128 breast129,130,131 oral cavity,132 larynx,133,134 and stomach.135 
These applications are covered in many review articles.54,73,136,137 There are also 
applications in other diseases besides cancer including atherosclerotic plaques138 and 
dementia.139  Several fibre optic probes have been proposed for in vivo applications, for 
use on the skin and gynaecological applications during colposcopy.140 The first 
endoscopic in vivo use of Raman spectroscopy of human gastrointestinal tissue was 
reported in 2000 by Shim et al.141 also detailed in a thorough review.54 
 
The following sections review applications of Raman in the upper gastrointestinal tract. 
This is followed by instrumentation common to both Raman probes and laboratory 
based spectrometers. A review of both the practical considerations and applications of 
Raman probes for potential targeted biopsy (Section 2.3.4 and 2.4.2) and Raman 
mapping applications (Section 2.5) is also included.  
532 nm 
785 nm (NIR) 
633 nm Raman peaks - masked by 
fluorescence background 
for the 532 nm spectrum 
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2.2.1 Raman studies in the upper gastrointestinal tract 
Locally, several studies have been carried out ex vivo using a customised laboratory 
based Raman microscopy system.1,2,108,121,122,123 In one study carried out by Kendall et 
al., 87 histopathologically homogeneous samples were taken from 44 patients.1 Cross 
validated PCA fed LDA tissue classification models were generated to separate both 
three, and nine different pathology groups. The multivariate classification model 
developed gave sensitivities of 73-100% and specificities of 90-100%. Additional 
potentially useful tissue groups are discussed in the results section including, amongst 
others, fibrous connective tissue and smooth muscle.  An important advance in these 
studies was that for the first time, a consensus histopathology opinion was obtained from 
three independent expert pathologists.1,121,122 This partially overcomes the problem that 
the pathology is subjective, and improves the histopathology opinion as a ‘gold 
standard’. This concept was used in this thesis to improve the robustness of the tissue 
classification models (Section 5.2). Kendall et al. used attributed peak assignments to 
biochemical constituents to support the Raman classification model, for example a 
decrease in glycogen levels consistent with increased proliferation,5 increase in nucleic 
acids and decrease in carotenoids.1 Further investigation of the biochemical changes 
using Raman mapping has supported this.123  
2.3 Raman instrumentation and practical considerations 
2.3.1 Modern Raman system components 
A typical Raman microscopy system is shown in Figure 2-4, a schematic diagram of the 
customised Renishaw Raman spectroscopy system (System 1000, Renishaw Plc. 
Wotton-under-edge, UK). The individual components are described in further detail in 
the following sections. A cylindrical lens can be added into the path of the laser resulting 
in a line focussed laser beam. This has practical uses which are described in Section 
2.5.2.  
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Figure 2-4: schematic diagram of the standard Raman microscopy system (Renishaw System 
1000) 
2.3.1.1 Laser 
The laser light is delivered to the system via two adjustable steering mirrors. The 
wavelength selection is important and as mentioned previously, there has been a general 
trend towards NIR wavelengths. Locally, 830nm has been shown to be optimum with 
reduced tissue fluorescence, whilst still working within the optimum region for the 
CCD.  
2.3.1.2 Microscope 
A typical Raman microscopy system is shown in Figure 2-5, showing the microscope on 
the left and the spectrometer on the right. The laser is hidden behind the spectrometer. 
The internal components of the spectrometer were shown previously in Figure 2-4. A 
microscope is used to view the sample, illuminate the sample at the target volume and 
collect the scattered light. The collection of scattered light depends on the numerical 
aperture of the objective which is given by NA = sinθ. (where θ is half of the angular 
aperture). It also depends on the spot size, for a smaller spot size there is greater 
intensity of light within a smaller region, but consequently the sample volume and hence 
the number of molecules within it is smaller. 
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2.3.1.3 Filters, slit and gratings 
Holographic notch filter or edge filters are used to separate the Raman signal from the 
elastic scatter.3 Following transmission through the edge filter, the collected beam then 
passes through the slit, which reduces the divergent components of the beam. Although 
this limits the amount of light passing through, it improves the spectral resolution. The 
diffraction grating disperses the light into its spectral components and disperses the light 
onto the detector. Multiple elements of the detector can be used to detect a range of 
wavelengths simultaneously. The grating density (locally this is 300 lines/mm) affects 
the spectral resolution. The angle of the grating determines which region of the spectral 
range is detected. The grating can also be moved during the spectral acquisition, referred 
to as a dynamic scan, to cover a wider spectral range whilst maintaining high spectral 
resolution, the trade off being that spectral acquisition are slower. The latter points have 
practical implications for Raman spectroscopic analysis since this will need to span the 
spectral range of interest and this is investigated in Section 6.1.2. 
 
 
Figure 2-5: Photograph of the Renishaw System 1000  
2.3.1.4 CCD camera 
A CCD is made up of an array of small detectors (~25 µm). The CCD can be rapidly 
read out by transferring charge from one detector element to the next in sequence. There 
are two main types of CCD in use for Raman spectroscopy, back thinned and deep 
depletion CCDs. Back thinned devices suffer from etaloning, and deep depletion CCDs 
are favourable for NIR applications.117  
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Calibration ensures that the correct wavelength is detected by the correct CCD element. 
One of the problems hindering the clinical development of Raman spectroscopy is a 
reliable calibration routine such that the measurements are reproducible and also 
comparable with spectra taken from another Raman system.  This is especially important 
when building spectra libraries.142 
2.3.2 Sources of noise and signal to noise ratio (SNR) 
Signal to noise ratio (SNR) is related to the intensity of the incident light. It is 
proportional to the square of the intensity multiplied by the acquisition time, thus if the 
intensity is increased the collection time can be reduced to achieve the same SNR and 
vice versa.143 The signal is limited by shot noise, arising due to the random quantum 
nature of photon interactions. It is given by N±√N where N is the number of counts. 
Increasing the number of counts reduces the relative effect of shot noise, provided the 
Raman signal is greater than any background signal.  
 
Dark noise is minimal with modern CCD detectors. Cooling the CCD reduces the 
number of counts generated by thermal effects. Temperature stabilization is also 
important and the effects of temperature on Raman spectrometers are investigated in 
Section 7.2.2. Cosmic rays also cause large spikes which can have a significant effect on 
the spectrum if not averaged out or removed (manually or using automated algorithms). 
This has particular implications for Raman mapping as discussed in Chapter 6.  
 
Many groups have investigated the impact of SNR on Raman spectral analysis.144,145,146  
This is discussed further in Section 6.3, since this aspect has particular importance for 
rapid Raman mapping applications. De Paula et al. studies the use of Raman 
spectroscopy for identification of atherosclerotic plaques, using mathematically added 
noise they investigated the effect of SNR on subsequent multivariate classification. They 
concluded that short acquisition times, as low as 20ms, could be used to distinguish 
calcified, atherosclerotic and non-pathological plaques.144 However, in this study, 
spectral features were very visibly different (due to strong Raman signatures for inherent 
calcification and lipids) and as a result the limit of PCA and other multivariate 
techniques was not tested.144   
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2.3.3 Spatial and spectral resolution 
Resolution is defined as the ability to separate two distinct objects. Considering spectral 
resolution, this is the ability to resolve separated Raman peaks (in the wavenumber 
direction). Overlapping Raman bands makes this issue complex and derivative spectra 
are often calculated to highlight shoulder of Raman bands.  
 
Spatial resolution has been investigated by many groups for Raman probe (lateral and 
axial)147 and spectral mapping applications for both Raman,148 and IR.149,150  Bhargava 
has published a thorough evaluation of FTIR imaging for histology diagnosis, 
demonstrating the effects of imaging parameters (similar to those used for Raman 
mapping (see Section 2.5) in particular spatial resolution (with the step size used as a 
nominal spatial resolution, determined by binning data acquired at 6.25µm to larger 
pixels 10-50µm) and SNR (random Gaussian noised artificially added to the spectra).150 
The aim of this study is not to determine spatial resolution for Raman probe and 
mapping applications, however, concepts are discussed later regarding the implications 
for clinical histology.  
 
2.3.4 Raman probes 
Light is transmitted through fibre optics via total internal reflection. For visible 
wavelengths, glass or plastic fibres can be used with a similar material with a lower 
refractive index chosen for the cladding. However, as the wavelength approaches the IR 
region silica and silica doped material are used as the core and cladding respectively. 
The obvious problem with this is that silica is Raman active and this can cause problems 
when performing Raman probe spectroscopy. 151,152 Fluorescence and optical properties 
of other materials used to construct the probe also need to be considered, for example 
optically transparent glues should be used.151   
 
For in vivo measurements in the oesophagus, a front viewing fibre is not ideal, and De 
Lima et al. report a side viewing probe suitable for fluorescence applications and have 
since reported on a catheter based Raman probe with manoeuvrable tip.153 
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2.3.4.1 Limitations of Raman Probes 
The weak Raman signal, makes rapid in vivo Raman diagnosis via endoscopy 
technically challenging.  Fluorescence and Raman backgrounds are generated by the 
probe itself, which can mask Raman signals and contribute to shot noise.  This results in 
subtle differences in probe spectra which require sophisticated multivariate statistical 
techniques.141,151 
 
Scatter within the probe and optical fibres causes a background signal that must be 
removed using background subtraction techniques such as that discussed in Section 
2.3.4.2, or by using an appropriate filter positioned at the distal probe tip, however, this 
is technically difficult due to the intricacies and precision required since the filters are 
often angular dependent.  
 
A further problem for in vivo studies is the possibility of spectral artefacts caused by 
angle and pressure changes, however this has been investigated and analysed by PCA 
and found to be insignificant.141 
2.3.4.2 Removing probe background and fluorescence 
The broad background spectrum is due to tissue and fibre optic autofluorescence, cross 
talk and backscatter.147,154 In the literature, probe background is generally removed using 
a 5th order polynomial fit (for 785nm and 830nm Raman probes) to reveal narrow 
Raman peaks from the tissue,133,141,155,156 however the particular fit used is dependent on 
the wavelength, filtering and spectrometer.  
 
The probe background can also be removed by subtraction of a background signal. The 
background signal may be acquired, for example, with the probe covered by a black 
plastic cap,125 or from roughened aluminium.157 In the latter case, Boere et al. reported 
an angular dependence of the background signal, which was accounted for in the vector 
subtraction method.157 Shim et al reported that subtraction using such methods was 
inconsistent.147   
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In summary, there are discrepancies regarding the source of the background signal and 
furthermore, background subtraction methods are unreliable, resulting in the need for 
alternative methods of dealing with background subtraction.   
2.3.4.3 Safety concerns 
As mentioned previously, the power of the laser and its effect on the tissue is one of the 
limitations for probe design in vivo and consequently, the focus on probe design is to 
maximise the collected Raman signal and to utilise optimal data processing.151  
 
At NIR wavelengths, thermal damage is possible, however, more importantly, DNA 
strand breaks can occur in the UV region and hence this should be avoided. Tests have 
been carried out to assess the temperature rise in tissue caused by NIR lasers light. A 
250mW, 830nm laser focused to a spot size of 500 µm spot size did not produce a 
detectable temperature rise in tissue (<0.8ºC) after an exposure time of 1 minute.141 In 
another study by Mahadevan-Jansen et al., using a laser with power of 15 mW (785nm) 
at the probe tip and a spot size of 900 µm, it was calculated that this power produced an 
increase in temperature of 1.5 ºC in 5 minutes, insufficient to cause cytotoxicity. It is 
also suggested that powers up to 80 mW could be used, which would cause a calculated 
temperature rise in cervix tissue of 6 ºC/min, enabling a reduced acquisition time of 15-
20 s.140 This reduction in acquisition time would be more clinically useful since multiple 
point measurements could be made. Ideally, this should be reduced further to 1-2s, and 
recent reports in the literature suggest this is feasible.158 Further more it is later shown in 
this study that providing large spectra database is used multivariate techniques can 
tolerate poor signal to noise.  
   
Considering the probe system used in this study, similar to that used by Shim et al., with 
an output power of used <80 mW at the probe tip and an exposure time of 1 minute, no 
thermal damage would result,141 especially in vivo as perfusion of blood would reduce 
any temperature rise further. Studies are also carried out within this report to investigate 
the effect of reducing acquisition times and the effect this has on tissue classification 
models (Section 6.3).  
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2.3.5 Raman probe details 
To provide some history, to date the main probe used for biological applications is the 
Visionex probe (Enviva, Visionex Inc, Atlanta, Georgia, USA), since this was the only 
commercially available probe suitable for passing down an endoscope channel. 
However, production of the Visionex probe (see Figure 2-6) ceased before work on this 
thesis commenced. Several groups have been investigating alternative designs, such as 
the Emvision (also shown in Figure 2-6) and also some larger probes for skin 
applications which are not suitable for endoscopic use.160 The Visionex and Emvision 
probes are described in subsequent sections. Details of the novel single out-put fibre 
probe are confidential and as a result are not described, but for the proposes of this study 
this is not of significance and it is sufficient to consider the probe as a single out-put 
fibre whilst the other probes utilise multi-fibre collection.   
 
 
Figure 2-6: Photograph of a selection of Raman probes. From left to right: Emvision probe 
(830 nm), Visionex (785 nm), Visionex in a removable rigid casing (830 nm) and a novel 
single output fibre probe  
2.3.5.1 The Visionex and Emvision probes 
The Visionex probe consists of a central excitation fibre of 400µm diameter which is 
surrounded by seven 300 µm diameter bevelled collection fibres to maximize collection 
efficiency (see Figure 2-7). The angle of the bevelled fibres is described by the gaser 
level (5 and 10) for the Visionex probes. The higher the gaser level the smaller the 
sampling depth, i.e. the greater the degree of ‘beam steering’.147  The probe fibres have a 
numerical aperture of 0.22. A band pass filter is incorporated approximately 2.5cm from 
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the tip in line with the excitation fibre and a long pass filter in line with the collection 
fibers.147 The probe (Figure 2-7), is approximately 2mm in diameter and can pass down 
the biopsy channel of an endoscope. The probe reportedly samples to a depth of 500 µm 
and a tissue volume of 1 mm3 for the gaser level 10 probes.56,155   
 
Figure 2-7: Photograph of Visionex probe and illustration of tip56 
  
Two different Raman probe designs are shown in Figure 2-8, which illustrates the 
reduction in sampling volume for a bevelled fibre probe, which is advantageous for 
detecting precancerous changes in the surface epithelial layers. The Emvision probe 
(Figure 2-8), manufactured by Eric Marple is effectively a gaser level 0 probe, i.e. with 
no beam steering. Other probes are being investigated by other groups and these are 
discussed in the following section.  
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Figure 2-8: left) Schematic diagrams of the two different Raman probe designs illustrating the 
excitation and collection regions for an unbevelled fibre probe (e.g. Emvision), right) and a 
bevelled fibre probe (Visionex) 
2.4  Raman probe studies for targeted biopsy  
Raman probes have been extensively tested ex vivo for targeted biopsy and some studies 
have been carried out in vivo. In the past, the majority of the latter have been in easily 
accessible sites such skin, 159,160 oral cavity (tongue, teeth),154 and cervix140, however, 
there are reports of in vivo applications in the upper GI tract by Shim et al.,141 and (a 
recent abstract by) Wong Kee Song et al..161 There have also been reports for in vivo 
tumour margin assessment162 and applications in stomach,156 bladder,155 prostate,155  
colon,163 and lung.164 
2.4.1 Probe studies ex vivo 
Several groups have begun to assess the performance of in vivo probes ex vivo, as the 
first step towards in vivo measurements. Ex vivo measurements have the potential for 
diagnosis in a theatre situation since the probe systems are mobile and can potentially 
provide an immediate diagnosis for excised tissue samples, which may be beneficial in 
assessing tumour margins or allowing earlier treatment if required. In a study by Huang 
et al., a Raman probe system designed for in vivo measurements of the skin was used for 
ex vivo measurements of bronchial tissue samples.165 This was the first application of 
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Raman spectroscopy in the bronchus. Measurements were made on 28 samples (biopsies 
and resected specimens) taken from 10 patients. Biopsies were taken under Laser 
Imaging Fluorescence Endoscopy (LIFE) guidance. The pathology results showed 12 
normal samples, 6 adenocarcinoma and 10 squamous cell carcinoma. The results were 
grouped as either normal (normal and inflammation) or malignant (adenocarcinoma and 
SCC).165 Univariate techniques were used to investigate the differences between normal 
and malignant with respect to the mean of the Raman intensity ratio of the 1445 and 
1655cm-1 peaks (CH2 bend and amide I). A peak ratio of 1 was used as the decision 
point, a sensitivity of 94% and specificity of 92% was achieved.  
 
Boere et al. developed a multivariate classification model based on a database of spectra 
acquired using different Visionex probes (standard Visionex and also Visionex with a 
200 µm CaF2 offset) and on different days.166  Raman spectra were acquired from 66 rats 
oesophagi opened longitudinally. A suture was placed at the point the measurements 
were taken so that the area could be located upon histology. The study concluded that 
the probe lacked reproducibility, even after filtering. The filtering methods, including 
correction for backscatter (see Section 2.3.4.2), caused loss of biological information 
which limits the diagnostic capabilities, although it was reported that >93% of spectra 
were correctly classified. Boere et al. stated that the sampling volume of the Visionex 
probe (830nm) was 100-600 µm, which was reduced to 400 µm with the addition of the 
CaF2 offset window. However, no evidence was provided to support this.  
 
A Visionex Raman probe system has also been used ex vivo to discriminate malignant 
and benign bladder and prostate samples with overall accuracy of 84% and 86% 
respectively.155  
 
Several real time Raman probe systems have been reported such as that described by 
Motz et al., who reported a sapphire ball lens probe (1 excitation fibre, 15 collection 
fibres) capable of acquiring spectra in 1s then a further 1s for analysis.167 Another real 
time software system was reported by Baker Schut et al., in which spectra were 
projected onto a previously developed LDA model in real time.154  
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High wavenumber Raman spectroscopy has also been explored since silica signal is not 
present at the high wavenumber region. Spectral contributions have been shown to 
contain similar diagnostic spectral information by Koljenovic et al. in a mapping study 
comparison to validate future high wavenumber probe applications.128  
2.4.2 In vivo Raman applications 
Mahadevan-Jansen et al. reported the first in vivo Raman application (Visionex probe, 
785nm) in the cervix, and successfully identified high grade precancerous changes 
which were verified by taking biopsies at that point.140 The algorithm based on the peak 
height ratios at 1659 to 1321 cm-1 (amide I to CH2 twist) and 1659 to 1452 cm-1 (amide I 
to CH2 bend) correctly identified high grade precancerous changes, but it was not stated 
in how many patients. Furthermore, biopsies were not taken from sites diagnosed as 
normal using the probe system so the histology could not be confirmed. A typical 
spectrum from normal and precancerous spectra was presented, considering only the 
region between 900 and 1800 cm-1. Spectra were similar to ex vivo system.  
 
A further in vivo study was carried out on 13 patients undergoing routine colposcopy 
procedures by Utzinger et al.125 A univariate algorithm based on peak intensities at 
1454cm-1 to 1656cm-1, which on average was greater for dysplasia and 1656 to 1330 cm-
1
, which on average was lower for dysplasia. Multivariate analysis was not possible due 
to the limited sample size. Haka et al reported in vivo tumour margin assessment during 
breast surgery using the sapphire ball lens probe described previously.162  
2.4.2.1 Application of Raman probes in the upper GI tract 
The first in vivo use of Raman spectroscopy of human gastrointestinal tissue was 
reported in 2000 in a feasibility study.141 Emphasis was on the investigation of artefacts 
from pressure and angle, both of which were found to be negligible as discussed 
previously in Section 2.3.4.1.141 Raman spectra were acquired in vivo from 5 patients 
using a custom built fibre optic probe system. A diagnostic algorithm was developed 
using LDA, with cross validation. Barrett’s samples were classified with 86% sensitivity 
and 88% specificity, with an overall accuracy of 87%. High risk lesions (i.e. HGD and 
adenocarcinoma) were classified with 88% sensitivity and 89% specificity with 89% 
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accuracy overall. Shim et al. compared the spectra of blood and oesophageal tissue and 
found that there was no contamination of the heme vibrational modes in the oesophageal 
spectra, even when measured tissue is covered in blood.141 This and other contaminant 
were studied to provide negligible contributions to epithelial Raman spectra.  
 
A larger in vivo study was carried out more recently by Wong Kee Song et al. in 
2006,161 although results are yet to be published in a scientific journal. In this study, 
spectra were acquired using a custom built probe at 785 nm from at least 6 Barrett’s sites 
in each of the 100 patients.  In this study, a model was developed to differentiate non-
dysplastic samples from dysplasia (i.e. LGD, HGD and early adenocarcinoma) with an 
overall model accuracy of 80% (sensitivity 80%, specificity 79%). These results were 
improved to 88%, 88% and 88% respectively when the groupings were changed and 
LGD was included in the non-dysplastic group. This effectively creates a two group 
model for high risk and low risk pathologies. An important realisation in this study was 
that the inclusion of reactive/inflammatory changes did not alter the diagnostic 
accuracy.161  
 
Teh et al. have recently reported a Raman probe study to detect gastric cancers. In this 
study, 76 samples/spectra from 41 patients resulted in a cross validated PCA-fed LDA 
model which discriminated normal and dysplastic gastric samples with good sensitivity 
and specificity (95.2% and 90.9%). However, it must be noted that there appear to be 
artefacts in the background subtracted spectra used in the classification model.156  
2.4.3 Developmental probes 
Yamamoto et al. reported on a miniature Raman probe comprising hollow optical fibres 
and a ball lens although the probe has yet to be evaluated for biological applications.168 
De Lima et al, reported recently on a catheter based probe (1 excitation fibre, 5 
collection fibres and 1 fibre for ‘optoclinical treatments’) with a mechanism for 
manoeuvring the distal probe tip.153 Another catheter based probe has also been 
reported.169 However reports are recent and presented only in abstract form. To date 
little information is provided about the particulars of the probe design.  
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2.5 Raman mapping and applications for potential histology 
A further extension of Raman spectral analysis is the combination with spatial 
information to produce a 3D spectral data cube which can be used for imaging, referred 
to as a Raman mapping. Three different methods of Raman mapping were first described 
by Delhaye and Dhamelincourt, including point mapping, line mapping and global 
imaging.170 Raman mapping allows the possibility of multiplexed disease marker 
measurement without the use of stains.   
 
As mentioned previously, Raman scatter is a relatively weak process. As time has 
progressed technological advances have enabled the acquisition of Raman point tissue 
spectra in relatively short acquisition times. Imaging applications of Raman have 
generally relied on point mapping, which is widely regarded as a slow technique. 
However, there has been some limited use of global imaging (flat field illumination 
coupled with liquid crystal tuneable filters and array detection (ChemImage).59,171 Point 
and line mapping are described below to provide background details enabling the 
description of a recent technological development of line mapping referred to here as 
rapid Raman mapping. Global imaging is not described further here and the reader is 
referred to Treado and Nelson.59 
 
In previous studies our group has shown that Raman spectroscopy is capable of 
detecting and classifying pre-cancerous and cancerous changes with a high sensitivity 
and specificity.1,2 Further studies have gone on to elucidate biochemical changes 
occurring during the progression to cancer in the oesophagus.123,172,173 The first 
demonstration of Raman mapping for the biochemical analysis of the bladder was made 
by Stone et al.174 Other groups have used Raman mapping to investigate precancerous 
changes in the bladder,175 bronchus,176 and brain.177 Other Raman mapping studies have 
been carried out on healthy tissue such as the breast,178 and also hard tissue applications 
such as bone.179   However, the long overall mapping times have limited the size of the 
datasets which can be acquired and consequently the biochemical information which can 
be gleaned using multivariate analysis. Furthermore, long overall mapping times have 
hindered the progression of the technique into the clinical environment.  
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There are limited papers published which compare different Raman mapping 
techniques180 and the most recently developed techniques for rapid mapping have yet to 
be evaluated. For details of Raman imaging, the reader is referred to the following 
reference.59 In order to explain novel technology, Raman mapping techniques are 
described in brief below. In the following explanations, there are some references to the 
results section (Section 6.2.1.1). The details of some of these new technologies are 
described below and compared to existing mapping techniques in Chapter 6. 
2.5.1 Point Raman mapping 
During point spectral mapping (Figure 2-9a), a spectrum is acquired using effectively 
the entire length in one dimension (actually the edges are removed to reduce noise) of 
the charged couple device detector (CCD) with the collection pixels region spanning the 
width of the laser line to maximise the collected signal. The rest of the CCD is not read 
out to minimise dark current readout noise and readout time.  The sample is stepped 
along to the next position using an XY translational stage and the next spectrum is 
acquired and so on until a grid of spectra is obtained, often referred to as a spectral data 
cube. The overall mapping time is often limited by the acquisition time (per spectrum) 
when measuring tissue samples since they are not strong scatterers. The acquisition time 
may be of the order of 1-30 s depending on the tissue type and even as long as 120 s 
when measuring single cells.181 Typically the total mapping time is roughly equal to the 
total number of spectra multiplied by the acquisition time. Additionally, there is a stage 
translation delay and CCD readout time delay for each of the spectra. This is of the order 
of 1.6s (combined CCD readout and stage translation, calculated from a 0.1 s acquisition 
point map using a Renishaw system 1000 – see Section 6.3.1). For shorter acquisition 
times, the speed of the XY translational stage and, often most significantly, the readout 
time of the CCD can significantly limit the rate at which spectra can be acquired. 
Furthermore, factors such as extended scanning and auto-focusing reduce the rate of 
spectral acquisition. In one study, Krafft et al. reported an acquisition rate of only 30 
spectra per hour based on an acquisition time of 30 s whilst using auto-focus during the 
mapping of brain tissue182. 
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Figure 2-9: a) Illustration of point Raman mapping in which a spectrum is acquired at each 
position on a grid, b) High spatial resolution line mapping using a barrel lens to produce a 
line focused laser. Many spectra are acquired simultaneously by separating out the lines on 
the CCD, c) Low spatial resolution line mapping in which the entire laser line is used to 
sample a large area of the sample utilising vertical binning of the CCD pixels and d) 
 - 44 - 
Illustration of rapid Raman mapping in which the CCD readout is synchronized with the 
movement of the stage to allow constant readout of Raman spectra thus reducing dead time 
between spectra  
A development of point mapping was the introduction of a cylindrical lens to create a 
line-focused laser, often referred to as line mapping.  
2.5.2 Line mapping 
A line focused laser can be used in two different ways as illustrated in Figure 2-9b and 
Figure 2-9c. First, line mapping can achieve spatial separation of the laser line using the 
CCD pixels, resulting in an increased spatial resolution as illustrated in Figure 2-9b. This 
is achieved by reading out each CCD line separately creating multiple spectra, the trade 
off being a reduction in the signal of each spectrum since only a portion of the laser light 
is used to illuminate the area of the tissue imaged by that CCD pixel. A further draw-
back is that since the power varies along the length (~50µm for the x50 objective used in 
this study) of the laser line (approximately Gaussian) this method of line mapping results 
in a variation in the intensity of the spectra along the laser line. A correction can be 
performed, but this can be unreliable for inhomogeneous samples such as biological 
tissue. Schlucker et al.,180 concluded that the signal to noise and images of a Si and 
aluminium test phantom were similar for point mapping and line mapping (spatial 
resolution from both methods was of the order of 1.1 µm), but line mapping (corrected 
using a manufacturers line map correction) was faster. However, in the study by 
Schlucker et al., the focus for the point mapping laser was reported as being 1.1 µm 
using a x50 objective, significantly smaller than the point focus achieved with the 
system in our laboratory due to the wavelength and the type of the laser used, which 
explains how they were able to achieve similar spatial resolutions with the two different 
mapping methodologies.   
 
The second method for line mapping is to utilise the expanded laser line to sample the 
mapped region in fewer steps (Figure 2-9c). In this case, an increased signal to noise 
ratio is achieved compared to the high resolution line-focused mapping (since the entire 
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laser line is used to generate each spectrum), but the trade off is reduced spatial 
resolution. 
 
Line mapping is still limited by CCD readout (especially for short acquisition times), 
although this is reduced when portions of the laser line read out independently for higher 
spatial resolution since the readout time is spread over multiple spectra. In fact, it is 
possible to set up the system to in between settings, for example using only half the line 
focussed laser line.  
 
These two techniques were rigorously compared by Schlucker et al., along with wide 
field imaging concluding that depending on the application, line mapping was faster that 
point mapping.180    
2.5.3 Rapid Raman mapping 
Rapid mapping systems have been developed by several manufacturers including WITec 
(Ulm, Germany) and Renishaw. This study focuses on Renishaw StreamLine™, 
although the concepts discussed can potentially be applied to any imaging system 
capable of rapidly acquiring large Raman datasets. Considering StreamLine™ 
technology (Figure 2-9d), referred to as rapid Raman mapping from here forth, provides 
a novel and fast method of acquiring Raman maps. The sample is stepped along the laser 
line and the position of the stage is synchronised with the readout of the CCD (as 
illustrated in Figure 2-9c). Each spectrum is effectively made up of an accumulation of 
spectra as the entire laser line passes over each part of the sample. There is a short delay 
at the beginning of each column in the grid as the laser line passes over the first pixel 
and then following spectra are acquired at an increased rate. This enables high spatial 
resolution mapping without the reduction in intensity trade off (associated with spatial 
separation line mapping) and consequently eliminates the variation in SNR due to the 
laser profile, as illustrated in Figure 6-9d. There is still however a reduction in signal 
intensity and SNR compared to point/line mapping using the entire laser line.  A further 
advantage is that constant readout (i.e. reduced dead time between sequential data points 
compared to point mapping) of spectral data results in the acquisition of spectra and 
maps at an increased rate. This uses the multichannel advantage of the CCD in two 
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dimensions simultaneously to get full spectra readout that is orders of magnitude higher 
than the actual exposure time per spectrum. These advances have facilitated the 
acquisition of thousands of spectra within a matter of minutes compared to previous 
mapping techniques which took hours and even days. 
 
Compared to traditional line mapping, rapid mapping provides many advantages. There 
is an increased rate of spectral readout due to the synchronised readout of the CCD with 
movement of the XY translation stage, and also high lateral spatial resolution. High 
lateral spatial resolution line mapping (in which each line of the CCD is used to spatially 
separate the laser line) is subject to the variation in laser intensity across the laser profile 
(approximately Gaussian) as shown previously in Figure 6-9.  
 
Gendrin et al.183 recently reviewed the impact of spectral imaging on the field from the 
perspective of pharmaceuticals (with some biological examples). Discussing the 
advantages of obtaining both spatial and spectral information, the author also 
highlighted the multidisciplinary challenges raised by the advent of spectral imaging 
with the need for a combination of traditional spectroscopic skills (biochemical and 
instrumentation), chemometric, signal processing and image processing skills. 
 
De Paula et al. studied the use of Raman spectroscopy for identification of 
atherosclerotic plaques; using mathematically added noise they investigated the effect of 
SNR on subsequent multivariate classification. They concluded that short acquisition 
times as low as 20ms which result in poor quality spectra could be used distinguishing 
plaques (calcified, atherosclerotic or non-pathological). However, in this study, spectral 
features were very visibly different (due to strong Raman signatures for inherent 
calcification and lipids) and as a result the limit of PCA and other multivariate 
techniques was not tested.138 
2.5.4 Relevant points from FTIR mapping studies 
As discussed previously, spatial resolution of spectral imaging is a key parameter. For 
mapping studies, it is important to distinguish the spatial resolution from the step size, 
which determines the pixel size. A consequence of finite spatial resolution is spectral 
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mixing between adjacent pixels. This has been investigated by Bhargava, who 
investigated the effects of nominal spatial resolution (step size) on the classification 
performance. They went on to attribute complications to what are referred to as 
“boundary pixels” which are pixels resultant of spectral mixing of neighbouring pixels, 
as described previously. The effect of over-sampling (increasing the number of pixels 
which represent a given area) was also considered, concluding that over-sampling can 
result in improved boundary definition, but spectral mixing is still an issue.150 
2.6 Practical considerations for sample preparation 
The substrate used for Raman spectroscopy and Raman mapping in particular, is 
particularly important practical consideration since it is vital that the substrate does not 
have a strong Raman signature. Stone and Kendall investigated different substrates 
concluding CaF2 was the most suitable for Raman applications.108,121 Various other 
substrates are still routinely used including glass,131 and quartz.169  
 
Formalin fixed samples are not suitable for in vivo mimicking Raman spectroscopy, due 
to the fact that the fixation process induces biochemical changes in the tissue.184  Sample 
storage is also an issue, and Shetty investigated the effects of long term storage (at -
80°C) of tissue samples, concluding that the effects of prolonged storage on Raman 
spectra was insignificant.124 Samples should also be snap frozen in liquid nitrogen to 
prevent formation of ice crystals. However there are reports in the literature which do 
suggest there are subtle peak of the amide I due to freezing of tissue samples.185 
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Chapter 3 Data Analysis 
This section summarises the techniques used for pre-processing data and subsequent 
chemometric techniques used for developing a classification model. The main emphasis 
is on techniques actually used in this study, but also touches on other competing and 
complementary techniques that will be investigated in the future.   
3.1 Data pre-treatment 
Where possible, raw data should be energy sensitivity corrected to account for CCD 
efficiency across the wavenumber range (see Section 4.4). Spectra are also interpolated 
to unitary wavenumber divisions since the spectral wavenumber values are determined 
by the positions of the CCD pixels.  
 
Data pre-processing reduces systematic and random errors in the Raman spectra.186 For 
single spectra, smoothing techniques such as the Savitsky-Golay filter, removes high 
frequency fluctuations. This is achieved by isolating low frequency fluctuations through 
fitting polynomial functions to a number of points around each spectral point. 187  
 
Normalisation eliminates differences in absolute intensity. Normalisation can either be 
carried out with respect to a well defined peak, but overlapping bands etc. can be 
problematic, or with respect to the total area. Another alternative commonly used is 
where the centred and normalised to a given variance (normally unity).187 
 
A common approach to standardise data is mean centring in which the mean of the entire 
dataset is subtracted from each individual spectrum. This also allows scaling of test 
datasets.187 
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The elimination of background signals is also problematic and this has been discussed in 
Section 2.3.4.2.  
3.2 Chemometrics 
3.2.1 Empirical analysis 
Empirical analysis includes calculation of difference spectra, peak assignment, absolute 
peak heights and peak ratios. Subtracting spectra is useful to give a general indication of 
the main differences between spectra. For example, subtraction of the mean normal 
spectra from the mean cancer spectra indicated shows a spectrum with peaks in the same 
position as glycogen showing that there is less glycogen in cancer samples as expected 
due to increased proliferation. Although this method is crude, it can be a useful starting 
point. Peak ratios take it one step further and several groups have developed successful 
classification models based on peak ratios. A commonly used peak ratio is 1651 cm-1 to 
1445 cm-1 (Amide I C=O stretch vs lipid vibrational mode CH2, CH3) which has been 
used on several sites, including the cervix,140,113 breast131 and bronchus165 to discriminate 
between normal and abnormal/malignant tissue samples.  The technique is simple and 
often used for feasibility studies. However, it is limited since it only takes into account a 
small region of the spectra, and complex biochemical changes would affect the entire 
spectrum. Although using more than one intensity ratio may improve this, a significant 
amount of spectral information is still wasted. Multivariate methods utilise the entire 
spectra enabling more subtle changes to be detected. 
3.2.2 Principal component analysis (PCA) 
Principal component analysis (PCA) forms the basis for multivariate statistical 
analysis.188  PCA is a data compression technique which removes collinear variations, 
variations in spectral features that arise from the same source, and retains only spectral 
features with independent variations.  The first principal component (PC) is such that it 
is representative of the highest variance in the spectral dataset; the second principal 
component is representative of the next highest variance. This continues until the 
principal components represent only noise. The principal component scores represent the 
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fit coefficient/weight of each PC. The most significant principal components can then be 
used to separate different groups. This is most easily visualized by plotting the scores in 
principal component space, although this is difficult in multiple dimensions.  
 
This is referred to as an unsupervised model since the process separates the groups with 
no prior knowledge of their classification.  
 
Many groups have used PCA for analysis and separation of Raman (and other 
vibrational) spectroscopic data.50,132,138,189 A model can be trained against a gold 
standard using linear discriminant analysis (LDA), for example by inputting pathology 
information.  
 
3.2.3 Linear discriminant analysis (LDA) 
LDA is referred to as a supervised method, since the model is generated with groups 
separated based on prior knowledge of the classification groups. The process of LDA 
maximises the variance between the different groups and minimises the variance within 
each group and creates a discriminant function which describes this. Many groups have 
used PCA fed LDA for separating different Raman spectroscopic tissue 
pathologies.1,50,103,133,155,175 The number of PCs (i.e. using the minimum) used for LDA is 
an important variable to prevent overfitting the data (fitting noise components etc.).  
 
Alternative chemometric techniques such as artificial neural networks are described 
below with regards to imaging, but these techniques can also be applied to point spectra. 
PCA and LDA are established techniques and as a result these are chosen for use in this 
study.  
3.3 Model validation  
Ideally, a model will be tested using an independent dataset. However, due to limitations 
with patient and sample numbers this is not always possible. Retaining a number of 
samples to generate an independent validation dataset means that the number samples to 
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produce the model training set is reduced, thus limiting the training model, which ideally 
will have as many samples/patients as possible. A method of overcoming this is leave-
one-out cross validation.  
3.3.1 Leave-one-out cross validation 
After a model is generated, it can be tested by removing one spectra (which may include 
all spectra from a sample/patient) and regenerating the model. The removed spectrum is 
then fed into the LDA classification model to determine the classification based on the 
new model. This is then repeated by removing each spectrum (again this may refer to all 
spectra from one sample/patient) in turn.  
 
This technique has been widely used for validating classification models in the other 
tissues,133,155,192, and oesophageal tissue.1  
3.4 Chemometrics for spectral imaging 
Univariate imaging (or functional group imaging) is one of the simplest forms of 
displaying biochemical information from a spectral image, however, multivariate 
techniques as described previously, utilise the entire spectra and all of the biochemical 
information contained within it.  
 
Principal component analysis has been applied by many groups for spectroscopic image 
processing of both Raman and FT-IR applications.148,181,190 The reader is referred to 
Raman textbooks for further details.187  
 
Hayden et al. investigated the effects of sampling parameters and compared for Raman 
line images using PCA, demonstrating that improved results were obtained using the 
higher magnification, concluding that this was due to an increased dataset size.148   
 
Principal component analysis has been used by many groups as an unsupervised method 
of data reduction to produce pseudocolour PC score images of Raman and FTIR spectral 
images.148,182,190 Various other forms of cluster analysis (Hierarchal cluster analysis, k-
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means cluster analysis, fuzzy C-means) have also been used as unsupervised methods of 
imaging for spectral imaging. 175,178,191 
 
Many groups have generated supervised multivariate tissue classification models using 
LDA based on spectra, or mean spectra extracted from Raman maps, however, few 
groups have taken the step to produce images from the classification results. Supervised 
methods include artificial neural networks (ANN),138,191 and LDA, although after a 
search of the literature, only one paper which uses (LDA) for Raman imaging could be 
found (based on an LDA model spectral averages from cluster analysis trained with 
histology).192 Mansfield et al. have reported the application of LDA for FTIR imaging of 
skin cancer,193 and Krafft et al. reported LDA applied to FTIR imaging of gliomas.194  
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Chapter 4 Materials and methods 
The following chapter describes the materials and methods involved in a preliminary 
study carried out with the Visionex probe system for targeted biopsy ex vivo (described 
in Section 2.3.5) and how this model was developed, include trial of different 
preprocessing and the addition of consensus pathology.  Materials and methods for the 
Raman mapping (for automated histopathology) studies and also studies which impact 
both in vivo and ex vivo clinical applications of Raman spectroscopy are also included.   
4.1 Oesophageal tissue sample collection 
Informed written consent was obtained from patients undergoing routine upper 
gastrointestinal endoscopic surveillance of Barrett’s oesophagus, endoscopic mucosal 
resection (EMR) treatments and radical oesophagectomy. Ethical approval for this study 
was obtained from Gloucestershire Local Ethics Committee. 
 
Tissue samples were collected during EMR and oesophagectomy procedures. Both EMR 
and resected samples were approximately 1cm in diameter. In the latter case, samples 
could be obtained from disease free regions of the resected oesophagus. Biopsy samples 
have also been harvested during routine endoscopic surveillance, including a small 
number of jumbo biopsies, although these have not been used in this study. Samples 
were placed in a cryovial and immediately snap frozen in liquid nitrogen. 
 
Included in this preliminary study were 50 EMR and resected samples obtained from 39 
patients used in this preliminary study.  
4.2 Histopathology definition  
Pathology information was obtained from three expert pathologists specializing in 
gastrointestinal pathology, Prof. N. Shepherd, Prof. K. Geboes and Prof. Bryan Warren. 
However, this was not possible for all samples due to time limitations and pathologist 
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commitments. A comparison was made between the pathology diagnosis from each 
histopathologist and a consensus opinion and majority diagnosis determined.  
 
Samples were measured on fresh or defrosted samples. From the early stages of the 
study, following spectroscopic measurement, samples were formalin fixed after 
measurements, sectioned and stained with H&E for histological diagnosis. 
Subsequently, samples were snap frozen after measurement and frozen sections were 
then stained with H&E. This allowed the remainder of the sample to be retained for 
further spectroscopic measurements.  
 
For rapid Raman mapping, 15-20 µm tissue sections were cut onto calcium fluoride 
(CaF2) substrates which have a low background signal with only one Raman peak at 
~320 cm-1 which is outside of the finger print region (400-1800 cm-1). For these 
sections, consecutive 7µm sections were sectioned and stained with H&E for 
histological diagnosis. Furthermore, some frozen sections were stained with H&E to 
improve correlation of morphology and biochemistry of the Raman maps.   
 
Although only a low number of classification groups were used in this preliminary study 
due to the limited number of patients/samples, the pathologist provided a range of 
diagnosis from 9 classifications listed below, along with abbreviations. These could be 
then used in the future when the model is extended. Pathologists were encouraged to 
highlight uncertainty, in keeping with pathology criteria in which clinical samples are 
diagnosed as indefinite for dysplasia.  
 
• Normal squamous – NSq 
• Cardiac mucosa – CM 
• Fundic mucosa – FM 
• Intestinal metaplasia – IM 
• Low grade dysplasia – LGD  
• High grade dysplasia – HGD 
• Adenocarcinoma – Adeno 
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• Squamous dysplasia – SqDysp 
• Squamous cell carcinoma – SCC 
• Inflammation 
 
Further tissue groups were also identified for mapping sections which often contained 
submucosa  including: 
• Fibrous connective tissue 
• Smooth muscle 
• Lymphoid aggregate 
• Glands 
• Duct 
• Goblet cells 
• Nerve 
• Blood vessels 
• Laser damage 
• Fibrosis 
4.3 Wavelength selection 
As discussed previously, 785-830 nm is the ideal wavelength range of choice for Raman 
spectral measurements of biological tissue. 830 nm has been chosen as the wavelength 
of choice, supported by previous studies and commonly used by other groups.108,138 In 
general, two different types of Renishaw spectrometers were used in this study, one for 
probe based studies and a laboratory based microspectrometer for mapping experiments. 
These are discussed in detail below. Two model variations of these were used in 
preliminary studies, where relevant these are noted in the methods of that particular 
study. System calibration issues are discussed separately below.  
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4.4 Raman system calibration 
There must be a calibration to ensure that the conversion from channel number to 
wavenumber is reproducible. An intensity calibration is also required since there is 
wavelength dependence in the efficiency of the detector (due to filtration), efficiency of 
the gratings and quantum efficiency (QE) of the detector.195 Different calibration 
methods are listed below:  
 
• Offset calibration – Silicon is often used to monitor any shift in wavenumber 
since it gives a well defined single peak at 520cm-1. Although a quick and easy 
test, it does not check calibration across the entire wavenumber range.  
• Neon argon lamp – this can be used to test the CCD across the entire wavenumber 
range, however it requires that the laser light is blocked.2,125 A calibration 
standard which has Raman spectra peaks has advantages over neon argon atomic 
emission lines.142 Cyclohexane is also used locally (in combination with neon 
argon source) and by other groups since it does not require the laser line to be 
blocked. White light calibration (diffusely scattered by BaSO4) – this provides 
calibration traceable to national standards. Raman intensities can be corrected for 
wavelength dependent detector efficiency using the emission spectrum of a 
calibrated tungsten band lamp.3,196  
• Fluorescence –A recent paper by Etz et al. reports on a doped glass standard for 
relative Raman intensity calibration developed by the National Institute of 
Standards and Technology (NIST). However calibration is only carried out at one 
wavelength (785nm).197 Locally, green glass is used as secondary standard 
traceable standard which can be related to the calibrated white light source. 
 
The Raman systems within the department have been wavelength calibrated using neon 
argon atomic emission lines. The emission lines provide well defined bands within the 
wavenumber range of interest as described previously in Section 4.4. An example of 
three neon argon calibration spectra acquired using the probe system spectrometer can 
be seen in Figure 4-1. 
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For the probe system, the neon argon calibration was carried out when the system was 
initially set up. For the laboratory based spectrometers, this was also carried out, and 
additionally, neon argon spectra were acquired routinely before each spectral acquisition 
to monitor temporal changes, although the spectra are not used to calibrate the system on 
a daily basis, the data is merely stored in case retrospective correction is required. A full 
calibration is performed if the system is realigned or the laser is replaced.  
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Figure 4-1: Neon argon emission lines measured with the Renishaw RA100 spectrometer 
(three independent measurements (blue, cyan and green) acquired from Oct 2005 to July 2007  
Green glass is used as secondary standard (to an NPL calibrated tungsten lamp) for 
intensity calibration. For the laboratory based Raman systems, the green glass standard 
is measured using the x50 Leica objective (1s acquisition) prior to any tissue 
measurement Green glass correction is not required for mapping measurements since the 
data is only self-compared, i.e. data analysis is not carried out over weeks or months as 
tissue classification models are and thus drift in system performance is not an issue.  
 
Green glass calibration measurements were only carried out sporadically. A 1s 
acquisition was used for the probe system. Green glass correction was not deemed vital 
for the probe model since measurements were carried out in large batches so system drift 
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was not generally a problem, however replacement of the CCD and realignment did 
result in some issues which is discussed in Section 5.5. 
 
 
4.5 Methods – 1) optical biopsy 
The methods section has been constructed such that the heading numbering correlates 
with the relevant section in the results chapters. For example, the methods described in 
Section 4.5.1 can be found in section 5.1 and so on.  
 
Raman spectra were acquired from endoscopic mucosal resections (EMR) and resected 
tissue specimens using a Visionex probe (Gaser level 10, described previously in Section 
2.3.5). A diode laser (Process Instruments) with wavelength of 830nm was used for 
excitation, which was connected to the excitation fibre. The collection fibres (arranged 
in a linear array) were passed through a further laser line rejection filter and connected to 
a Renishaw RA100 spectrometer (Renishaw plc., Wotton-under-edge, UK). The 
Renishaw System 100 spectrometer is a simple design, shown in Figure 4-2. The 
collection fibres direct the Raman scattered photons via a lens, mirror, and grating, onto 
the CCD detector. The spectral resolution of the probe spectrometer is approximately 
15cm-1. 
 
Figure 4-2: Photograph of the Renishaw System 100 spectrograph  
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The spectrometer and spectral acquisition is controlled via GRAMS (Graphic Relational 
Array Management System), a 32-bit software package for collecting Raman spectra via 
the Renishaw spectrometers.  
 
The Raman probe was positioned vertically in a jig as shown in Figure 4-3. The sample 
was then placed on CaF2 on a z-translation stage. The sample was raised until in (gentle) 
contact with the probe. Prior to each spectral tissue measurement, the probe 
spectrometer was calibrated using a Si standard. A 1s acquisition time was used. If a 
spectral offset was detected (from the expected 520cm-1) position, a wavenumber offset 
correction was applied. For large offsets, the system was shut down and rebooted with a 
full system motor check and the wavenumber calibration process repeated. A tolerance 
of ±0.5cm-1 has previously been shown to be acceptable.108  
 
 
Figure 4-3: left) Photograph of the Visionex Raman probe and spectrometer, right) 
photograph of the Visionex probe, z-translation stage and substrate   
4.5.1 Raman probe background signal 
As described previously, reports in the literature state that current methods of 
background subtraction are unreliable. To investigate this further, the most widely used 
technique was tested which involves the iterative subtraction of a polynomial described 
by Leiber et al. 198  Considering the Visionex probe, a 5th order polynomial is suggested. 
The technique was tested on a series of spectra acquired using the Visionex probe and 
Rensihaw RA100 spectrometer described above is 4.5. 
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An acquisition time of 4x15s was used for these measurements. Spectra from 96 samples 
were averaged into three pathology groups (defined by one expert pathologist). The 
mean spectra were compared before and after background subtraction. Artefacts due to 
the probe background and also from the background subtraction process itself are 
compared to results in the literature. The results can be found in Section 5.1 
4.5.2 Comparison of Raman probes 
A second probe for potential in vivo optical biopsy was obtained from Eric Marple, and 
is referred to as the Emvision probe. As described previously in Section 2.3.5.1, this 
probe has the same fibre set up as the Visionex probe, however the probe does not have 
the filters at the tip, nor the bevelled fibres which limits the collection volume/depth.  
 
It was not evident whether or not this probe would be suitable for in vivo diagnosis in the 
oesophagus and since there appears to be no evidence of its use in the literature. It was 
decided that an initial comparison would need to be carried out, firstly and most 
importantly to investigate the sampling volume.   
 
To compare the two different probes, depth profiles in air and water were measured, 
using diamond as the target sample. The Raman probes were held vertically in a jig. The 
sample was placed on a CaF2 substrate on a vertical translation stage. Initially, spectra 
were acquired in contact with diamond chip with an acquisition time of 1s. The stage 
was then lowered at 50µm intervals and a spectrum acquired at each position.  
 
The collection efficiency of the probes was determined using the magnitude of the 
diamond peak (with respect to the baseline), divided by the acquisition time and power 
at the sample. The power at the sample was measured using a calibrated power meter 
with optical diffuser.   
 
Depth profiles were also plotted, with the peak intensity, normalised with respect to the 
value at the probe tip. This was repeated for both probes in air and water. A comparison 
of the calibration standards was also carried out. Results of these measurements can be 
seen in 5.2 
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4.5.3 Preliminary three group Visionex model 
Previous measurements had shown that 4x15 s acquisition maximised counts and signal 
to noise ratio without CCD saturation so this protocol was adopted for all future tissue 
measurements using the Visionex probe system. 163 spectra were acquired from 50 
EMRs and resected samples taken from 39 patients, a break down of the pathology can 
be seen in Table 5-1. The biopsies were then formalin fixed, sectioned and H&E stained 
for pathology diagnosis. The pathologist classified the samples as 1 of 9 groups listed in 
Section 4.2.1.  
 
The majority of samples were snap frozen and defrosted before measurement, however 
some samples were measured fresh. Record was made of how the sample was stored 
prior to measurement and spectra analysed to assess the effects of fresh and frozen 
tissue. In addition, 6 of the samples were clinical samples (needed for diagnosis) and 
therefore measured fresh and the sample was subsequently put through the normal 
diagnostic route. PCA was used to investigate any subtle variation in spectra acquired 
from fresh and frozen sample, discussed and no evidence was found (see Appendix B). 
Clinical samples were put through the normal diagnostic route for patients undergoing 
routine surveillance for Barrett’s oesophagus, but the pathology report did not provide 
sufficient detail for this study and these samples have been excluded from the 
classification model. They were however used in a comparison of fresh and frozen tissue 
spectra.  
 
After each Raman spectrum was acquired, clinical biopsy forceps were used to localise 
and remove the region on the sample from which the Raman measurement was made to 
mimic the situation in vivo. The biopsy samples were then either formalin fixed or snap 
frozen (if required for further measurements). Subsequently, 7µm frozen sections were 
stained with H&E for histological diagnosis following standard H&E protocol. For the 
initial model, pathology opinion was obtained from one expert histopathologist. The 
tissue samples were large enough to allow multiple measurements to be taken from 
different regions. On average, three spectra were acquired from each, starting at one end 
 - 62 - 
of the sample and working along, and thus on average three samples were obtained from 
each larger sample. These were treated independently since each has individual 
pathology diagnosis.  Initially, the idea was to correlate these probe measurements with 
OCT images taken from the same regions and also the gold standard histopathological 
analysis. However, this proved fruitless since the OCT images were not of sufficient 
quality and it was impossible to correlate pathology results from inhomogeneous 
samples. Furthermore, OCT images were acquired from distinct borders in the tissue for 
example on the edge of a lesion in an attempt to emphasise the differing appearance with 
tissue type, but this was sub-optimal for the Raman method since a homogeneous tissue 
sample is required for best results and correlation with pathology.  
 
Tissue inhomogeneity, due to the size of the biopsy samples used, was a problem. An 
attempt was made to overcome this problem by eliminating samples that were 
inhomogeneous with respect to the 3 group model, i.e. inhomogeneous samples were 
accepted providing the different pathologies present were all covered by umbrella of the 
three group definitions. This was applied between pathologists as well as within the 
samples, e.g. if one pathologist’s diagnosis was adenocarcinoma and the second 
pathologist’s diagnosis was HGD, the sample was accepted into the model and placed in 
the high risk group.  Conversely, if a sample was reported as containing both NSq and 
HGD, the sample was rejected. The pathology break down for the preliminary model 
based on the opinion of one pathologist is shown in Table 4-1.  
 
Table 4-1: Pathology break down based on the opinion of one pathologist for ALL samples 
measured in the preliminary Visionex study  
Pathology Number of samples/spectra 
NSq 11 
Barrett’s CM 14 
Barrett’s FM  5 
Barrett’s IM 16 
LGD 11 
HGD 23 
Adeno 18 
SqDysp 0 
SCC 0 
Discarded 65 
Total 163 
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Many samples were not used in the model since it is necessary to ensure models are 
trained with reliable groups and as a result, criteria for rejecting samples were relatively 
strict. Samples were discarded from the study if the sample only contained submuscosa 
(caused by sample accidentally being placed epithelial surface down), the pathologist 
was uncertain of the diagnosis, the sample contained mixed pathologies (i.e. not within 
the boundaries of the three group pathology model), or there was poor staining which 
prevented accurate diagnosis. A further two Barrett’s FM samples were rejected since 
spectrally, they appeared to be stomach samples (obtained from 
oesophagectomy/gastrectomy) with high lipid content. This resulted in a total of 96 
samples/spectra the following groupings for the preliminary Visionex probe model, as 
summarised in Table 4-2.  
 
Table 4-2: Pathology breakdown based on the opinion of one pathologist for samples using in 
the PCA fed LDA three group tissue preliminary Visionex probe classification model   
Pathology Number of samples/spectra Model Groups 
NSq 11 NSq (11) 
Barrett’s CM 14 
Barrett’s FM  3 
Barrett’s IM 16 
Barrett’s (33) 
LGD 11 
HGD 23 
Adeno 18 
Neoplasia (52) 
SqDysp 0 
SCC 0 
Discarded 67 
 
Total 163 96 
 
4.5.3.1 Data analysis  
Data analysis was carried out using Matlab and the PLS toolbox (Eigenvector 
Technologies, Manson, Washington, USA). Acquisition parameters described above 
minimised the occurrence of saturated spectra.  Cosmic rays were removed using the 
‘zap’ function in GRAMs. Further cosmic rays (detected using the multivariate analysis 
process) were removed in Matlab by linear interpolation of the regions either side of the 
cosmic ray.  
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Spectra were interpolated to 1 wavenumber per point. Spectra were normalised, 
smoothed (Savitzky–Golay filter with a 2nd order polynomial and window of 21) and 
mean centred prior to principal component analysis. This was supported by previous 
studies within the group which also used these settings.121 This was repeated with and 
without background subtraction (normalisation following background subtraction in this 
case) according to the procedure and Matlab program by Leiber et al.199 to investigate 
the model performance with different pre-processing steps. Iterations of number of PCs 
fed into the LDA model were carried out from 3PCs to 30PCs. The final model was then 
cross validated by methodically removing one sample (i.e. one spectrum) and 
recalculating the model. (See section 5.3) 
4.5.4 Visionex probe model following replacement of the CCD 
The above model was extended following the same methods described previously, but 
due to a CCD failure, and subsequent alignment issues, the models have been separated 
for clarity. These results can be seen in Section 5.4 
 
145 spectra were acquired from 145 samples obtained from 28 patients. This was 
reduced to 88 samples from 20 patients after rejecting samples and spectra according to 
the aforementioned criteria.  
 
Table 4-3: Pathology breakdown based on the opinion of one pathologist for samples using in 
the PCA fed LDA three group tissue Visionex probe classification model (following 
realignment after CCD replacement) 
Pathology Number of samples/spectra Model Groups 
NSq 19 NSq (19) 
Barrett’s CM 2 
Barrett’s FM  1 
Barrett’s IM 15 
Barrett’s (18) 
LGD 6 
HGD 9 
Adeno 36 
Neoplasia (51) 
SqDysp 1 
SCC 2 
Discarded 54 
 
Total 145 88 
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4.5.5 Visionex combined model 
In order to maximise the size of the tissue classification model, methods of combining 
the two previously calculated models was investigated. This is also an issue which is 
significant for translation to a clinical environment since tissue classification models 
would need to be robust to changes in equipment and in particular for the probe, 
potential alignment issues which may occur as the spectrometer is transported in a 
theatre environment for example. Three different methods of combining the two datasets 
were compared. 
 
The combined dataset contained 184 samples/spectra from 59 patients.   
4.5.5.1 Combining the datasets without pre-processing 
A first step towards investigating this was to combine the raw data from both models 
and evaluate the subsequent tissue classification model. This was feasible since PCA fed 
LDA has been shown to be relatively insensitive to probe backgrounds so it was possible 
that variation in the background would not effect classification.  
 
The model was recalculated simply by combining the two datasets, both normalised, 
smoothed and mean centred. A PCA fed LDA model was generated using 15 PCs.  
4.5.5.2 Removal of probe background variation using PCs to independently 
reconstruct the datasets 
A further option is to reconstruct the dataset minus the artefact, in this case the probe 
background. In order to achieve this, PCA was carried out on the datasets independently, 
the probe background was identified in the PC loads and the date reconstructed minus 
the PCs in question. The two reconstructed datasets were then combined and PCA 
recalculated with 15 PCs fed into the LDA tissue classification model.  
4.5.5.3 Removal of the probe backgrounds using energy sensitivity correction 
The third option for combining the datasets is to use an energy sensitivity correction as 
described previously in Section 4.4. Green glass calibration standards were acquired as 
and when possible for the probe system. Mean green glass calibration spectra were 
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determined for pre and post alignment issue. The mean spectra were interpolated to the 
same wavenumber range as the tissue spectra. A ratio of the absolute (reference green 
glass) and the mean green glass calibration file is used to correct for the energy 
sensitivity of the spectrometer. The two different datasets were corrected with the ratio 
for the corresponding mean green glass correction. The datasets were then combined and 
PCA-LDA carried out using 15PCs. The results can be seen in 5.5.3.  
 
4.5.6 Short acquisition (4 s) Visionex probe model 
Whilst the above mentioned spectra were acquired with an acquisition time of 4x15s, a 
spectrum of each sample was also acquired using a shorter acquisition time of only 4s. 
The purpose of this was to demonstrate that diagnosis is potentially feasible in clinically 
practicable time frames. Results of this model can be seen in Section 5.6. Datasets from 
the preliminary and post alignment Visionex models were combined to maximise sample 
numbers since consensus (of three pathologists) pathology was used to train the 
classification model, which resulted in a high rejection rate of samples. A breakdown of 
the samples in each pathology group can be seen in Table 4-4.  
 
Considering the samples rejected after consensus pathology, the majority of 
disagreements were for neoplastic samples with 42 samples rejected. This was often due 
to pathologists failing to mention focal regions of other pathologies, e.g. Barrett’s or 
normal within the samples. 11 Barrett’s samples were also rejected, whilst only 2 NSq 
samples were rejected. In the latter case, the good agreement between pathologists with 
NSq samples is expected since identification is less subjective compared to different 
Barrett’s sub-types and neoplastic changes.  
 
Table 4-4: Pathology breakdown for the 4 s Visionex combined model trained with consensus 
pathology opinion from three expert pathologists 
  # samples correctly classified 
NSq 28 
Barrett’s 40  
Neoplasia 42 
Total 110 
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4.5.7 Single output fibre probe tissue classification model 
The custom built probe, which consisted of a single excitation fibre and single collection 
fibre, (with diameters of 62.5 µm and 105 µm, respectively) was connected to a custom 
built spectrometer with similar performance characteristics to the Renishaw System 100 
spectrometer used above. The probe, schematically shown in Figure 4-4, differs from 
other probes which generally rely on multiple collection fibres to increase collection 
efficiency. The probe contains a notch filter and fluorescence filter near the tip to 
remove elastically scattered light and reject background fluorescence signal.  
 
 
Figure 4-4: Schematic diagram of the single collection fibre probe 
 
Thirty spectra were measured from 30 homogeneous biopsy samples from 30 different 
patients with an acquisition times of 4x15 s and 4 s. The samples were placed on a 
vertical CaF2 and moved laterally until in contact with the (unpackaged) probe, which 
can be seen in Figure 4-5. 
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Figure 4-5: Experimental set up for the single collection fibre probe ex vivo 
 
The consensus histology diagnosis from three expert pathologists was used to train a PC 
fed LDA model (15 PCs, data normalised and mean centred). A breakdown of the 
sample numbers in each pathology group can be seen in Table 4-5. 
 
The consensus histology diagnosis from three expert pathologists was used to train a 
PCA fed LDA model.  
 
Background subtraction was not used for the PCA-LDA model, but was performed to 
enable comparison of spectra with the Visionex probe spectra.  
 
Spectra were also measured with shorter acquisition times (4s) to determine the 
feasibility for more realistic time scale Raman measurements. This was based on the fact 
that there was scope to improve throughput of the probe by a factor of 4, thus enabling 
1s acquisition times in the future.  
Table 4-5: Summary of the number of samples for each pathology group for the single 
collection fibre probe 
  # samples correctly classified 
NSq 13 
Barrett’s 8 
Neoplasia 9  
Total 30 
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4.6 Methods – 2) Rapid Raman mapping for potential automated 
histopathology 
The general construction of a Raman microscopy system has been described previously 
in Section 2.3. To summarise the system components for the microscopy systems used in 
the mapping studies.  
 
Typically, the core of the StreamLine instrument is a Renishaw inVia Raman 
microscope, although in these experiments Raman point spectra and maps were acquired 
using a customised Renishaw Raman System 1000 spectrometer coupled to a 
microscope fitted with a Leica x50 long working distance objective (NA 0.5). A diode 
laser with a wave-length of 830 nm was used with 70 mW at the sample (270 mW at 
source).  A dielectric coated edge filter is used to reject Rayleigh scattered photons, 
which have been found to have good long term stability.121  
 
A grating (300 lines/mm) was used to disperse the scattered light which was measured 
with a deep depletion charged couple device (CCD) detector. A peltier cooled deep 
depletion CCD was used. The spectral resolution of the probe spectrometer is 
approximately ~10cm-1. 
 
For mapping experiments, the sample is placed on an x-y translation stage which is co-
registered with spectral readout. The mapping system can work in three modes, as 
described previously in Section 2.5 – point, line and rapid (line) mapping. 
4.6.1 A preliminary study of rapid Raman mapping parameters 
To test the optimum objective lens for rapid Raman mapping a series of objectives were 
tested using a prototype rapid mapping system (785nm) at Renishaw Plc. The rapid 
Raman mapping system was only set up for use with a x50 objective. Two were 
available for use, the NPlan x50 and the Leica x50 long working distance objective. The 
Nplan objective is recommended by the manufacturer due to the higher throughput, but 
locally the Leica x50 objective has been used for tissue classification models and 
mapping since the objective does not have a glass background. The thickness of the 
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mapping section was chosen to maximise Raman scattered photons from the tissue 
section (whilst not taking the section beyond 1-2 cells thick). This was based on work 
carried out previously in the group.108,121,123  
 
Raman spectra were acquired using both spectra to compare the signal to noise for each 
objective. An acquisition time of 5 s was used. Raman maps (of NSq and FCT) were 
acquired using both objectives as a further comparison. The Nplan x50 objective  map 
was acquired with an acquisition time of 5 s, step size of 27.5 µm step size, and Leica 
x50 long working distance map was acquired with a 5 s acquisition time and step size of 
11 µm. The area of the 11 µm map was cropped to the same mapped area as the 27.5 µm 
map. Spectra were not normalised or mean centred in this case. It was decided that 
intensity variations may be relevant to pathology for mapping studies. The latter is also 
important for mapping studies containing large areas of CaF2 since this will dominate 
the mean spectrum.   
 
A 1200 lines/mm grating was available which provides improved spectral resolution 
over a shorter wavenumber range. This was tested by running a trial map a step size of 
6.6 µm and acquisition time of 30 s. The map dimensions were 141x111 spectra 
resulting in a total of 15651 spectra.  
4.6.2 Comparison or rapid Raman mapping with point mapping and line 
focus mapping 
Rapid Raman mapping as described in Section 2.5 utilises spatial separation of the CCD 
to achieve increased lateral spatial resolution. In theory, there should be no difference in 
signal to noise for different step size settings, since each spectrum is effectively made up 
of accumulations of the entire laser length. However, it was noticed that there was a 
slight reduction in signal to noise with decreasing step size. Although not significant, it 
was necessary to investigate this since it may be necessary to increase acquisition time 
for small step size maps to counter act the reduction in signal to noise ratio.  
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To evaluate this, repeated rapid Raman maps (line maps were used to reduce dataset 
sizes) were carried out on both Si and tissue with a constant acquisition time of 0.1 s and 
40 s respectively, with the step size varying from 52.8-1.1 µm.  
 
Mean map spectra were compared, along with individual spectra from the same position 
in the map. The signal to noise ratio (at 1000 cm-1) was determined, along with the 
signal to baseline ratio (at 1000 cm-1 and 1450 cm-1).  
4.6.3 Principal component analysis in combination with rapid Raman 
mapping for potential automated histopathology 
In this study, two samples from two different patients have been mapped. Due to the 
heterogeneous nature of the samples the pathologist annotated each sample with the 
various pathologies according to the list defined in Section 4.2. 
 
In the following experiments, the SNR was monitored for a range of maps methodically 
acquired with various combinations of acquisition time and spatial resolution parameters 
(step size). This study presents the results of this investigation and demonstrates that 
total mapping time for oesophageal biopsies can potentially be reduced to a clinically 
practicable timescale 
 
Repeated maps were carried out on tissue sections, methodically varying the spectral 
acquisition time and step size. There are several variables to take into consideration – for 
a constant area map, a higher resolution map (i.e. smaller step size) results in a larger 
number of spectra compared to a lower resolution map (i.e. larger step size) of the same 
area. The total number of spectra is an important consideration since the size of the 
dataset has an impact on the reliability of any multivariate analysis used. However, for a 
lower spatial resolution map the total number of spectra is reduced, thus the acquisition 
time can be increased to obtain higher quality spectra in the same overall time scale. The 
quality of the spectral dataset is also an important factor when attempting to identify 
subtle biochemical changes using multivariate techniques.  
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Acquisition times ranged from 0.1-20 s. For each acquisition time, the step size was also 
varied between 7.4-25.3 µm. The mapping parameters are summarised in Table 6-3. The 
total mapping time was limited to a maximum of 24 h since longer maps were not 
practicable. The total number of spectra in each map varied between 0.9x104 and 
10x104. The approximate mapping time using standard point mapping was calculated 
based on a CCD readout and XY translation delay of 1.65 s per spectra (1.2 s reported 
by Schlucker et al.180). This value was determined by running a map (traditional point 
map mode) with an acquisition time of 0.1 s, step size of 6 µm and calculating the delay 
according to actual map time minus the best case scenario map time (i.e. number of 
spectra multiplied by the acquisition time) and dividing this by the total number of 
spectra in the map. To account for the difference in Raman signal intensity for the rapid 
Raman spectra compared to point mapping (which varies with step size, in a similar 
manner to line mapping), the acquisition time used in the estimate of the overall point 
mapping time was scaled by a factor equal to the step-size divided by the length of the 
laser line. Including this scaling factor ensured that the advantage of rapid Raman 
mapping was not overestimated. 
 
Work has also been carried out elsewhere by Sasic et al., to investigate the effects of 
reducing the acquisition time (from 30 s to 3 s) with Raman mapping of pharmaceutical 
beads analysed using principal component analysis.145 In this and a previous study,146 
Sasic et al., used the relative standard deviation (RSD) to compare maps with varying 
degrees of noise within the raw spectra, but the effect of varying the size of the dataset 
was not considered. Since the performance of multivariate techniques improves with 
increased dataset size, the number of spectra within a map is an important variable to 
consider and this is the first paper to investigate the effects of this with Raman mapping.  
Krafft et al. also demonstrated that PCA could be used to evaluate low SNR data 
acquired from mapping single cells.181 However, the focus of this study was on the 
recovery of biochemical information rather than the implications of reducing the total 
mapping time. To date, little work has been carried out to investigate the effect of 
reducing the total mapping time on the data obtained from biological tissue samples. 
Many of these studies have used mathematically modelled noise rather than actual 
data.144,145  
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It is well known that larger datasets improve the performance of multivariate techniques. 
Subsequently it was hypothesised that sufficient diagnostic information, for screening 
out non-relevant samples, could be extracted from low SNR spectra providing that the 
dataset was sufficiently large. An initial trial experiment was carried out on a sample 
containing normal squamous epithelium to demonstrate feasibility, and results can be 
seen in Appendix C.  
 
Signal to noise (SNR) measurements were carried out on spectra measured on a 
relatively homogeneous tissue sample containing connective tissue and smooth muscle 
as diagnosed by an expert pathologist Figure 6-10. Further SNR and relative standard 
deviation (RSD) measurements were made using a sample containing circumferential 
normal squamous epithelium. To determine the optimum mapping parameters, the step 
size (and thus total number of spectra) was varied from 9.5-31.7 µm whilst optimizing 
the acquisition time to maintain a constant total mapping time of 4.5 h (Table 6-4). 
 
Data analysis was carried out using Matlab and the PLS toolbox (Eigenvector 
Technologies, Manson, Washing-ton, USA). Saturated spectra and cosmic rays were re-
moved by replacement with the nearest neighbour. Principal components (PCs) were 
calculated and pseudocolour PC score maps were generated. Any remaining cosmic rays 
appearing in the score maps were blanked out and the PCs recalculated so as not to 
distort the loads. The relative standard deviation (RSD) (the ratio between the standard 
deviation and the mean at a given peak position177) measured at the 1000cm-1 
phenylalanine peak, expressed as a percentage, was used as a measure of the SNR to 
enable comparison between the different maps. This technique was adopted since the 
SNR of the raw spectra was low making it difficult to determine accurately. The focus of 
the laser causes variation in the spectral intensity and SNR at the edge of the sample and 
in areas where the calcium fluoride substrate has been measured. To overcome this, a 
region 1/16th of the total map area was selected over the region of connective tissue for 
the RSD measurements. The area was kept constant for all maps to enable direct 
comparison. The RSD calculations were performed on normalised data to give an 
indication of SNR variation only. Spectra with saturations and cosmic rays were not 
 - 74 - 
included in the RSD calculations. Although not directly attributable to the acquired 
spectra, the ‘signal to noise ratio’ (‘SNR’) of the principal component loads was also 
calculated at the 932 cm-1 peak (the strongest peak in the 5th PC load) to provide a 
relative comparison between the loadings for the different mapping parameters. This 
was done for the fifth principal component only. The fifth PC was chosen since the 
psuedocolour score map provided good correlation with the morphology of the H&E 
sections which was underpinned by good correlation biochemically with the PC load. 
 
This is the first study reporting rapid Raman mapping of biological tissue. Raman maps 
containing larger numbers of spectra (100,000+ spectra) of biological tissue are 
presented. There is only one paper in the literature reporting Raman mapping of 
oesophageal tissue,123 in which maps contained approximately 2000 spectra (see 
Appendix D for an examples), therefore, this study presents a significant improvement 
over map size and image quality (total number of spectra and spatial resolution) due to 
an increase in the size of the spectral dataset.  The effect of varying mapping parameters 
and the subsequent effect on the PCA is also shown, in particular the consequences of 
reducing the signal to noise ratio for such large datasets is investigated. This is also the 
first study to demonstrate that Raman mapping times for biopsies has reduced 
sufficiently to enable the technique to be used as a histological screening tool. 
4.6.4 Raman mapping and linear discriminant analysis to evaluate the 
importance of lateral spatial resolution for histology diagnosis  
As described previously, fresh tissue samples were immediately snap-frozen in liquid 
nitrogen and stored in a -80°C freezer until measurements were carried out. For each 
sample, a 15 µm frozen section was cut onto a CaF2 substrate for Raman spectral 
mapping, as previously described. A contiguous 7 µm section was obtained and stained 
with H&E for diagnosis by an expert gastrointestinal registry pathologist. Regions of 
connective tissue (smooth muscle (SM) and fibrous connective tissue (FCT)), normal 
squamous (NSq), Barrett’s (BO), low grade dysplasia (LGD), high grade dysplasia 
(HGD) and adenocarcinoma (Ad) were identified. Biopsy samples are typically 1-2 mm 
in diameter.  
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Mapped samples were also stained with H&E following Raman mapping to enable 
better correlation with morphological features. The diagnosis was verified on the 
mapped section H&E (on CaF2) by a second histopathologist. Two samples from two 
different patients have been mapped in this study.  
  
Raman maps were acquired using a customised Renishaw Raman System 1000 
spectrometer with StreamLine technology described previously in Section 2.5.3. 
 
An initial rapid pre-scan was carried out using a crude step size (26.4 µm) and short 
acquisition time (0.5 s). This allowed general morphological features to be visualised so 
that a region of interest could be identified. Further maps were acquired with step size of 
8.4, 4.2 and 2.1 µm with a 15 s acquisition time (to achieve spectra with good signal to 
noise ratio). It was decided that it was optimum to generate the tissue classification 
model using good quality spectra, with the prospect of reducing the acquisition times in 
the future based on results from the previous chapter.  
 
Cosmic rays and saturated spectra were removed, followed by PCA. However, in the 
case of these maps, data was normalised and mean centred since the PC components 
would be used to generate an LDA model. Raman maps are not normally normalised and 
mean centred since this makes identifying changes due to tissue thickness difficult to 
identify. Also, normalisation including CaF2 can bias the mean, especially if large areas 
of the substrate are mapped. However, since the spectra were to be later used in an LDA 
model (described below), of which CaF2 would be included as a group in the model this 
was deemed the best pre-processing protocol.  
 
Pseudocolour PC score maps were then generated as described previously. However, a 
novel method of displaying the PCs images was developed to assist with identifying 
different regions of pathology. The pixels of the Raman map were colour coded with the 
upper and lower extremes of the PC scores and those pixels falling into the central range 
of the scores were left transparent to enable the images to be overlaid. This represented 
the pixels/spectra with the most significant contributions from the positive and negative 
aspects of the PC loads, respectively. The corresponding PC loads were colour coded 
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accordingly to enable correlation of biochemical constituents from peaks within the PC 
loads with morphological information from the pseudocolour PC score image.  
 
Bhargava stated that “the effect of limited spatial resolution on data classification 
[FTIR] in not entirely clear.”150 In this study, Bhargava investigated the effect of low 
spatial resolutions (nominal step size). This study looks at the converse of this and 
investigates the effect of high spatial resolution on classification models, the effects of 
which are also unclear. This was not feasible for FTIR data, highlighting the advantage 
of Raman spectroscopic mapping.  
 
To compare the different step size maps, PC fed LDA was carried out (using the first 10 
PCs). Spectra were selected using the threshold process described above which 
highlights regions of pathology. Spectra were classified as either calcium fluoride 
(CaF2), tissue border (TB),* high grade dysplasia (HGD), fibrous connective tissue 
(FCT) and luminescence (Lum). Spectra which ambiguously belonged to more than one 
group (either due to the fact that there are not distinct boundaries or the spectra found to 
have overlapping PC load contributions) were classed as ‘unknown’.  
 
Two PC fed LDA models were generated for each map. The first with the unknown 
group included as a separate group to investigate misclassifications within the LDA. For 
the second model, the unknown group was excluded from the model and subsequently 
projected onto the classification model as an independent test data set.   
 
To further test the tissue classification model, the number of spectra in the training 
dataset was refined with a stricter tolerance level on the threshold level which was used 
to select the spectra. A region of unknown spectra (i.e. test dataset) was also defined at 
the boundary of different tissue types.  
 
                                                 
*
 The idea of classifying pixels as border pixels was also used by Bhargava et al. in which they were 
referred to as boundary pixels and reported as a cause of misclassification.150 
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This was taken one step further by selecting small and well defined regions of each 
tissue pathology (and CaF2), with the remainder of the map projected onto the model as 
an independent test set.  
 
As an extension of this, two samples were stitched together to add further tissue 
pathologies and to test the classification between different samples. Small well defined 
regions of pathology were identified in the map using the threshold procedure. The 
remainder of the map spectra were used as an independent test dataset.  
 
4.6.5 Rapid Raman mapping as a research tool to elucidate biochemical 
changes associated with carcinogenesis 
Previous studies of rapid Raman mapping have investigated the limitations of the system 
with respect to clinical implementation of the technique. A further, additional benefit of 
the technique is the application of rapid Raman mapping to investigate subtle 
biochemical changes occurring in tissue which will help to support clinical 
implementation and help us to understand carcinogenesis processes.  
 
Oesophageal tissue sections were prepared as described previously. Rapid Raman maps 
were acquired of two samples containing Barrett’s mucosa. The first was acquired with 
an acquisition time of 60 s and step size of 1.1 µm and the second mapped with an 
acquisition time of 40 s and step size of 3.2 µm.  
 
PCA was carried out on the samples. The larger maps were cropped to focus on regions 
containing only Barrett’s glands to remove variance associated with other pathology 
types present in the sample. Peak assignments of the PC loads were carried out to 
investigate biochemical constituents.  
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4.7 Methods – 3) Factors limiting translation of Raman spectroscopy 
to the clinical environment 
4.7.1 Comparison of the Raman probe spectra and Raman microscopy 
spectra  
Previous work has been based on Raman microscopy systems ex vivo. To compare the 
two systems, Raman spectra from two cancer samples were measured using both the 
Visionex probe (4x15 s acquisition time) and the Raman System 1000 
microspectrometer (4x15 s acquisition time) with the x50 Leica long working distance 
objective.  
 
Spectra were normalised and plotted to enable comparison of the background and 
Raman peaks.  
 
4.7.2 Practical considerations 
Clinical implementation of Raman spectroscopy for histological diagnosis will require 
large scale clinical studies to validate methods and to develop large spectral libraries.   
In order to achieve this, optimum parameters must be determined to maximise collected 
data for both accuracy of diagnosis and widespread population and pathology 
representation.  
 
Highly accurate models are clearly fundamental. In a perfect situation, classification 
models will be infinitely large and comprising of high quality spectra. In a practical 
sense this is not possible and as with all medical techniques there are trade offs. 
Considering Raman probe applications for targeted biopsy and Raman mapping for 
automated histopathology, it is evident that this trade of is spectral quality vs. spectral 
quantity.  
4.7.2.1 Ambient light sources 
A range of ambient light sources were tested for peaks within the Raman spectral 
fingerprint region. This was in part rule out spectral contamination sources for 
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laboratory experiments (tissue classification models etc.) and also for prospective 
clinical implementation in a theatre environment.  Confounding factors are presented 
with recommendations for practical implementation both experimentally and in a 
clinical environment. 
4.7.2.2 The effect of ambient temperature Raman spectrometers 
The Visionex probe and microspectrometer have been described previously in Sections 
4.5 and 4.6.  
 
As described previously, the silicon peak (Si) is used to perform a wavenumber 
calibration. If the peak was not positioned correctly, an offset correction was applied. 
The system was switched on and allowed to stand for at least 30 minutes before 
measurements were carried out. This was to allow the system to stabilize since problems 
with Si peak position drift were encountered within this time.  
 
To investigate the effect of ambient temperature on peak position, the air conditioning 
unit setting was altered in 2ºC intervals ranging from 19 to 31ºC (the actual room 
temperature was also measured). Polymer spectra were acquired using two Renishaw 
System 1000 spectrometers (830 nm, 5 s, x50 objective) and a Visionex probe system in 
combination with a Renishaw System 100 spectrometer (830 nm, 30 s). Spectra were 
also acquired from a neon argon lamp (1 s). At each air-conditioner setting, the systems 
were allowed to reach temperature equilibrium for 2 hours. Peak positions were plotted 
against actual room temperature.  
 
A Raman map of the polymer standard was also acquired whilst ramping the 
temperature up from 19-28ºC using S1000 (1). A 2 mm square was mapped with a step 
size of 2 µm, with acquisition time of 2 s.   
 
4.7.2.3 Reproducibility and transferability 
One of the key areas currently limiting clinical implementation of Raman spectroscopy 
is reproducibility and transferability. Comparison of spectra between systems will be 
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vital for generating large tissue classification models in the future. These areas are 
investigated and potential methods for comparing systems suggested.  
 
4.7.3 The combination of chemometric analysis and Raman spectroscopy 
for pathology diagnosis – data quality versus data quantity 
To investigate this, the classification performance of different models was assessed from 
a perspective of practical clinical implementation, with the aim of determining optimum 
parameters for future clinical implementation studies. The number of pathology groups 
included, dataset size and spectral quality were considered. The overall experimental 
time and analysis time was also considered. 
4.7.3.1 Determining optimum parameters for large scale clinical trials 
The final step before clinical implementation is large scale clinical trials to validate 
techniques. Considering both the Raman probe and also Raman mapping, pitfalls are 
discussed and recommendations made for robust protocols.   
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Chapter 5 Results and discussion: 1) Evaluating 
Raman probes for potential in vivo optical 
biopsy 
5.1 Raman probe background signal 
The background subtraction process can successfully remove the large background, 
although as mentioned previously, the consistency of this method still requires further 
validation. A further area of concern is the broad spectral artefacts in the regions 600-
750 cm-1, 750-900 cm-1 and 1150-1230 cm-1, marked by an asterisk in Figure 5-1. The 
latter has also been identified in other studies using the Visionex probe and attributed to 
silica,56 although, the lower wavenumber region was not included in this study, the peak 
in the 750-900 cm-1  region is shown in one figure, although not mentioned in the paper 
itself. However, it is referenced one of the later papers.141 From measurements obtained 
in this group, it is believed the background signal may also be attributable to system 
alignment since the probe background has been seen to vary after realignment.  Further 
work is needed to investigate the sources of the background signal.  
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Figure 5-1: Mean spectrum (96 spectra acquired using the Visionex probe 4x15 s acquisition 
time) illustrating silica peaks marked with * 
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5.1.1 Background subtraction using iterative subtraction of fifth order 
polynomial  
An example of three mean spectra (taken from the preliminary three group Visionex 
probe model) can be seen in Figure 5-2. The mean background subtracted spectra 
(subtraction of a 5th order polynomial)199 in each of the three classification groups 
(normal, Barrett’s and neoplasia) are shown in Figure 5-3. From the background 
subtracted spectra, it can be seen that more spectral peaks are evident. However, peak 
assignment with these spectra should be treated with caution due to silica spectral 
contributions and possible artefacts resulting from the background subtraction process.  
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Figure 5-2: Mean spectra from Visionex probe - Green (normal squamous), blue (Barrett’s) 
and red (neoplasia) 
Considering peaks common to each tissue groups at 1660 cm-1 (amide I), 1140 cm-1 
(CH2 and CH3 deformation), 1172cm-1 (C-N stretch, protein, hydroxyproline).  
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Figure 5-3: Mean spectra Visionex probe (background subtracted) for normal (green), 
Barrett’s (blue) and neoplasia (red) 
It is evident that the background subtraction process removes variation at the lower 
wavenumber regions and broad spectral background peaks are evident in the regions 
1150-1230 cm-1 and 750-900 cm-1, previously attributed to silica in accordance with 
literature. This reduction in the variance at lower wavenumbers using background 
subtraction is also evident in the mean centred spectra (see following sections). 
However, it remains unknown as to whether or not removing this variance is correct or 
even beneficial.  
 
Although it is useful to note that there is spectral information superimposed on the peak 
in the region 1150-1230 cm-1, other spectral peaks in this region could also be attributed 
to collagen/glycogen (shoulder at 1130 cm-1), tyrosine from protein, collagen 
(hydroxyproline)(1175 cm-1 and 1201 cm-1). This suggests that there is an increased 
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amount of glycogen in normal tissue, as expected, since glycogen is the cellular energy 
store which is used up in rapidly proliferating cells.5  
 
Peaks can also be identified in the amide I region (1653-1658 cm-1), CH2, CH3 
deformation (1446-1455 cm-1) and phenylalanine (1005 cm-1). Although, due to 
uncertainty regarding the background subtraction process it is difficult to draw any real 
conclusions from these peaks at this stage and more work is required in this area 
  
The peak at 493 cm-1 is tentatively attributed to glycogen, which appears to be narrower 
and shifted to the lower wavenumber range compared to Barrett’s and neoplastic mean 
spectra. However, background peaks have been noticed in this region when measuring 
thin tissue biopsy samples, which is potentially due to the substrate (CaF2). Although 
unlikely since the tissue samples are bulk tissue samples, 5-8 mm thick, without 
knowing the sampling volume (reported to be of the order of 500 µm in the literature155) 
some substrate contribution is possible since the optical properties of the tissue may vary 
with pathology for example considering the dense nature of tumour tissues, which 
potentially could be more optically opaque than normal epithelium. Potential 
contributions should not be disregarded since the investigation of the optical properties 
of tissue pathology is an active area of research in itself. To investigate the effects of 
sampling depth further, the depth profile of two different Raman probes were measured 
since sampling volume, based on the above mentioned details was considered an 
important parameter.  The results of this are discussed below.   
5.2 Comparison of Raman probes 
The first comparison of the Raman probes was their signal collection efficiency. Firstly, 
the power at the laser source, which was measured as 320 mW, was compared to the 
power measured at the probe tip. The power at the probe tips was measured to be 50 
mW and 25 mW for the Visionex and the Emvision probes respectively. The throughput 
of the excitation fibre for the Emvision probe was approximately half that of the 
Visionex probe. This agreed with previous measurements using an alternative 
connection fibre (to link the laser and excitation fibre for the probe), the power at the 
 - 85 - 
probe tip was found to be 22 mW and 9 mW for the Visionex and Emvision probes 
respectively. In both cases there are considerable losses, although this is expected when 
working with fibre optics. This poor throughput for the Emvision probe is attributed to 
the fact the probe system alignment is optimised for the Visionex probe.  
 
Throughput of collection fibres is more important for collection efficiency 
considerations. The collection efficiency of the two probes was calculated using the 
height of the diamond peak with respect to the baseline and found to be 
3.4x104counts/mW/s for both the Visionex and Emvision respectively. Therefore the 
probes have equal collection efficiency, but the Visionex returns higher single due to 
higher illumination powers with the current set up. There is scope for improving 
throughput as technology relating to fibre connections, and fibre optics is constantly 
improving.  
 
A key further consideration for Raman probe designs is sampling volume, as discussed 
previously. To recap, since precancerous changes occur in the epithelial layer, it was 
concluded that the sampling volume should not exceed 100-200 µm in depth to prevent 
significant spectral mixing with underlying stromal tissue. To briefly investigate the 
sampling depth, a study was carried out in which a diamond chip was placed at the 
bottom of a beaker of water. Spectra were acquired (1s) at 50 µm intervals. The resultant 
spectra for the Visionex and the Emvision probe can be seen in Figure 5-4. 
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Figure 5-4: Series of depth profile spectra of diamond in water using left: Visionex probe and 
right: Emvision A probe (first Emvision prototype probe) 
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It can be seen that there is a variation in signal intensity, and also background between 
the probes. This was in part accountable by the power output at the probe tip (discussed 
above. To enable better comparison, the ratio of the peak height (at the maximum signal 
intensity at the probe tip, i.e. 0 µm) was plotted against distance from the probe tip (in 
microns), as shown in Figure 5-5. The distance from the probe tips at which the intensity 
is reduced to half the initial intensity were found to be 150 µm and 280 µm in air for the 
Visionex and Emvision probes respectively. In water the half intensity depths were 
found to be 90 µm and 305 µm respectively.  
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Figure 5-5: The ratio of the peak maximum (at the 1332 cm-1 diamond peak) with the peak 
maximum at 0 µm distance from the Visionex probe in left) air and right) water. 
The results agree with the expected profile based on the delivery and excitation volumes 
described in Figure 2-8, since the signal intensity rapidly falls off with the Visionex 
probe compared to the Emvision probe. Also, considering the Emvision probe, the ratio 
rises above 1 at 50 µm from the probe tip indicating that the intensity at this point is 
slightly greater than that at the probe tip (i.e. 0 µm). This is also expected since, 
considering the collection and delivery fibres shown in Figure 2-8, there is a region for 
which, on the central axis, there is a volume for which there is no overlap between the 
collection and excitation regions. This is less so in the Visionex probe and not evident in 
the depth profile. The refractive index of water will affect the beam steering, which is 
the likely cause of why the beam steering is more affected).  
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This could also be due to issues with the experimental setup since Raman spectra from 
crystal lattices are known to be dependent on the angle of interface and since diamond 
was used as the Raman scatterer, this may account for the variation in intensity with 
distance from the diamond. The position of the diamond was kept constant for both 
experiments to minimise effects, but this cannot be ruled out. This potential void in the 
sampling volume may be significant for detecting precancerous changes in surface 
epithelial layers, so it was concluded that further work would need to be done in the 
future to investigate the sampling volume in more detail. One potential method of 
overcoming this problem was to introduce an offset to the Emvision probe tip. This 
offset would need to be reproducible, for example a physical barrier e.g. on the probe tip 
to create an air gap. Another option is to use calcium fluoride or quartz, substances 
which are commonly used as Raman substrates. However, in the latter case, work would 
need to be carried out to investigate the effects at refractive index boundaries, and also 
to investigate the optimum offset since to determine the thickness of the offset window, 
depth profiles would need to be measured using the offset material as a test medium. 
Offset windows are also likely increase background signals.166   
 
There are some other minor issues with the design of this experiment, including the fact 
that water does not mimic the scattering properties of tissue. Also, it was difficult to 
ensure that the diamond was on axis, especially at depth. It was decided that maximising 
the signal at each depth by adjusting the position of the diamond laterally was not 
feasible since that assumed maximum intensity was on the central axis. Lateral profiles 
would be required to confirm this.  Also, the depth profile appeared to vary with 
medium, as expected, since neither had the same scattering and attenuation properties of 
tissue quantification of the sampling volume and depth would have been fruitless. 
Generating a suitable scattering phantom with the same scattering and attenuation 
coefficients as tissue was not a trivial study in itself.  
 
Due to the number of points raised in this study it was concluded that significant work 
needed to be carried out on this area, which was beyond the scope of this thesis. As a 
result an MSc student took on the project to investigate these issues in more detail and 
investigations are ongoing.  
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As a simple test, the diamond chip was measured through an EMR sample which was 
estimated to be 4-5 mm thick. The diamond peak could be detected with both probes 
with an acquisition time of only 1s. Although diamond is an extremely strong Raman 
scatterer, and Raman signals from tissue constituents are not of the same magnitude, this 
demonstrates that Raman signals can potentially be detected at depth which will have 
implications for spectral mixing.  
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Figure 5-6: diamond chip measured through an oesophageal EMR (1 s acquisition) 
As discussed above, the sampling depth of the Emvision probe is greater than the 
Visionex probe. However, it has been found in a study by our group (results not 
published), supported by other reports in the literature,200,201 that there is a biochemical 
difference between stroma from normal and diseased regions.  
 
Based on this there is also an argument for using Raman probes with a larger penetration 
depth in combination with probes with a smaller sampling depth, but for tissue 
classification in both cases it is important to know which depths of spectral contributions 
so that spectral mixing can be accounted for. 
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5.2.1 A comparison of probes using calibration standards  
Calibration standards measured with the Visionex and Emvision probe illustrate that the 
background broad spectral peaks may not necessarily be attributable to silica since the 
spectral peaks are in different positions. They appear to be the effect of a broad 
luminescence background that is transmitted through the filters.  
 
However, this does imply that green glass correction may be a potential method of 
background subtraction since the background peaks may be specific to the broad probe 
background shape. A correction is made for the energy sensitivity throughput of the 
system using mean luminescence spectra measured from a green glass calibration 
standard measured at each spectrometer configuration.  The results of this are discussed 
in Section 5.5.3.  
 
Figure 5-7: Green glass calibration spectra for the Visionex and Emvision probe (Renishaw 
system 100 spectrometer), measured in contact, with a 1 s acquisition time. 
 
600 800 1000 1200 1400 1600 1800
0.01
0.015
0.02
0.025
0.03
0.035
0.04
green glass - 5seconds acquisition
in
te
n
si
ty
 
(a.
u
)
wavenumber (cm-1)
Visionex
Probe A
 - 90 - 
5.3 Preliminary three group Visionex model  
5.3.1 Preliminary three group Visionex model with background 
subtraction   
No differences were noted between fresh and frozen samples as found by previous 
studies within the group.108,121 Background subtracted spectra acquired from the 
oesophageal samples with the Visionex probe were used to generate a PC (15PCs) fed 
LDA model. The LDA model was trained using the pathology diagnosis from each 
sample (which could be correlated to each individual spectrum). Samples were separated 
into three different pathology groups, defined as NSq, Barrett’s (including IM, fundic 
and cardiac Barrett’s) and neoplasia (which includes LGD, HGD, adenocarcinoma and 
SCC). Figure 5-8 shows the scatter plot of the linear discriminant (LD) scores, with the 
normal, Barrett’s and neoplasia represented by green, blue and red respectively. 
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Figure 5-8: Left) Scatter plot of LD1 vs. LD2 for the three group training (normal – green, 
Barrett’s – blue, neoplasia – red) right) Plot showing the percentage classified in each of the 3 
groups 
Separation can be seen between the three groups visually, although there is some 
overlap. This can probably be attributed to the fact that the sample numbers are small 
and the spectral differences are subtle due to the large probe background.  The overall 
training performance of the classification model is illustrated in Figure 5-8. Reasonable 
correlation can be seen between the Raman prediction and the pathology opinion. The 
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overall training performance was 76%. Sensitivities were calculated in the range 70.0-
100.0% and specificity in the range 84.1-91.8%. 
 
In addition to the relatively poor Raman signal (compared to microscopy based Raman 
spectra which were used to generate previous classification models), discrepancies can 
be attributed to the fact that there are not discrete steps in the progression to cancer and 
as a result, subtle changes between the spectra may cause spectra to be misclassified. 
Artefacts due to the background subtraction process may also cause problems.  
 
Furthermore, the pathology opinion, used to train the model is not a perfect ‘gold 
standard’ due to the difficulties in classifying samples based on morphology. Obtaining 
a consensus opinion will improve this. The number of spectra and % correctly classified 
is summarized in Table 5-1.  
 
Table 5-1: The number of spectra in each group and the percentage of spectra correctly 
classified for the preliminary three group PCA-LDA model with background subtraction 
 # spectra % correct 
Normal 11 (out of 11) 100.0 
Barrett’s 23 (out of 33) 70.0 
Neoplasia 39 (out of 52) 75.0 
Total  96  
 
It is evident that the number of spectra in each group is not balanced, with the number of 
normal spectra significantly lower than the Barrett’s and neoplasia groups. This is due to 
the fact that normal tissue samples are difficult to obtain (only available from patients 
undergoing the oesophagectomy procedure). It is also important to note that although 
these samples are defined as normal, they are harvested from normal regions of the 
oesophagus of patients who have advanced cancer in another region. For this reason, the 
normal results should be treated with caution since there may be subtle biochemical 
changes that are picked up in the spectra, but not in the histopathological diagnosis.  
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5.3.1.1 Interpretation of PC loads for the Visionex probe tissue classification 
model 
PC loads for the preliminary Visionex probe model (three groups) are shown in Figure 
5-9. 
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Figure 5-9: PC loads 1-6 for the preliminary Visionex probe (background subtracted) tissue 
classification model). 
The first PC load identifies the probe background. Further PCs identify biochemical 
constituents which enable the separation of the different pathology groups. General peak 
assignments indicate protein contributions (1005, 1453-1463, 1640 cm-1) and peaks at 
487, and 1089-1110 cm-1 which can tentatively be attributed to glycogen. The peak at 
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785 cm-1 could possibly be attributed to the strongest peak in the DNA fingerprint 
region.  
 
In general, peak assignments on the PC loads are difficult, especially for the probe 
spectra which are of poorer spectral resolution than Raman microscopy spectra.  
 
Of particular concern is the evidence of the probe background despite background 
subtraction. To investigate this further, the model was recalculated without background 
subtraction. 
5.3.1.2 Three group Visionex model – analysis without background subtraction 
The process was repeated without the background subtraction to check the effectiveness 
of the process. The overall training performance of the PCA-LDA model was 83.3% 
with sensitivity and specificity of 81.8-90.1% and 87.3-95.3% respectively. The results 
are summarised in Figure 5-10 and Table 5-2. 
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Figure 5-10:  left) Plot of LD1 vs. LD2 for the three group training model generated without 
background subtraction right) Performance of the classification model generated without 
background subtraction 
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Table 5-2: The number of spectra in each group and the percentage of spectra correctly 
classified for the preliminary three group PCA-LDA model without background subtraction 
 # spectra % correct 
Normal 10 (out of 11) 90.1 
Barrett’s 27 (out of 33) 81.8 
Neoplasia 43 (out of 52) 82.7 
Total 96  
 
An improved performance was demonstrated, which shows that the PCA-LDA process 
is sensitive enough to detect subtle biochemical changes despite the large fluorescence 
background, and perhaps is less of an issue than previously thought. These results also 
suggest that the process of background subtraction does not adequately remove 
background signal and accentuates silica peaks which could be potentially mistaken for 
spectral peaks relating to biochemistry. It is proposed that background subtraction 
should be not used for multivariate models without further validation. The benefit of the 
background subtraction, however, is that it clarifies the peaks used when determining the 
constituent components of the spectrum which further supports the model. The mean 
background subtracted spectra have been shown in Figure 5-3. However, if the 
background subtraction process is unreliable as suggested previously, the usefulness of 
this is in doubt.  Investigation of further techniques is required in this area.  
 
It is possible that the mean centring process acts to remove the background sufficiently 
since the background is actually contained within the mean spectrum. The plot of the 
mean centred spectra (Figure 5-11) highlights a possible problem at the low 
wavenumber region suggesting that the background is less consistent in this region.   
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Figure 5-11: Mean centred spectral data colour coded with pathology group 
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It is evident that there is significant variation at the lower wavenumber range (i.e. 450-
600 cm-1), likely to be caused by variation in the probe background. This indicated 
truncation to remove this region was potentially beneficial (as investigated in Section 
5.3.3. 
 
PC loads 1-6 can be seen in Figure 5-12 for comparison with the previously calculated 
model with background subtraction. In general, the background appears to be 
represented in PC load 1 and 2, with the remaining PC loads containing similar peak. 
 
Results suggest that background subtraction should not be used for PCA fed LDA tissue 
classification models, which is also supported by Shaver.187 Since an improved training 
performance was achieved without background subtraction, and it is advantageous to 
minimise data processing, especially if artefacts are introduced, it was decided that 
further models would be generated without background subtraction. To confirm this, 
model iterations were carried out varying the number of PCs used to train the model.  
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Figure 5-12: PC loads 1-6 for the three group preliminary Visionex probe model (without 
background subtraction) 
5.3.2 Assessment of the number of PCS for training model generation 
Figure 5-13 shows the overall accuracy for the preliminary probe tissue classification 
model trained with different numbers of PCs. The number of PC loads contributing to 
the model was increased from 3 to 30 and the model recalculated. This was repeated for 
both models with and without background subtraction. Similarly, the sensitivity and 
specificity ranges are also shown in Figure 5-14.  
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Figure 5-13: Overall accuracy of the three group preliminary Visionex PC-fed LDA model 
(trained with the pathology opinion from 1 pathologist) calculated for with (green) and 
without (blue) background subtraction 
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Figure 5-14: sensitivity range for the three group preliminary Visionex PCA-fed LDA model 
(trained with 1 pathologist opinion) – with background subtraction (green) and without 
background subtraction (blue) 
The overall training performance was generally higher without background subtraction. 
The sensitivity ranges were similar, whilst there was a slight improvement in specificity. 
This is a useful finding supported by Shaver who states that background subtraction of 
polynomials should be used with caution when used with multivariate analysis since the 
background subtraction routine can introduce large variance which can detract 
multivariate techniques from more subtle and real variance.187  
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5.3.2.1 Cross validation of the three group model 
Leave one spectrum (i.e. sample) out cross validation was carried out on the three group 
model generated without background subtraction. One spectrum was acquired from each 
sample, so leave one spectrum out is a reasonable test of the model. However, it must be 
remembered that more than one biopsy sample is harvested from each EMR, and 
furthermore, in some cases, more than one EMR is harvested from the patient, so leave 
one EMR out or leave one patient out would be a more rigorous test, and this will be 
carried out in the future once a consensus pathology opinion is obtained.   
 
The model performance dropped when leave one spectrum out cross validation was 
carried out, with only 70.0% of the spectra correctly classified compared to 83.3% 
previously. The main cause is limited sample numbers, in particular in the NSq group. 
Therefore further samples are required to validate the model. 
5.3.3 Trial model with the wavenumber truncation 
It is also noted that there is significant probe background below 800 cm-1 and reports in 
the literature140,155  suggest that this region should be excluded from the analysis. The 
model performance could potentially be improved by eliminating this region from the 
analysis, or possibly selecting regions of interest in the spectra. Since the only 
problematic region is below 600 cm-1 the spectra were truncated to this value. There was 
no improvement in training model performance, with an overall training performance of 
82.3% (based on 15PCs fed into the LDA model) with sensitivity and specificity of 
72.7-100% and 84.1-95.3% respectively.  The results are summarised below.  
 
Table 5-3: The number of spectra in each group and the percentage of spectra correctly 
classified for the preliminary three group PCA-LDA model without background subtraction 
and truncated to 600-1800cm-1 
 # spectra % correct 
Normal 11 (out of 11) 100.0 
Barrett’s 24 (out of 33) 72.7 
Neoplasia 44 (out of 52) 84.6 
Total 96  
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Figure 5-15: left) Scatter plot of LD1 vs LD2 and right) Performance for the three group 
training model generated without background subtraction and truncated to 600-1800 cm-1 
5.4 Visionex model (following CCD replacement) 
It is well known, as discussed previously that energy sensitivity correction is required to 
correct for CCD sensitivity across the wave number range of interest. In particular this is 
required to correct for alignment issues which alters the light collection path causing 
subtle variations in the energy sensitivity profile. It has also been touched upon that this 
will vary from system to system which introduces issues with transferability of data. The 
following applies within a system when the alignment is changed, for example following 
the replacements of a major component such as the CCD. The following results were 
acquired after a laboratory relocation and also CCD replacement on the Renishaw 
system RA100 spectrometer which is used in combination with the Visionex probe. 
Based on the calibration data (see Figure 5-24), it was possible to pinpoint the source of 
variation in the probe background to the CCD change and exclude the laboratory move 
as the source of the alignment change.  
 
In this model, a significant portion of the spectra were removed due to poor tissue 
staining and therefore uncertain pathology diagnosis, cosmic rays and also mixed 
pathology samples.  
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The initial model was generated including all samples to investigate the effects of mixed 
samples and cosmic rays on the model performance. The model performance was less 
than 70% with very poor sensitivity and specificity. Upon recalculation, with cosmic 
rays and mixed samples removed, model performance improved to 90.1% with 
sensitivity and specificity 89.5-94.4% and 92.9-100% respectively. This highlights the 
importance of filtering the training dataset before model generation.   
 
There were still misclassifications, but upon further investigation, these were two Nsq 
samples which were classified as neoplasia. These two samples actually came from a 
larger sample which also contained adenocarcinoma (1 pathologist reported this as 
mucin, the second reported as query cancer – these spectra were excluded from the 
model since pathology was uncertain.). However, spectra from the NSq regions of this 
sample were included since a definitive diagnosis was given (by two expert 
pathologists). 
 
Table 5-4: The number of spectra in each group and the percentage of spectra correctly 
classified for the three group PCA-LDA model without background subtraction following 
CCD replacement/alignment 
 # spectra correctly classified  % correct 
Normal 17 (out of 19) 89.5 
Barrett’s 17 (out of 18) 94.4 
Neoplasia 46 (out of 51) 90.2 
Total 88  
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Figure 5-16: Three group probe training model generated using the Visionex probe after 
system realignment  
 - 101 - 
5.4.1 Cross validation 
The cross validation of the model resulted in an overall model performance of 86.4% 
with a sensitivity and specificity of 83.3-89.5% and 89.2-97.1% respectively. The scatter 
plot is shown below in Figure 5-17. This model was more robust, most likely to be due 
to the higher sample numbers in the NSq group.  
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Figure 5-17: Cross validated (leave one sample/spectrum out) for the three group Visionex 
probe training model generated with 15PCs 
5.5 Combined Visionex probe model (pre and post CCD 
replacement/realignment) 
5.5.1 Combining the datasets without processing to remove variation in 
background 
The combined dataset consisted of 184 spectra obtained from 184 biopsy samples from 
59 patients. A three group LDA model generated based on the histology diagnosis from 
one expert histopathologist (Prof. N. Shepherd). The three pathology groups were 
defined as Normal squamous, Low Risk (Barrett’s and Low Grade Dysplasia (LGD)) 
and High Risk (High Grade Dysplasia (HGD) and cancer). The results can be seen in 
Figure 5-18 and summarised in Table 5-5. The overall performance of the classification 
model was 72% with a sensitivity and specificity of 78.4-83.3% and 83.5-96.1% 
respectively. The majority of misclassifications were between LGD and HGD in the 
Low risk and High risk groups.  
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Figure 5-18: LDA classification model trained using the pathology opinion of 1 expert 
pathologist for the combined (pre and post alignment) Visionex probe 
Table 5-5: The number of spectra in each group and the percentage of spectra correctly 
classified for the combined (pre and post alignment) three group PCA-LDA model without 
background subtraction  
 # spectra correctly classified  % correct 
Normal 25 (out of 30) 83.3 
Barrett’s 40 (out of 51) 78.4 
Neoplasia 82 (out of 103) 79.6 
Total 184  
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Figure 5-19:left) Mean centred spectra for the combined dataset without pre-processing to 
remove probe backgrounds (colour coded for pathology group (NSq – green, Barrett’s – blue 
and neoplasia – red), right) mean spectra for each group background subtracted  
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5.5.2 Removal of probe background variation using PCs to independently 
reconstruct the datasets 
A further option is the removal of the PCs relevant to the CCD background by 
performing PCA on the separate models, identifying the relevant PC, removing this PC 
and reconstructing the dataset from the PC scores and PC loads. The two different 
datasets, could in theory then be recombined and PCA re-run in the absence of the 
background PCs.  
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Figure 5-20: Three  group Visionex tissue training classification model generated using data 
combined from before and after CCD replacement, with the background PCs removed  
Table 5-6: The number of spectra in each group and the percentage of spectra correctly 
classified for the preliminary three group combined (pre and post alignment) PCA-LDA 
model with the background PCs removed 
 # spectra correctly classified  % correct 
Normal 25 (out of 30) 83.3 
Barrett’s 34 (out of 51) 66.7 
Neoplasia 76 (out of 103) 73.8 
Total 184  
 
The model performance was 73.4% with a sensitivity and specificity of 67.6-83.3% and 
83.5-90.9% respectively. 
 - 104 - 
400 600 800 1000 1200 1400 1600 1800
-3
-2
-1
0
1
2
3
4
x 10
-3
Raman shif t (cm-1)
In
te
n
si
ty
 
(a.
u
)
Neo
BO
NSq
 
Figure 5-21: Mean centred spectra for the combined dataset reconstructed without 
background PCS (NSq – green, Barrett’s – blue and neoplasia – red) 
5.5.3 Removal of the probe backgrounds using energy sensitivity 
correction 
As discussed previously, green glass calibration data had not been acquired routinely, 
however after analysis of all of the green glass calibration data acquired over the three 
years, it was evident that there was very little change from month to month and two 
distinct groups were clearly visible correlating with alignment variation which coincided 
with the CCD change.  It was deemed sufficient to average the green glass correction 
files for both before and after the CCD change and use a generic correction file to 
correct each separate batch of spectra.  
 
 - 105 - 
400 600 800 1000 1200 1400 1600 1800
0.01
0.015
0.02
0.025
0.03
0.035
Raman shift (cm-1)
in
te
n
si
ty
 
(a.
u)
 
 
pre CCD change
post CCD change (realigned)
 
Figure 5-22: green glass calibration spectra (normalised) before and after system alignment 
problems following replacement CCD 
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Figure 5-23: white light correction function (ratio of white light energy sensitivity function 
and the green glass calibration mean spectrum)  
Figure 5-24 shows the two different datasets corrected using the green glass calibration 
mean spectrum. Although, general background is corrected, ripples are still evident and 
furthermore, there is still an obvious split in the dataset at approximately 900cm-1.  
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Figure 5-24: Green glass correction of the probes datasets before and after realignment 
following CCD replacement  
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Figure 5-25: Three group PCA fed LDA scatter plot for the green glass corrected training 
model (pre and post alignment following CCD replacement)  
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5.6 Short acquisition (4 s) Visionex probe model 
The Visionex model was re-generated with consensus pathology from 3 expert 
histopathologists (110 samples in total). Figure 5-26 shows the scatter plot and bar graph 
indicating the number of classifications and misclassifications. Model performance 
improved with consensus pathology opinion to train the model with an overall 
performance of 82%. The sensitivity and specificity were 77-86% and 87-95% 
respectively. The number of correctly classified samples is summarised in Table 5-7. 
 
Figure 5-26: LDA tissue classification training model for the Visionex probe (4 s) 
Table 5-7: Tissue classification training model for the Visionex probe (4 s) 
  # samples correctly classified % correctly classified 
NSq 24 (out of 28) 86% 
Barrett’s 31 (out of 40)  78% 
Neoplasia 35 (out of 42 ) 83% 
Total 110  
 
5.7 Single output fibre probe tissue classification model 
Comparing the collection efficiency by measuring the silicon standard peak at 520 cm-1 
the single-fibre probe performed better than the multi-fibre Visionex probe (163 
counts/mW/s and 74 counts/mW/s respectively). 
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The results from the novel single output fibre probe are also promising. The 4x15 s 
classification model (trained with consensus pathology) was able to discriminate normal, 
low risk and high risk with an overall performance of 90% with a sensitivity and 
specificity of 85-100% and 95-100% respectively.  
 
 
Figure 5-27: Classification model for the single output fibre probe (4x15 s) 
Table 5-8: Tissue classification model for the single output fibre probe (4x15 s)  
  # samples correctly classified  % correctly classified 
NSq 11 (out of 13) 85 
Barrett’s 7 (out of 8) 88 
Neoplasia 9 (out of 9) 100 
Total 30  
 
Model performance of the single probe indicate that it is comparable with the multi-fibre 
Visionex probe, although sample numbers are very low, this produces an indication of 
similar future performance compared to the Visionex probe. 
 
The results from the 4 s model were also promising with an overall model performance 
of 86% with a sensitivity and specificity of 86-88% and 88-100% respectively. Four 
seconds was chosen since optical components had not been optimised and it was thought 
to be possible to increase throughput by a factor of 4 leading to a potential sampling 
time of 1 s in the future. A comparison of raw and background subtracted tissue spectra 
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is shown below illustrating a reduction in background artefacts with the single fibre 
probe compared to the multi-fibre Visionex probe. The large background from the multi-
fibre Visionex probe dominates the spectrum, whilst for the single fibre probe more 
tissue spectral peaks are evident. Comparing the silicon standard peak at 520 cm-1 the 
single-fibre probe performed better than the multi-fibre Visionex probe (163 
counts/mW/s and 74 counts/mW/s respectively). This may be attributed to the beam 
steering since there is no penetration of 830 nm light in Si.  
 
Figure 5-28: Comparison between Visionex probe spectra and single output fibre probe 
spectra acquired with an acquisition time shown in brackets. The top spectra are raw spectra, 
the bottom spectra are background subtracted (5th order polynomial)  
Although the Visionex probe has been shown in this study and others to successfully 
classify pathologies,158,202 a smaller probe with a reduced background Raman signal 
would be more suitable for in vivo diagnosis in the oesophagus, further more the 
Visionex probe is no longer manufactured and thus an alternative is required. Initial 
results from the single-fibre probe are encouraging, the sample size is small (30 samples 
from 30 different patients) and a larger study with more samples and patients is required 
to further validate the model. More samples will enable separation of a greater number 
of pathology groups. The sampling depth of the single-fibre probe is less than the 
Visionex probe and as a result should ensure that there is no spectral contribution from 
underlying stroma. Further work is required to verify this. Cross validation needs to be 
carried out to ensure the classification models are robust. Development of a large 
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consensus pathology model using the optimised design of the single-fibre probe is now 
required before in vivo use.  
 
Cross validation was not carried out for this model since limited sample numbers did not 
permit this.  
5.8 Summary 
These results have shown that the Visionex probe can successfully discriminate three 
oesophageal pathology groups ex vivo with good sensitivity and specificity in a cross 
validated PCA fed LDA model. It was concluded that the current version of the 
Emvision probe was not suitable for oesophageal applications due to the large sampling 
depths, since as described previously, probing the superficial layers (~200 µm) will be 
most beneficial for detecting the earliest pre cancerous changes. As a result, the 
Emvision probe was not pursued for further investigation, however, the Emvision probe 
may have a role in detecting deeper cancers or with adaptation by the addition of an 
offset window for detecting more superficial pathologies. The novel single collection 
fibre probe proved to have potential with a resulting classification performance 
comparable with the Visionex, although a further large scale model is required in the 
future.   
 
In summary, Raman probes (Visionex and novel single collection fibre) have been 
shown to have potential for biopsy targeting ex vivo and that improvements in the single 
output fibre design could result in further improvements. This implies that further time 
and effort should be invested in large scale in vivo trials once relevant modifications to 
the probe and housing have been carried out to make it suitable for in vivo use (i.e. C.E 
marking etc.).  
 
In the future, targeted biopsy could be taken to the next step and provide in vivo 
diagnosis. This would have significant implications to clinical practice since in vivo 
diagnosis would allow immediate treatment at the time of diagnosis, resulting in reduced 
trauma to the patient since only one endoscopy session would be required, and would 
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also alleviate the stress of waiting for histology diagnosis. The results of this study can 
also be extended to other treatment sites, in particular other epithelial tissues which often 
follow the same route of carcinogenesis.  This could also lead to a significant reduction 
in cost to patient surveillance programs by minimising the number of biopsies requiring 
detailed processing and histopathological analysis.  
 
The classification model performance is consistent with published results using similar 
probes. Perhaps a two group model is more clinically realistic since this could be set at a 
level which reflects the clinical borderline between surveillance and opting for 
treatment. Biochemically, there is no foundation for merging Barrett’s and NSq and this 
is potentially a source of error and should be avoided. Thus, as sample numbers permit, 
separation into more groups is likely to be more advantageous for improving 
classification performance rather than grouping dissimilar pathologies to bolster group 
numbers.    
 
 
 - 112 - 
Chapter 6 Results and discussion: 2) Evaluating 
rapid Raman mapping for potential 
automated histopathology 
6.1 A preliminary study of rapid Raman mapping parameters 
Before the rapid mapping system could be used to its full potential, the system needed to 
be fully tested and evaluated. System parameters which needed investigation included 
the objective used (see section 6.1.1), grating selection (Section 6.1.2), signal to noise 
ratio (Section 6.1), step size and acquisition time (Sections 6.1-6.4). The substrate and 
thickness of tissue sections is also a consideration, and these were determined based on 
previous work within the group which concluded 15-20 µm sections on CaF2 were 
optimum for Raman mapping.108,121,123 Optimum system parameters also needed to be 
determined for future mapping studies and a potential large scale clinical mapping study.  
6.1.1 Determining the optimum objective for rapid Raman mapping 
A comparison of the two objectives was carried out and example spectra acquired with 
an acquisition time of 5 s can be seen in Figure 6-1.  
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Figure 6-1: Raman spectra of connective tissue acquired using the prototype rapid Raman 
system (line focussed) at Renishaw Plc. (785 nm) with an acquisition time of 5 s – Nplan 
(green) and x50Long working distance (blue). An arbitrary offset has been applied since the 
spectra overlap 
The Nplan x50 objective was recommended by the manufacturers but it was concluded 
that the signal to baseline ratio, and signal to noise ratio were comparable and as a 
results the Leica long working distance x50 objective was chosen since the reduction in 
the glass background was considered a significant advantage. Furthermore, peak 
assignment discrepancies due to the glass background present for the NPlan objective 
was also considered to be a potential problem for future tissue classification. 
 
As an additional comparison, both objectives were used to obtain maps of a normal 
squamous epithelium island within Barrett’s oesophagus.  Raman maps were acquired 
with an acquisition time of 5s. Two different step sizes were used to ensure maps fitted 
into the allocated time slots available for the system. The pseudocolour PC score maps 
and corresponding PC loads (PCs 1-4) are shown in Figure 6-2. PC score images and 
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loads for PCs 5-8 can be seen in Appendix E. At the time of the mapping experiment the 
differences in signal to noise with varying step size/dataset size was not known (see 
following section for further details), but despite the difference in step size, it is still 
evident that there are background peaks evident in the PC loads (PC 1, 2 and 4),† and 
although other PC loads are similar, the objective background signal will make fitting 
biochemical constituents to the data difficult and also prevent comparison with previous 
tissue classification models. These results confirm that the Leica x50 long working 
distance objective is optimum for future Raman maps for potential automated 
histopathology. 
 
 
                                                 
†
 Recall that the maps were not mean centred, therefore the first PC load represents approximately the 
mean spectrum. 
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Figure 6-2: PCs 1-4 for comparison of maps acquired with the Nplan x50 objective, 5 s, 27.5 
µm step size (left) and Leica x50 long working distance objectives, 5 s, 11 µm step size (right) 
Note that PC3 and PC4 for the Leica x50 objective, the colour bar is inverted and thus the PC 
load is also inverted  
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6.1.2 Rapid Raman mapping with high spectral resolution 
An example map of a region of normal squamous epithelium mapped with the 
1200lines/mm grating is shown in Figure 6-3. The wavenumber range was centred at 
1100 cm-1. The overall map time was approximately 15 hours.  
 
Briefly, subtle biochemical variations are evident with what appears to by glycogen and 
protein peaks dominating the PC loads, however as previously mentioned this is 
inconclusive without the remainder of the fingerprint region. 
  
Although initial results were promising it was difficult to attribute biochemical changes 
based on only a portion of the spectra fingerprint region. 
 
Figure 6-3:An example of a rapid Raman map of NSq epithelium acquired with a 1200 
lines/mm grating, x50 NPlan objective, 8.8 µm step size and 30 s acquisition time 
 
Figure 6-4: PC1 load (corresponding to pseudocolour PC score map in Figure 6-3), and mean 
regions 1 and 2 illustrated in Figure 6-3 
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Tentative peak assignments show that the main component separating the two regions is 
the glycogen, see peaks at 936, 1083 and 1127 cm-1. However, this is difficult to confirm 
with the limited wavenumber range. Furthermore, collagen peaks in this wavenumber 
region (931-940, 1003, 1048 cm-1) are very similar to glycogen, making this difficult to 
confirm. The peaks at 1003 and 1030 cm-1 could also be attributed to other protein 
structures other than collagen. A combination of the above mentioned constituents is 
likely.201  To iterate this point, Figure 6-5 shows the similarities of glycogen and 
collagen IV in this spectral range. Identification of unique peaks (in this example) for 
glycogen at 492 cm-1 and for collagen at 1381 cm-1 would help biochemical analysis. 
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Figure 6-5: Comparison of (normalised) glycogen and collagen spectra (as shown previously, 
measured with the 785 nm  
 
There is obviously the potential to repeat maps with the wavenumber range centred at 
different regions and subsequently stitch together retrospectively to form a larger 
wavenumber range. This is feasible for applications in the research laboratory (discussed 
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further in Section 6.5), but it is likely that this would be technically demanding and time 
consuming for application in the clinical environment. CCDs are available which enable 
high spectral resolution Raman spectra over a wider wavenumber range which may 
improve tissue classification for Raman mapping and as technology becomes cheaper 
this may become feasible.  
 
It was concluded that future measurements would be carried out using the 300 line/mm 
grating since this spectral resolution has been shown to be sufficient for the separation of 
9 pathology groups by Kendall et al.1  
 
A comparison was also carried out with mid-IR absorption spectroscopy, the results for 
which can be seen in Appendix F. 
6.2 Comparison of rapid Raman mapping with point mapping and 
line focus mapping 
6.2.1 Comparison of rapid Raman map spectra with line focus spectra 
Rapid Raman mapping provides a significant time advantage over traditional point and 
line focus mapping techniques as confirmed later in Table 6-3. However, for 
completeness, these rapid line maps were compared to traditional line focus mapping 
(described previously).  
 
Considering the raw spectra there appeared to be degradation in the quality of the rapid 
Raman spectra compared to point Raman spectra. To investigate the sources of 
discrepancy, a 40s rapid Raman map spectrum was compared to a point spectrum, line 
map (high spatial resolution line map co-added), as shown in Figure 6-6. The signal to 
baseline ratio and magnitude of the peaks at 1000 and 1450cm-1 are shown in Table 6-1.  
 
 - 119 - 
600 800 1000 1200 1400 1600 1800
1000
2000
3000
4000
5000
6000
7000
Raman shif t (cm-1)
in
te
n
sit
y 
(co
u
n
ts
)
 
 
Spectrum extracted from StreamLine map
Point spectrum (StreamLine)
Co-added spectra from high res line map
 
Figure 6-6: Spectrum extracted from a 40 s rapid Raman map (52.8 µm step size), 40 s point 
spectra, co-added line map (individual spectra from 1.1 µm spatially separated line map (1 
laser length) co-added to simulate a point spectrum)  
Table 6-1: Signal to baseline ratio and magnitude of the peak height at 1000 and 1450 cm-1  
 Signal to baseline 
ratio (at 1000 cm-1) 
Magnitude  (at 
1000cm-1) 
Signal to baseline 
ratio (at 1450 cm-1) 
Magnitude (at 
1450 cm-1) 
Point spectrum 1.3 1431 1.6 1685 
Line map (high spatial 
resolution co-added) 1.3 1574 1.6 1728 
Spectrum extracted from rapid 
Raman map 1.2 748 1.5 968 
     
 
 
There is good agreement between the co-added line spectrum and the point spectrum, 
visually and considering the magnitude of the peaks (Table 6-1), but there is a reduction 
in intensity of the rapid Raman map spectrum. This appears to be an intensity reduction 
since both the magnitude of the peak and signal to baseline ratio are reduced.  
 
It is difficult to determine the origins of this discrepancy without access to in depth 
software and system settings and the difference was reported to the manufacturer. It is 
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expected that the Raman signal and background increase with acquisition time and that 
the signal to noise ratio improves according to the square root of n, due to the shot noise 
dependence. Therefore it is expected that for small step sizes, which are effectively 
spectra made up from additive multiple accumulations across the length of the laser line, 
the spectra would have a poorer signal to noise compared to spectra acquired using the 
entire laser length. In theory, the total intensities should be equal to that of the entire 
laser line, just split over multiple pixels. However, in this study there appears to be a 
reduction in signal intensity. From a research point of view it is sufficient to 
acknowledge the presence of this increased background and make suitable allowances to 
account for this when performing rapid mapping experiments.  
6.2.1.1 Results – variation in signal to noise for rapid Raman line maps with step 
size 
Figure 6-7 shows typical spectra extracted from the centre of each rapid Raman line 
maps (line maps i.e. only one column of spectra with the centre spectrum halfway 
vertically in the map). Visually, there was a slight deterioration in SNR with extremely 
small step sizes (i.e. 3.2, 2.1 and 1.1 µm) but also a reduction in background. To 
quantify this, the signal to baseline, a method also used by Hayden et al., was 
determined to quantify this and the results are summarised in Table 6-2.   
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Figure 6-7: Spectra extracted (from the same positions) from rapid Raman maps acquired 
with different step sizes. The step size is shown to the right of each spectrum 
The signal to baseline ratio (defined as the peak height divided by the average of the 
troughs either side of the peak, taking into account any noise present) was used as a 
comparison between the spectra since this eliminates variation in signal background. 
The overall magnitude of the signal was also considered along with the signal to noise 
ratio, although this quantity is difficult to quantify accurately for good and poor quality 
spectra. The SNR of the spectra were expected to decrease with decreasing step size 
since fewer CCD pixels were binned. Since it appeared, that the baseline signal was also 
increasing along with the Raman signal, spectra were also normalised and re-plotted to 
investigate whether or not normalisation was sufficient for eliminating background to 
enable direct comparison of the spectra. This is more evident in the normalised and 
offset plot shown in Figure 6-8.  
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Figure 6-8: Central spectra from the rapid Raman line maps (normalized and plotted with an 
arbitrary offset)  
Since each of spectrum is effectively an accumulation of the entire laser line length, the 
overall signal from a set of spectra spanning the length of the laser line should be 
equivalent to that from a single spectrum acquired using the entire laser profile, but as 
shown in the previous section, there is a slight discrepancy.   
 
Table 6-2: Signal to noise ratio (at 1000 cm-1)  and signal to baseline ratio (at the 1000 cm-1 
and 1450 cm-1) for the series of rapid line maps acquired with varying step size and 
acquisition of 40 s 
Step  
size 
Map 
dimensions 
Signal to noise ratio (at 
1000 cm-1) 
Signal to baseline ratio (at 
1000 cm-1) 
Signal to baseline ratio (at 
1450 cm-1) 
1.1 1 x 1000 5.1 1.09 1.19 
2.1 1 x 501 6.7 1.10 1.20 
3.2 1 x 335 9.1 1.11 1.21 
4.2 1 x 253 11.7 1.11 1.21 
5.3 1 x 203 16.2 1.11 1.21 
6.3 1 x 170 17.8 1.11 1.21 
12.7 1 x 86 25.0 1.11 1.21 
25.3 1 x 44 34.5 1.11 1.19 
52.8 1 x 22 35.5 1.09 1.19 
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It is evident that there is little difference in the signal to baseline ratio with step size, 
however, there does appear to be a slight reduction in the signal to baseline for small 
step sizes (below 3.2 µm), although to 1 decimal place, there appears to be no variation. 
This confirmed that taking the mean of a larger number of spectra counteracts the slight 
degradation in signal to noise with decreasing step size. This data was based on line 
maps acquired with rapid Raman mapping technology, but when mapping rectangular or 
square maps the total number of spectra increases by a square factor for each reduction 
in step size. Consequently, a reduction in noise would be further reduced by averaging 
effects.  This is investigated in the following sections. 
 
Figure 6-9 demonstrates the variation in signal intensity and SNR across the line profile 
of the laser, with 50 individual spectra acquired by spatial separation of the CCD. The 
profile from a map acquired of Si (1 s) is also shown to illustrate that the variation 
occurs due to the laser profile rather than an intensity variation in the tissue. In contrast, 
the rapid Raman map of the same region is shown which demonstrates that there is no 
variation with intensity of the laser profile and that this factor is no longer an issue.  
Bernard et al. also demonstrated this result in another study of rapid Raman mapping for 
geological applications.203  
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Figure 6-9: a) Variation in intensity along laser line of a line focused laser beam (left axis is 
1µm step size along the sample and right axis is Raman shift 450-1850 cm-1) measured on 
oesophageal tissue, b) Example oesophageal tissue spectra from the line focused line map 
illustrating the variation in SNR along the laser line (CCD pixels position is indicated to the 
right of each spectrum), c) Variation in signal intensity (at 520 cm-1 peak) along the line 
focused laser line (for line mapping) measured on a piece of silicon, d) Example spectra at 1.1 
µm step size acquired using the rapid Raman mapping system on the same region of tissue as 
plots a and b, with the spectrum number equivalent to one pixel in plots a-c 
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6.3 Principal component analysis in combination with rapid Raman 
mapping for potential automated histopathology 
 
6.3.1 Evaluation of rapid sampling parameters for Raman mapping 
technology for potential automated histopathology 
The results of this study were published in Hutchings et al.204,205 (the latter can be found 
in Appendix G). Figure 6-10 shows the H&E stained section, contiguous to the sample 
used in maps A-J, illustrating regions of fibrous connective tissue (FCT) and smooth 
muscle (SM). The contiguous section to the sample used in maps I-V is also shown 
illustrating circumferential normal squamous (NSq) and fibrous connective tissue.  
 
Figure 6-10: Annotated H&E (re-stained) section of the contiguous section to the frozen 
section used in the repeated mapping studies a) Maps A-J – sample containing areas of 
smooth muscle (SM) and fibrous connective tissue (FCT) are identified and b) Maps I-V – 
sample containing circumferential normal squamous epithelium (NSq) and fibrous connective 
tissue (FT) 
PC loads 1-8 are shown in Figure 6-11. PC 5 was chosen for subsequent analysis since 
this map demonstrated the best biochemical and morphological fit with the pathology 
diagnosis of the tissue sample. This is further demonstrated in Figure 6-12 in a 
comparison between the difference spectrum of collagen and actin and PC load 5.  
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Figure 6-11: PCs 1-6 for map D  
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Figure 6-12: Difference spectra for collagen – actin (normalised and subtracted). NB Raman 
spectra were acquired at 785 nm 
6.3.1.1 Signal to noise ratio variation in repeated maps 
Figure 6-13 shows pseudocolour score maps (PC5 for maps B-D, F-H and PC9 for maps 
A and E). Maps A-D were measured with varying acquisition time whilst maintaining a 
constant mapped area and step size of 25.3 µm.  
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Figure 6-13: Fifth PC pseudocolour score map and corresponding principal component load 
(Maps A and E displays ninth PC). Maps A-D are for a constant step size of 25.3 µm with 
increasing acquisition time from left to right of 0.1, 0.5, 1.7 and 20.0 s. The total mapping 
time is shown in brackets for comparison. Maps E-H are repeated maps using a step size of 
7.4µm with increasing acquisition time from left to right of 0.5, 1.7, 3 and 5 s (see Table 6-3 
for mapping parameters) 
Maps E-H show each of the various acquisition times whilst maintaining a constant 
mapped area and a step size of 7.4 µm. Maps C, I, J and F (Figure 6-14) show maps 
acquired with a constant acquisition time of 1.7 s with various step sizes. The fifth 
principal component load (PC9 for map A and E) exhibits opposing positive and 
negative peaks which are similar to the difference between actin and collagen spectra 
(see Figure 6-12 which compares PC5 and the difference spectra of collagen and actin – 
NB measured at 785 nm), which is consistent with the biochemical signatures of smooth 
muscle and connective tissue respectively. This agrees with results published by 
Koljenovic et al. who reported the biochemical difference between smooth muscle and 
fibrous connective tissue in bronchial tissue using PCA and K-means cluster analysis.177 
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However, further work is required to investigate biochemical differences in more detail 
since, as can be seen in Figure 6-12 there are discrepancies between the difference 
spectra and PC load indicating that there are contributions from other biochemical 
constituents. 
 
Morphologically, this also agrees with pathology identified in the H&E sections. For 
maps A and E, PC 9 exhibited the same morphological appearance and similar loads and 
as a consequence were used instead of PC 5. PCs 1-4 (PC scores and loads can be seen 
in Appendix H) describe the mean spectra, difference between tissue and calcium 
fluoride substrate, small regions of luminescence, and protein distribution. Fibrous 
connective tissue and smooth muscle are in fact very similar biochemically and as a 
result this was a good test for detecting very subtle biochemical changes.  Further 
detailed biochemical analysis with this data is possible (beyond the scope of this thesis) 
but this demonstrates that it is possible to detect gross biochemical changes even with 
poor SNR spectra. 
 
Figure 6-14: Fifth principal component pseudocolour score map and corresponding principal 
component load for maps C, I, J and F all with a constant acquisition time of 1.7 s with 
decreasing step size (thus increasing total number of spectra) from left to right of 25.3, 15.8, 
10.6 and 7.4 µm (see Table 6-3 for mapping parameters) 
Figure 6-15 shows typical raw spectra from maps with acquisition times of 0.5 s, 1.7 s 
and 20 s exhibiting the quality of the raw spectra within the maps.  
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Figure 6-15: Typical raw spectra with an acquisition time of a) 0.5 s, b) 1.7 s and c) 20.0 s 
taken from map B, C and D respectively 
The values for the RSD of the raw spectra calculated at the peak at 1000 cm-1 are shown 
in Table 6-5. They clearly demonstrate that the RSD reduces with increasing acquisition 
time as expected. For Map D, an RSD value of 2 was considered as a benchmark since 
the 20 s acquisition time provided a reasonable SNR of the raw spectra. The relative 
‘SNR’ values measured at the 932 cm-1 peak of the principal component loads are also 
shown in Table 3. The corresponding ‘SNR’ for PC 5 load of map D was also high (>50) 
as expected. Similarly high ‘SNR’ values for the loads were achieved with shorter 
acquisition times provided the total number of spectra was large enough. As expected 
the relative ‘SNR’ of the loadings also increased with increasing number of total spectra 
with maps C, I, J and F. with the ‘SNR’ increasing from 12 to 44. 
 
Figure 6-16 shows maps acquired with a constant mapping time of 4.5 hours. From left 
to right, maps I-V were acquired with increasing acquisition time and step size detailed 
in Table 6-4. 
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Figure 6-16: Fifth PC pseudocolour score map and corresponding PC load for maps I-V (left 
to right) all acquired with parameters adjusted to give a total mapping time of 4.5h (see Table 
6-4 for parameter details) 
There is good correlation with the pathology indicated on the H&E section with 
circumferential normal squamous identified by the negative peaks of the 5th PC load.  
Visually, the degradation in the spatial resolution is evident whilst there is little 
difference between the PC loads. The RSD and ‘SNR’ results are shown in, which 
demonstrates a slight decrease in the RSD as the acquisition time and step size are 
increased. This was mirrored for the previous set of maps (C, I, J and F), all acquired 
with an acquisition time of 1.7 s, illustrating that this increase in RSD is not linked to the 
reduction in spectral acquisition time, but more likely due to the number of spectra 
contained in the area sampled for the RSD calculation.  The ‘SNR’ of the loads remains 
approximately constant. It should be noted that the ‘SNR’ values are not directly 
comparable with maps A-J since they have been measured on different samples obtained 
from two patients. 
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Table 6-3: Summary of mapping parameters for repeated maps. Maps A-D are for a constant 
step size of 25.3 µm, maps E-H are for a constant step size of 7.4 µm, maps C, I, J and F are 
for a constant acquisition time of 1.7 s. Overall mapping times are shown along with estimated 
mapping times for traditional point mapping (only applicable to the Renishaw system in these 
experiments) 
Map ID Step size (µm) Acquisition time (s) Total number of spectra Total mapping time (hours) 
    Rapid mapping 
(actual) 
Point mapping 
(estimated) 
      
A 25.3 0.1 0.9x104 0.1 4.2 
B 25.3 0.5 0.9x104 0.5 4.7 
C 25.3 1.7 0.9x104 1.5 6.5 
D 25.3 20 0.9x104 17 29.0 
      
E 7.4 0.5 10x104 2.0 49.6 
F 7.4 1.7 10x104 6.3 55.2 
G 7.4 3.0 10x104 11 60.4 
H 7.4 5.0 10x104 19 70.8 
      
C 25.3 1.7 0.9x104 1.5 6.5 
I 15.8 1.7 2x104 2.8 13.9 
J 10.6 1.7 5x104 4.0 27.3 
F 7.4 1.7 10x104 6.3 55.2 
      
 
 
Table 6-4: Maps I-V are repeated maps of the sample with parameters adjusted to maintain a 
constant total mapping time of 4.5 hours. Overall mapping times are shown along with 
estimated mapping time for traditional point mapping (only applicable to the Renishaw 
system) 
Map ID Step size (µm) Acquisition time (s) Total number of spectra Total mapping time (hours) 
    Rapid mapping 
(actual) 
Point mapping 
(estimated) 
I 9.5 2.4 4x104 4.5 23.6 
II 12.7 3.0 2x104 4.5 15.7 
III 19.0 4.7 1x104 4.5 9.6 
IV 25.3 8.2 0.6x104 4.5 9.1 
V 31.7 9.0 0.4x104 4.5 7.4 
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Table 6-5: Summary of the RSD for normalised spectra (16th of the total mapped area) within 
each map measured at the 1000 cm-1 peak and ‘SNR’ for the fifth principal component 
loading (PC9 for maps A and E) measured at the 932 cm-1 peak. Total mapping time (in 
hours) is shown in brackets next to the map ID for comparison 
Map ID RSD 
(normalised 
data) 
PC (5th) load ‘SNR’ 
   
A(0.1h) 16 <2 
B(0.5h) 7 4 
C(1.5h) 4 12 
D(17h) 2 >50 
   
E(2h) 11 8 
F(3.6h) 6 44 
G(11h) 5 >50 
H(19h) 4 >50 
   
C(1.5h) 4 12 
I(2.8h) 4 14 
J(4h) 5 28 
F(6.3h) 6 44 
   
I (4.5h) 6 8 
II(4.5h) 5 10 
III(4.5h) 4 10 
IV(4.5h) 4 8 
V(4.5h) 4 11 
   
 
6.3.1.2 Comparison with estimated point mapping times 
The ratio of the estimated point map time and overall mapping time for the rapid Raman 
maps, for various mapping parameters, is shown in Table 6-6. This illustrates the large 
reduction in mapping time achievable with rapid Raman mapping when compared to 
point mapping using a standard Renishaw Raman spectrometer.  
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Table 6-6: Summary of mapping parameters and comparison of  total mapping times with 
traditional point mapping times indicated by the ratio of the estimated total map time using the 
point mapping technique and the total map time using the rapid mapping technique 
Map ID Acquisition 
time (s) 
Ratio (estimated point map time/ 
rapid map time) 
   
A 0.1 37.1 
B 0.5 10.4 
C 1.7 4.2 
D 20.0 1.7 
   
E 0.5 25.0 
F 1.7 8.8 
G 3.0 5.4 
H 5.0 3.7 
   
Map ID Step size (µm) Ratio (point map time/ rapid map 
time) 
C 25.3 4.2 
I 15.8 5.0 
J 10.6 6.9 
F 7.4 8.8 
   
I 9.5 5.1 
II 12.7 3.5 
III 19.0 2.1 
IV 25.3 2.0 
V 31.7 1.6 
   
 
There is a clear advantage of increasing the number of spectra within the map in terms 
of the performance of multivariate techniques. In this study, larger datasets were 
achieved by increasing the spatial resolution but this would also be achieved by mapping 
a larger sample with the same or lower spatial resolution. Factors limiting the size of the 
dataset include the 32-bit operating system addressable memory restriction and Matlab's 
requirement for the entire matrix to be held in a contiguous block. In the case of this 
study, memory restrictions limited the spatial resolution achievable for mapping the 
entire biopsy sample since smaller step sizes would have generated excessively large 
datasets (mapping the sample shown in Figures 3-4 with 1.1 µm step size would result in 
excess of 5x106 spectra or 7.5 x109 data points (based on 1501 data points per spectrum). 
6.3.1.3 Relative standard deviation (RSD) and signal to noise ratio (SNR) 
variation 
From Figure 6-13 and Figure 6-14, for all maps shown except A and E, it is evident that 
the fifth PC load represents similar tissue features (in this example tentatively attributed 
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to collagen which is abundant in fibrous connective tissue and actin which is abundant in 
smooth muscle) in each of the repeated maps despite the variation in the number of 
spectra and acquisition time. For map A, noise dominated the ninth principal component 
load, although tissue peaks can be approximated. Considering map E, these spectral 
features appeared further down the PC loads at the 9th PC component. 
 
For all maps except for D, for which an acquisition time of 20 s was used, the SNR of 
the raw spectra was very low (results not tabulated). Therefore the RSD measure was 
used to allow comparison. Ideally a high SNR would be desirable to ensure that subtle 
biochemical changes are detected but from these results it is evident that PCA is 
powerful enough to extract gross biochemical information even with a very low SNR. 
The RSD calculations on the normalised data (Table 6-5) illustrate the reduction in noise 
with increased acquisition time. The lowest RSD, as expected, was for the longest 
acquisition time of 20 s for map D. In general, this was mirrored on the raw data without 
normalisation (results not shown), although RSD values tended to be higher than 
expected for larger maps indicating a larger variance, likely to be caused by the presence 
of luminescent spectra and cosmic rays highlighting the difficulty in ‘cleaning up’ large 
datasets. This could also be caused by focusing issues across the sample area. 
 
The relative ‘SNR’ values calculated for the PC loadings showed improved performance 
with longer acquisition times, in particular in the case of maps D and H for which the 
apparent noise was negligible with respect to the 932 cm-1 peak within the load.  
 
As expected, the relative ‘SNR’ of the loadings also increased with increasing number of 
total spectra with maps C, I, J and F.  An additional advantage of improved resolution is 
improved recognition of morphological features, which will make this technique more 
acceptable to the histopathologist.  
 
When considering the maps acquired with a constant mapping time of 4.5 h (Maps I-V) 
it is evident that there is little difference regarding the loads but increased spatial 
resolution would be beneficial. The advantage afforded by rapid Raman mapping is also 
greater for higher resolution maps. Increased spatial resolution would also reduce the 
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effects of under-sampling and the possibility of missing crucial subcellular biochemical 
information. This would have little consequence for the samples in this study, but may 
become clinically significant for a sample containing a focus of disease. 
 
The section shown in Figure 6-10 was initially thought to contain a region of 
inflammation or possibly adenocarcinoma to the bottom left, but this was inconclusive 
due to very poor staining. Following rapid Raman mapping, in which there was no 
evidence of a region of adenocarcinoma, this section was re-stained to obtain definitive 
diagnosis and found to only contain smooth muscle and fibrous tissue. This highlights a 
further potential advantage of spectroscopic diagnosis which could enable diagnosis of 
inconclusive sections based on distinguishing biochemical features from unstained 
tissue.  
 
From Table 6-6 it is evident that rapid Raman mapping is significantly faster than 
traditional point mapping (from the same manufacturer). As expected there is a 
correlation between the step size and the speed of the map acquisition and thus there is 
an inverse correlation with the total mapping time. For a step size of 25.3 µm (maps A to 
D) rapid Raman mapping was approximately 3 times faster than point mapping for long 
acquisition times and up to 38 times faster for short acquisition times. Data published 
previously by Hutchings et al.205  was based on best case scenario point mapping times 
which significantly underestimated overall mapping times for short acquisition times. 
With a step size of 7.4 µm (maps E to H) rapid Raman mapping was of the order of 4 
times faster than point mapping for longer acquisition times (5 s) and 25 times faster for 
short acquisition times (0.5 s). Due to the large number of spectra within the dataset the 
advantage of rapid acquisition of spectra is accentuated.  
 
One option, not considered in this investigation, is the potential to mismatch x and y step 
sizes to prevent under-sampling when using step sizes greater than the width of the laser 
line (7-8 µm). This is an area which will need further investigation before optimum 
mapping protocols can be determined. Further work must also be carried out to 
investigate the potential problems associated with under-sampling with regards to 
missing diagnostically significant information. The step size in this study has not been 
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reduced beyond that of the width of the laser line (7-8 µm for the x50 objective used in 
this study) due to size limitations on the datasets and also to prevent over-sampling but 
this is also an area for further investigation since this may provide further benefits with 
regards to increased spatial resolution and even larger datasets. This may be of particular 
interest when mapping cells at high resolution and leads to the possibility that 
biochemical changes within the tissue can now be investigated at the cellular level 
across larger areas of tissue. One consequence of this would be the need for 
improvement in computational facilities. The use of 64-bit computers has increased the 
datasets that can be managed since this work was undertaken.  
 
There is also potential to investigate noise reduction techniques and smoothing of the 
spectral data such as those available within the Wire 3.0 software and those described by 
Sasic et al.145  
 
Potential sample degradation has previously limited the maximum laser power that can 
be used with biological tissue samples, however with reduced acquisition times there is 
the potential to increase the laser power and thus improving the signal to noise ratio.  
 
Before an automated screening technique can be developed, further work is also required 
to develop automated algorithms capable of identifying ‘non-relevant’ samples so that 
only diseased samples are forwarded for diagnosis by an expert histopathologist. It will 
also be beneficial to reduce the thickness of the mapped tissue sections towards the 
thickness used for H&E histopathology (7 µm), although potentially longer acquisition 
times may be required to counteract the reduction in Raman scattered photons with the 
thinner tissue section. One way to counteract this may be to use mirrored slides which 
maximises the return signal to the objective. This will also have an impact on the spatial 
resolution which can be achieved at smaller step sizes.  
 
Each map contains a vast amount of biochemical detail and work is ongoing to explore 
information regarding the carcinogenesis process. 
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The use of PC load ‘SNR’ and RSD are relatively arbitrary methods of comparison, but 
methods were reproducibly determined for each of the maps to enable direct comparison 
between the repeated maps, however it must be noted that the values are not comparable 
between different samples due to differences in sample biochemistry and mapping 
conditions. 
 
It should also be noted that there was no evidence of spectral difference between the first 
and the last map, furthermore, maps were acquired in a random order to prevent any 
systematic errors with time and sample state.   
 
Rapid Raman mapping has enabled frozen tissue sections to be mapped on a clinically 
practicable timescale. The combination of large spectral datasets (generated by rapid 
Raman mapping) with multivariate analysis provides a powerful method of analysing 
tissue sections. The frozen tissue samples do not require preparation with histological 
stains, providing a significant advantage over current techniques. Frozen samples can be 
stored and subsequently stained if required. Furthermore, the process lends itself to 
automation using computed algorithms which removes the subjective element of 
histological diagnosis. Potentially a rapid pre-scan could be carried out at relatively low 
resolution with low SNR. Subsequent detailed high quality maps can then be acquired 
on regions of interest. In combination with multivariate classification models, there is 
the potential for the automated screening out of non-relevant samples, with those 
deemed as abnormal going on for diagnosis by an expert histopathologist. Consequently 
this would reduce the burden of ‘non-relevant’ samples which currently swamp the 
system and allow more time for analysis of the critically diseased samples.   
 
A large amount of work will be needed to develop a comprehensive database of tissue 
spectra before Raman mapping can be used in the clinical environment. Rapid Raman 
mapping provides a method of acquiring such data which will enable verification of this 
technique on a timescale that was previously not possible.  
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Raman spectral mapping has historically been significantly slower than the 
complimentary technique of IR absorption spectroscopy and a rigorous comparison of 
the two techniques is now required. 
 
There is a trade off with overall mapping time and signal to noise. Although the signal to 
noise ratio of the rapid Raman mapping spectra are not of the same quality as point 
mapping spectra (due to the line focusing and also the waterfall nature of reading the 
CCD which potentially translates residual CCD noise across the CCD), it is in effect a 
half way house or to word another way a technique which makes the compromise 
between rate of acquisition and the subsequent quality (and quantity) of the acquired 
spectra.  
 
Advances in mapping technology have also facilitated the use of alternative wavelengths 
since shorter acquisition times can be used. Diem at al. used 514nm with an acquisition 
time of 0.5 s for mapping cells.206 Considering the discussion previously regarding the 
spatial resolution achieved by Shlucker et al., this could potentially enable even higher 
spatial resolution Raman mapping in the future.  
6.4 Raman mapping and linear discriminant analysis to evaluate the 
importance of lateral spatial resolution for histology diagnosis  
The previous section has demonstrated the feasibility of measuring molecular signals 
from unstained tissue in relatively short time scales. Methodologies for utilising this 
information for clinical diagnosis are explained here, with particular emphasis on 
evaluating the spatial information for clinical utility.  A portion of the results from this 
study have been submitted for publication (November 2008, Analyst),207 a copy of the 
submitted manuscript can be seen in Appendix I. 
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6.4.1 Linear discriminant analysis of Raman maps  
6.4.1.1 Principal component imaging 
The results from one sample (Sample 1) are presented in detail, with the results from a 
second (Sample 2) sample added to demonstrate the technique can be used to identify 
other pathology groups. Figure 6-17 shows the white light montage image of Sample 1, 
acquired using a x2.5 objective. The small box indicates the region containing high 
grade dysplasia (HGD) and fibrous connective tissue (FCT) which was mapped 
repeatedly. It was noted that the regions between the HGD glands were also FCT. The 
H&E stained CaF2 image (i.e. the mapped tissue section) and contiguous section stained 
with H&E for histology purposes are also shown.  
 
 
Figure 6-17:  a) White light image and mapped area b) mapped tissue section stained with 
H&E (on CaF2) c) contiguous 7 µm H&E stained section of Sample 1 
Figure 6-18 shows PC2 as an example of a pseudocolour PC score images and 
corresponding PC load. The extremes of the colour bar are represented by a single 
colour, with the central portion remaining transparent. This allows the PC images to be 
overlaid, as shown in Figure 6-19, in which PCs 1-5 are shown overlaid with 
corresponding PC loads colour coded accordingly. 
 
The biochemical information contained within the PC loads is shown to be similar (for 
the two maps acquired with 8.4 and 2.1 µm). Although the two different regions of tissue 
can be identified in both maps, it is much easier to identify morphological structure in 
the smaller step size map as glandular features and this further supports the presence of 
HGD. 
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Figure 6-18: Example of how PC images are overlaid (pseudocolour PC 2 scores image and 
corresponding PC load for the 2.1 µm map) 
 
Figure 6-19: Pseudocolour PC score images overlaid for the 8.4 µm and the 2.1 µm step size 
map. PC loads are shown with corresponding colour coding  
6.4.1.2 Linear discriminant analysis (LDA) 
Initially, LDA models for six spectral groups were generated (see Table 6-7). As 
described previously, spectra were selected using thresholding of the PC score images, 
with ambiguous spectra (not clearly belonging to a single group) classed as ‘unknown’. 
For the 8.4 µm map, the overall training performance of the LDA model was 70.1% with 
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the overall training performance degraded by the large number of misclassifications for 
spectra in the ‘unknown’ group and also the CaF2 group. Sensitivity and specificity were 
58.7–92.9% and 88.1–99.9% respectively. The number of spectra within each group and 
the percentage correctly classified by the LDA model is summarised in Table 6-7.  
 
Table 6-7: Classification performance of the training (including the ‘unknown’ group) 
dataset of the LDA model (8.4 µm and 2.1 µm step sizes, 15 s acquisition time) 
  CaF2 TB FCT HGD Lum Unknown % correctly classified 
CaF2 354 27 0 0 0 0 94.4 
TB 62 111 3 0 0 13 82.7 
FCT 0 0 920 1 0 79 99.3 
HGD 1 67 234 2608 0 752 88.0 
Lum 0 1 13 0 140 13 96.3 
8.4 
µm 
Unknown 7 185 796 544 6 2655 71.7 
         
CaF2 5713 371 0 0 0 0 93.9 
TB 150 1386 13 0 0 1 89.4 
FCT 0 3 5145 0 0 252 95.3 
HGD 0 41 2952 52864 424 14322 74.9 
Lum 0 3 0 0 4070 0 99.9 
2.1 
µm 
Unknown 2100 1528 13533 14152 5046 32151 46.9 
 
For the 2.1 µm map, the overall training performance of the LDA model was 64.9%. As 
with the 8.4 µm model, the majority of the misclassified samples are from the 
‘unknown’ group (as expected) which consequently skews the overall performance 
value. There are also misclassification of FCT spectra (predicted as ‘unknowns’) and 
some discrepancies with CaF2 and tissue border. Table 6-7 shows the number of spectra 
within each LDA classification group. Sensitivity and specificity were 46.9 - 99.9% and 
83.4 - 98.9% respectively, but again, these values are skewed by the large number of 
misclassifications within the ‘unknown’ group. As described earlier, the ‘unknown’ 
spectra were those which ambiguously belonged to more than one group i.e. spectra 
which were identified by the FCT PC scores image, but actually lay within the HGD 
region of the map. This will obviously have an effect on the model since spectra in the 
unknown group will not be similar biochemically since it is likely to contain a range of 
pathologies.  
 
 - 143 - 
Figure 6-20 illustrates the model performance spatially to provide further insight. Figure 
6-20a and Figure 6-20c identify spectra (as black pixels) which are misclassified by the 
LDA model for the 8.4 µm and 2.1 µm maps respectively.  In Figure 6-20b and Figure 
6-20d, these misclassified spectra (pixels) are colour coded according to the group in 
which the LDA model classifies them for the 8.4 µm and 2.1 µm maps respectively. This 
additional spatial information provides an insight into whether or not the LDA 
prediction is sensible which can potentially provide useful information regarding initial 
group. The process is also subjective to a certain extent, albeit based on biochemical 
information from the PC scores images, PC loads and pathology opinion. 
 
 
Figure 6-20: Pseudocolour LDA pathology images for the 8.4 µm (a-b) and 2.1 µm (c-d) maps 
colour coded with pathology. Figures 4a) and 4c) show the locations of the misclassified 
spectra/pixels, whilst Figures 4b) and 4d) show the predicted pathology according to the LDA 
model for each of the misclassified spectra 
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In the 2.1 µm map PC score image (Figure 6-19), the FCT appears to extend into regions 
between HGD glands. In the LDA pathology classification, although over 25000 spectra 
are misclassified as FCT, spatially, many of the inter-glandular spectra are still classified 
as “unknown” (white) and luminescence. This is likely to be due to initial choice of 
LDA groups for which the LDA process would try to separate the groups, but it could 
possibly be due to a biochemical difference in the FCT depending on the location of the 
tissue. This issue is addressed in the next section in which the ‘unknown’ group is 
extracted from the model and used as an independent test set. There is also the 
possibility there is spatial and spectral averaging of nearby HGD and further work is 
required to verify the actual spatial resolution achieved with rapid Raman mapping 
systems.  
 
The central portions of the some of the glands appear to be misclassified as FCT, but 
again it is likely that a separate group would be required to account for these gland 
lumens which are likely to contain glandular mucin secretions etc. from the goblet cells. 
This may be based on protein signature of mucins, but further work is required to 
investigate this.  
 
Luminescence also appears to be very structural within the tissue and mostly, within the 
regions of FCT. The location of the luminescence within the FCT is more evident with 
the small step size map, highlighting the potential importance of high lateral spatial 
resolution mapping.  
 
Including spectra acquired from calcium fluoride in the mean centring may not be the 
optimum method, but it was concluded that calcium fluoride/other substrate would be an 
important constituent with any model since any discrepancy with substrate impurities 
may lead to misclassifications. This may also be important for regions of thin tissue 
which may contain contributions from both substrate and tissue. Further work will be 
needed to investigate this. 
 
 - 145 - 
6.4.1.3 Projecting the ‘unknown’ group as an independent test set 
Figure 6-21 shows the pseudocolour LDA image for the model generated excluding the 
‘unknown’ group as a separate test set and later projecting these onto the model. Both 
the 8.4 µm and the 2.1 µm maps are comparable, with spectral predictions consistent 
with morphological features and location in the image. 
 
Figure 6-21: Projection of the test set onto the LDA model (generated excluding the 
‘unknown’ group which was kept aside as a test set) for the 8.4 µm (a-c) and 2.1 µm (d-f) 
maps. Figures a) and d) illustrate tissue classification of the training set by the LDA model 
according to tissue pathology colour code with misclassifications as black pixels and the test 
set identified as white pixels. Figures b) and e) illustrate the predicted classification group of 
the misclassified spectra within the training set according to the LDA model and figure c) and 
f) show the projected test set results according to the classification by the LDA model 
The overall performance of the training set models improved from 70.1% to 94.4% 
(79.4-99.0% sensitivity  and 95.0-99.8% specificity ) for the 8.4 µm step size model and 
from 64.9% to 93.7%  (87.3-99.9% sensitivity  and 95.2-100% specificity ) when the 
unknown group was excluded as the test dataset. 
 
As with previous LDA models which included the ‘unknown’ group, FCT appears to 
extend in between the glandular features of the HGD. Previously, this was only 2.1 µm 
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map, but when using the ‘unknown’ group as a test set this is also evident in the 8.4 µm 
map (Figure 6-21). Again, the centre of some of the glandular HGD structures are 
classified as FCT (especially evident in the small step size map). This is likely to be 
incorrect, and as discussed previously, a further group, tentatively attributed to mucin, 
may need to be added to the model to account for such regions. However, there is also 
the possibility that FCT, which is relatively transparent, is misclassified as tissue border 
since it comprises a lesser contribution from tissue spectral features and more CaF2 due 
to spectral mixing with substrate spectra. Further work is needed to investigate the 
origins of these misclassifications. The projection model also suggests that regions of 
luminescence are surrounded by FCT.   
 
To further investigate the projection of test dataset (and the presence of luminescence 
within the FCT), the LDA model was recalculated with fewer spectra in the training 
dataset. An additional ‘unknown’ margin around each pathology group was defined and 
allocated to the test dataset i.e. each region of luminescence was surrounded by a region 
of test set pixels/spectra. Similarly, the region between HGD and FCT was blocked out 
and allocated to the test set. Results indicate more strongly that luminescence is 
structural within the FCT. Pixels at the edge of the tissue and also the gland centres are 
also projected to be FCT, reiterating the need for an additional group within the model. 
The results are shown in Figure 6-22. 
 
It is evident that reducing the training dataset does not impact on the ability to project 
the test set onto the classification model. Furthermore, improved training performance is 
achieved by ensuring the classification model is trained with well define spectral groups.  
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Figure 6-22: Projection of the larger test set (to account for tissue margins) onto the LDA 
model (generated excluding the test set) for the 8.4 µm (a-c) and 2.1 µm (d-f) maps. a) and d) 
illustrate tissue classification by the LDA model according to tissue pathology colour code 
with misclassifications as black pixels with the test set identified as white pixels. b) and e) 
illustrate the predicted classification group of the misclassified spectra according to the LDA 
model and figure c) and f) show the projected test set results according to the classification by 
the LDA model 
6.4.1.4 An example of normal squamous epithelium (Sample 2) 
The above process was repeated on a map (15 s acquisition and 8.4 µm step size) of 
Sample 2 (containing NSq and FCT), but in this case the size of the training dataset was 
reduced further. 
 
Results are shown in brief in Figure 6-23, which shows the white light image and pseudo 
colour LDA image, the training set (defined by relatively small, but distinct regions of 
NSq, FCT and CaF2), H&E of the contiguous section and also the mapped section 
stained with H&E (on CaF2). It can be seen in the figure that there are no black pixels 
indicating a perfect overall training performance of 100%.  
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Figure 6-23: left) Model training set defined by small region of NSq (green) FCT (yellow) and 
CaF2 (grey), centre) white light image of the sample with the projected tissue classification 
overlaid at the mapped region, right) annotated H&E of the consecutive section 
6.4.1.5 Combined maps 
To further test the LDA projection of map data onto the tissue classification model, the 
two maps (15s acquisition time and 8.4 µm step size), were combined to form a large 
map containing HGD (sample 1), FCT (from samples 1 and 2), NSq (sample 2) and 
CaF2 (from samples 1 and 2). The entire map was then reanalysed to investigate the 
feasibility of extending this to multiple tissue maps and tissue types.  
 
Again, small, distinct regions of each tissue type (NSq, FCT and HGD) and also CaF2 
were defined as the training dataset, with the test set defined as the remainder of the 
dataset. The H&E images from each sample have been reconstructed to indicate the 
pathology of the combined map as shown in Figure 6-24, the regions selected for the 
training dataset are also indicated. The mean raw spectrum for each training set group 
(CaF2, FCT, HGD, NSq and Lum) is shown in Figure 6-25. 
 - 149 - 
 
Figure 6-24: Reconstructed H&E for samples 1 and 2 to indicate pathology of combined map. 
The spectral regions selected for the training model are also indicated. Note the discontinuity 
in right hand H&E image which indicates the region cropped to ensure map dimensions 
agreed 
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Figure 6-25: Mean spectra for the training dataset (for the combined LDA map for Sample 1 
and 2). Plus and minus two standard deviations is also shown. Spectra have been plotted with 
an arbitrary offset for clarity 
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Further information can be gleaned from the difference spectra of the different groups. 
Examples of difference spectra between the NSq and the HGD training group spectra 
can be seen in Figure 6-26a and NSq and FCT in Figure 6-26b.  
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Figure 6-26: Difference spectra for the mean training set spectra a) NSq minus HGD and b) 
NSq minus FCT 
Considering Figure 6-26, the 481(483), 884(853), 937(940), 1337(1338), 1450(1455) 
cm-1 peaks present in both can be attributed to glycogen, consistent with normal 
epithelial tissue. There is also relatively more protein content in NSq compared to FCT 
and HGD illustrated by the peaks 937, 1005, (1034 not labelled), 1329 (peak shoulder), 
1458, 1655 cm-1. In Figure 6-26a negative peaks at 685, 779 cm-1 may be due to DNA. 
In Figure 6-26b negative peaks at 874 and 920 cm-1 (not labelled) in the NSq minus the 
FCT could also potentially be attributed to collagen.   
 
Figure 6-27c shows the classification for each spectra/pixel for the test dataset projected 
onto the LDA model generated using the training dataset.  
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Figure 6-27: Classification model generated based on a training set taken from two samples 
(Sample 1 and 2 combined to one map) Sample 1 is the sample containing HGD and FCT and 
sample 2 contains FCT and NSq. a) shows the training set performance with correctly 
classified spectra classified according to pathology colour code with misclassified spectra 
highlighted as black pixels, b) illustrates the groups into which the misclassified spectra are 
predicted and c) illustrate the predicted classification for the test dataset (previously white 
pixels)   
The overall accuracy of the training set classification model was 97.5% (98.8–100% 
sensitivity and 95.8 – 100% specificity). The number of correctly classified samples is 
summarised in Table 6-8.  
 
Table 6-8: Classification performance of the training model generated with the combined 
maps (sample 1 and sample 2) 
 CaF2 FCT HGD Lum NSQ Total % correctly classified 
CaF2 335 3 1 0 0 339 98.8 
FCT 0 524 13 8 0 545 96.1 
HD 2 5 161 0 0 168 95.8 
Lum 0 0 0 82 0 82 100.0 
NSq 0 0 0 0 158 158 100.0 
        
 
In general, projection of the test dataset (Figure 8c) agrees with histology diagnosis 
(Figure 6-17- sample 1, Figure 6-23 – sample 2), however there are discrepancies which 
occur within the basement membrane region of the NSq (i.e. the border between NSq 
Training data set (with 
misclassification) 
Training data set (with misclassed 
spectra prediction Training and projected test set 
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and FCT) which gets projected as HGD. Regions of luminescence, not previously 
identified in Sample 2 are also detected within the FCT.  
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Figure 6-28: Mean spectra for the projected data set and training set  
It can be seen from Figure 6-28 that there are a few a cases (in particular at the high 
wavenumber range of the CaF2 and Lum group) where the standard deviation is large. 
This is caused by the presence of cosmic rays in the test set. It appears that the LDA 
process is relatively insensitive to the presence of cosmic rays, but further work is 
required to verify this.   
 
The mean of the luminescence group for the projected spectra also contains evidence of 
Raman spectral peaks. This may be due to spectral mixing of adjacent pixels, but future 
work may reveal the biochemical composition of luminescent structures.   
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Admittedly this is not a full model containing all pathology groups, nor was the region 
of basement membrane included in the training dataset, but conclusions can still be 
drawn from this, since the result indicates that classification could be occurring based on 
biochemical signature of (potentially of dividing) cell nuclei densely packed in both 
HGD and also basement membrane regions. Furthermore, since epithelial cells originate 
at the basement membrane and migrate to the surface (where they are exfoliated), cells 
in the basement membrane region are also proliferating which could also further explain 
the misclassification. The misclassification could also be due to spectral mixing 
artefacts, as suggested by Bhargava et al. who also reported boundary epithelial pixels 
are misclassified as malignant.150 
 
This result indicates that misclassifications are highly likely if sub tissue classes are not 
included into the training dataset, and perhaps suggests that spatial averaging may be 
advantageous to avoid such issues. Further work is required to determine the optimum 
number of classification groups for pathology diagnosis.   
 
In a study by de Jong et al., increased levels of DNA and RNA in inflammatory regions 
of Raman maps of bladder sections were reported (although data was not shown).175 
Concluding this study, de Jong et al. comment that spectral databases will need to 
include a reference dataset for inflammatory tissues to prevent misclassification. It was 
previously noted that inflammatory changes could not be detected with a Raman probe 
and point spectra and it is likely that spectral mixing overwhelms this subtle change 
which is only evident when mapping tissue sections. In the future, a thorough 
investigation of spectral mixing effects will be required to determine optimum number 
of pathology groups required for tissue diagnosis. 
 
This study has shown that high lateral spatial resolution mapping is not necessarily 
needed for histological diagnosis. However, high lateral spatial resolution mapping does 
have advantages. There is the advantage of acquiring a large number of spectra which is 
amplified for reduced step sizes due to the square relation between step size and number 
of pixels. The additional spatial and spectral biochemical information could potentially 
facilitate the separation of more pathology groups.  
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LDA is a well known and accepted technique for spectral classification, and this thesis 
has shown its potential application in Raman imaging for histological diagnosis, 
supporting previously published work.192-194 These works have been based on tissue 
classification models generated previously, with mapping data projected onto the model. 
This approach was not possible in this study since maps were acquired on a novel 
mapping system, with different optics to previously generated tissue classification 
models. Furthermore, due to the nature of rapid mapping technology, there are 
differences in the step size and sampled volume compared to previously acquired model 
data. In the future, large tissue classification models can be generated, more rapidly than 
previous studies due to the rapid mapping technique. Training dataset sizes will 
approach those reported in IR studies, for example Bird et al. reported a study in which 
1.4 million spectra were analysed,191 and this will easily be achievable with rapid Raman 
mapping. Further work is still required to investigate the extent to which the technique 
can be exploited with respect to automated imaging and also larger sample numbers 
need to be included in the model. In this preliminary study projection of an unknown 
dataset onto the model allows validation of the model to a degree but using spatial 
information relating to morphology, but rigorous validation and testing will still be 
required when further samples are added to the model. Nevertheless, this is an important 
step in the move towards clinical implementation of vibrational spectroscopy for 
automated histopathology.   
 
Although, validating LDA as a potential method for automated histopathology was not 
the primary aim of this study, and it was merely used as tool of comparison, this study 
has shown that the technique holds promise for future application.  Other groups have 
favoured various other cluster analysis techniques such as k-means and ANN, but these 
techniques have failings, namely they are extremely computer intensive, they also force 
spectra into distinct groups, which is not realistic for two reasons. First, pathology 
groupings do not have distinct boundaries, especially for lower spatial resolutions where 
spectral mixing is known to have an effect on ‘boundary pixels’ and, second,150 in a 
similar manner, the carcinogenesis progression is not separated by distinct boundaries 
between pathologies. LDA has advantages over other, more widely used chemometric 
 - 155 - 
techniques for spectral imaging, since the technique could potentially facilitate the visual 
and spectral representation of spectral mixing. This idea was also proposed by Mansfield 
et al. regarding FTIR imaging, in which the probability was described by a mixed colour 
palate which mirrored the probability of a spectrum/pixel belonging to more than one 
classification group, which could account for spatial averaging and also uncertainty in 
the pathology classification due to subtle spectral differences. E.g. for a pixel/spectrum 
which was predicted to be in two groups, say connective tissue (yellow) and cancer (red) 
with equal probability would be represented by an orange pixel. The shade of which 
could be further determined by the probability weightings.  
 
Although LDA model performance provides a relatively arbitrary method of 
comparison, it allows a quick and easy method of comparing the maps acquired with 
different parameters. PC fed LDA models are also able to cope with low signal to noise 
spectra, where other techniques may fail. Since it is well known that the initial group 
choices are an important factor with LDA models, the initial grouping may play a large 
part in the model performance, but as the groups were the same in both the 8.4 and 2.1 
µm models, it enabled direct comparison of the two maps. The use of this ‘unknown’ 
group as an independent test set to validate the model provided confirmation that the 
classification was reasonable, supported further by spatial information relating to 
morphology.  
 
There is also the potential, as discussed above that the small step size map may identify 
more subtle biochemical features which may account for the larger number of 
misclassified spectra within the small (2.1 µm) step size map. As a result, the model 
performance for the small step size map could potentially be significantly better if the 
initial groupings are chosen more carefully. However, mapping at even smaller step 
sizes, may also induce greater heterogeneity in the maps, even from cells of the same 
pathology (due to sampling different parts of the cell within each image pixel).  It 
remains a question what needs to be distinguished for a specific pathology application 
and this is discussed further in Section 7.3. 
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There is also scope to reduce map times in this study. Acquisition times of 15s were 
used to maximise tissue classification performance, but as shown in the previous 
chapter, PCA is able to cope with relatively poor SNR spectra providing spectral 
datasets are large enough. Map times were of the order of 12h for the high spatial 
resolution maps, whilst the rapid prescan was acquired in approximately 10 minutes. 
This was sufficient for visualising morphology in the PC scores image, but when 
reduced to well-defined rectangular training sets, the dataset size was not sufficient to 
deal with the poor signal to noise.   
 
Further work ongoing within the group may lead to accurate biochemical fitting of the 
spectral maps and therefore images can be constructed of biochemical distributions also 
see Appendix D).124,172 
 
In summary, rapid Raman spectral mapping with LDA discrimination has the potential 
for automated tissue classification in the future. Greater numbers of samples and patients 
(to cover the likely variability in the population of interest), with detailed histopathology 
will need to be included into the training model. It also appears from this initial study 
that high lateral spatial resolution mapping is not essential for clinical diagnosis of bulk 
tissue types, but may have advantages in the future for discriminating further tissue 
types.  
 
This study has shown that the LDA projection imaging process can potentially be 
applied to multiple samples making it a suitable technique for automated histopathology 
in the future. Furthermore, spatial information from visually representing LDA 
classification as pseudocolour images can provide insightful information which will help 
to explain misclassifications based on morphological features which is not possible from 
traditional scatter plot representation. After a thorough search of the literature, this 
appears to be the first study in which multiple images are stitched together to investigate 
classifications between samples and also the first study to investigate misclassifications 
visually in this way. 
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6.5 Evaluation of rapid Raman mapping as a research tool to 
elucidate biochemical changes associated with carcinogenesis  
6.6 Background - goblet cells and mucins 
As described previously, Barrett’s oesophagus (intestinal metaplasia) is characterised by 
the presence of goblet cells. Goblet cells are simple columnar epithelial cells found in 
many parts of the body, in particular in the intestinal and respiratory tract. The function 
of the goblet cell is to secrete mucus which is comprised mainly of mucins 
(glycoproteins in electrolyte solution).208 Oesophageal submucosal glands have been 
shown to contain neutral, sialated, and sulphated mucins and furthermore this varies 
with Barrett’s subtype (IM, CM and FM).11,209,210  The presence of the sia-group in 
glycoproteins, which has been linked to cancers which metastasise, could be detected 
and potentially quantified using Raman spectroscopy using a peak at 880 cm-1, although 
this peak is also attributed to tryptophan residues.211  
 
It was hypothesised that Raman spectroscopic mapping could be used to obtain high 
spatial resolution images of goblet cells and furthermore gain insight into the 
biochemical constituents within goblet cells and potential biomarkers. This could help to 
understand the process of carcinogenesis and also provide biochemical evidence which 
may help to support tissue classification models which separate Barrett’s subtypes and 
premalignant changes.    
 
In order to elucidate subtle biochemical changes, a long acquisition time of 60 s was 
used to ensure good quality spectra. A step size of 1.1 µm was used. The entire sample 
was mapped, then cropped to the Barrett’s gland to highlight variance within the region 
of interest. The H&E section and large area map can be seen in Figure 6-29. The pseudo 
colour PC scores images and corresponding PC loads can be seen in Figure 6-30. 
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Figure 6-29: H&E stained section (of the mapped section on CaF2) and PC2 scores image of a 
region of Barrett’s (with goblet cells) surrounded by stromal fibrous connective tissue(FCT)  
Of particular interest is the ability of resolve the 4 nuclei in the centre of the Barrett’s 
gland in PC2 (indicated in Figure 6-30 with negative peaks (785, 859, 930, 1089, 1204, 
1233, 1255, 1314 and 1325cm-1) consistent with FCT and DNA.  
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Figure 6-30: Pseudocolour PC score images (PC2-5) for the cropped region of interest 
containing Barrett’s (with goblet cells) and surrounding FCT 
 
There is potentially some evidence of the sia-group peak at 880 cm-1, considering the 
negative peak in PC 5 but this was not conclusive in this sample.   
 
Cluster of nuclei 
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A second sample of Barrett’s was mapped with high spatial resolution, and the 
pseudocolour PC score images and corresponding PC loads can be seen in Figure 6-31. 
The glandular structure of the Barrett’s is clearly evident.  
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Figure 6-31: Pseudocolour PC score images (PC1-4) and corresponding PC load of a sample 
of Barrett’s (with goblet cells) mapped with a 40 s acquisition time and step size of 2.1 µm. 
The H&E of the contiguous section is also shown 
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In the second sample, there were also peaks at 880 cm-1, (positive peaks in PC 3 and 4). 
However, this is anecdotal at present and further work is required to investigate the 
presence of mucins in oesophageal tissue. Biochemical fitting may assist with this as 
suggested previously.  
  
It should also be noted that luminescence was again detected within the FCT regions, in 
this case, in the inter-glandular FCT, this strengthens the observations noted in the 
previous section (HGD and FCT using LDA).   
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Chapter 7 Results and discussion: 3) Factors limiting 
translation of Raman optical diagnostic 
techniques into the clinical environment 
7.1 Comparison with Raman microscopy system results  
Figure 7-1 compares the normalised Raman spectra acquired from two oesophageal 
cancer tissue samples using both the Visionex probe and Renishaw microscopy system 
1000 (labelled as system 1 - S1). The probe spectra were directly from the EMR, whilst 
the S1 spectra were acquired from the biopsy taken from the point of probe 
measurement. 
 
 
Figure 7-1: Comparison between probe (spectra with large background) and Renishaw system 
1000 (S1) for two cancer samples (spectra with well defined peaks) 
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As discussed previously, the amide I band, CH2, CH3 deformation and phenylalanine 
peak at 1005 cm-1 is visible even with the large probe background. The inferior spectral 
quality is obvious, especially with respect to spectral resolution (peak width). It is also 
interesting to note the probe spectra appear to be very consistent and two cancer samples 
taken from the EMR sample are very similar, whereas the spectra acquired using S1 
shows subtle differences, despite normalisation. This is likely to be caused by the 
smaller sampling volume of the microspectrometer. For the microspectrometer (x50 
objective) the laser spot size is ~15x25 µm, (~7x50 µm line focussed) whilst the 
sampling volume for the Visionex probe is considerably larger (of the order of mm).  
 
There is a possibility that the consistent probe background may be beneficial, since 
consistency is a key attribute when constructing tissue classification models. However, it 
is also likely that although the background is consistent, it is likely the background is 
masking subtle biochemical differences in the spectra. Further work is required to 
compare the two systems. 
7.2 Practical considerations for implementing Raman spectroscopy 
in a clinical environment 
7.2.1 Ambient light sources 
Ambient light can pose a problem with Raman spectrometer systems. This is especially 
problematic when translation to a clinical environment is considered, and potentially 
more problematic for probe based systems compared to laboratory based systems, such 
as those which could potentially be used for automated histology.  
 
LCD computer screens were found to be a very problematic source with very distinct 
peaks appearing in the Raman spectra as shown in Figure 7-2. Fluorescent lighting can 
also provide spectral artefacts.  
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LED light sources were found to over come these problems. Further work will be 
required to investigate endoscopic light sources for in vivo application and also effects 
from theatre lighting.  
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Figure 7-2: Raman spectra acquired using the Visionex probe of the LCD screen used in 
conjunction with the spectrometer computer control 
7.2.2 Effect of ambient temperature 
Table 7-1 shows the peak shifts which were noted in both System 1000 spectrometers 
for both the polymer standard and neon argon lamp. It is evident that there is potentially 
a contribution to the ambient temperature artefacts from both the spectrometer and laser. 
For the S100 probe system, a linear peak shift with temperature was not evident with the 
polymer standard so the range is stated.  
 
Table 7-1: Summary of the peak shifts for polymer standard and Ne-Ar calibration lamp with 
variation in ambient temperature 
System Polymer peak shift Ne-Ar lamp peak shift 
S1000 (1) 0.4 cm-1/ºC 0.1 cm-1/ºC 
S1000 (2) 0.6 cm-1/ºC 0.5 cm-1/ºC 
S(100) Range (max-min) 1.5 cm-1 -0.1 cm-1/ºC 
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7.2.2.1 Ambient temperature study using Raman mapping 
Figure 7-3 shows a pseudocolour score map of the 1st principal component. The region 
of increasing temperature is clearly evident as a region of low scores (blue-purple). A 
repetitive stripe pattern is also evident once the temperature has stabilised and this is 
attributed to temperature oscillation as the air-conditioning maintains a constant 
temperature, consistent with that noted by Fukura et al212. The region of oscillation is 
consistent with a peak shift of approx 0.5 cm-1.  The 1st PC load (not shown) exhibits 
derivative spectral features which is consistent with characteristic peak shifts.  
 
 
Figure 7-3: Raman map acquired with varying ambient room temperature. Left – 
pseudocolour PC score map of a polymer standard with correlating change in ambient 
temperature. Right – mean spectra taken from the red and green areas of the pseudocolour 
score map 
The effect of peak shifts on a multivariate tissue classification model was also 
investigated. A classification model was generated using spectra acquired from S1000(1) 
at 23 ºC. Considering the effect of this on a tissue classification model, work in 
collaboration with another group member demonstrated that when spectral data modified 
with an artificial peak shift of 5 cm-1 was projected onto the original classification model 
the percentage correctly classified dropped from 94% to only 75%. This is an important 
result as it demonstrates the importance of temperature stability of Raman systems. A 
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copy of a poster presented at the International Conference of Vibrational Spectroscopy 
can be seen in Appendix J.  
7.2.2.2 Summary 
Peak shifts can have significant effect on Raman spectra, and results are consistent with 
the literature.213 Shifts occurred in both the polymer standard and neon argon spectra 
suggesting that shifts were caused by expansion or contraction of spectrometer 
components with temperature as well as a potentially significant contribution from the 
laser source. The apparent linear shift across the entire wavelength range would make 
correction easier than for example if a breathing artefact was apparent. Initial results 
suggest that the effect is less pronounced when using the compact S100 spectrometer 
which may be due to the simplicity of the spectrometer, or due to the lower resolution 
spectra, although further work is required to investigate this. This could potentially ease 
the transition to clinical application, in theatre for example. The detrimental effect of 
temperature induced peak shifts on a tissue classification model is demonstrated 
highlighting the importance of temperature stabilisation over short and long time 
periods.  
7.2.3 Reproducibility and transferability 
Comparison of Raman probes has generally relied on measuring the sampling efficiency 
and determining the focal depth using Si. Attempts at measuring the sampling volume 
off axis have also been made using diamond chips.147 These measurements can give a 
good and simple method of comparing probes, but what is really of interest is the 
sampling volume and depth in tissue or a tissue equivalent material. Of interest is the 
ability to quantify a probe’s ability to detect subtle differences in materials with different 
Raman signatures. For example the ability to detect a small region of cancer within a 
region of normal or Barrett’s epithelium or a region of Barrett’s within normal 
epithelium. This is a situation which is difficult to mimic in a phantom due to difficulties 
in replicating optical properties of different pathologies. However, considering a 
situation for which this would be easiest, the biomarker would be a substance with a 
unique Raman peak allowing the substance to be easily identified within surrounding 
tissue, for example a calcification in tissue. However, for substances, for example 
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collagen and glycogen, which may be easily distinguishable using Raman microscopy, 
this is more difficult with probe spectra due to large backgrounds, which are often 
dominant at the lower Raman shift range 400-900 cm-1. A further aspect for 
consideration is the effect of substance concentration on a probe’s ability to detect a 
certain substance within tissue.  
 
7.2.4 A discussion of lateral spatial resolution: moving towards 
quantification when multivariate statistical techniques are used for 
imaging 
This study also highlights an important aspect of spatial resolution for clinical diagnosis 
and raises the question: what is the spatial resolution in a Raman image. Although 
studies have looked at the impact of spatial resolution for spectral imaging,148,180 this 
issue is non trivial since contrast and spatial resolution are inseparable for spectra data, 
an idea supported by other authors.149 One concept is that due to the multidimensional 
nature of the spectroscopic information (for Raman mapping for example the 3D spectra 
data cube) there are many contributing factors to the contrast and spatial resolution that 
can be achieved. The multivariate techniques used for analysis may be of particular 
importance. To the author’s knowledge there is nothing in the literature investigating 
this concept. Further work will need to be carried out in the future to investigate these 
concepts.  
7.2.4.1 Initial phantom designs 
In order to test the limitations of the system and investigate how performance varies for 
detecting different substance, the design of a phantom would need to incorporate the 
concentration of a substance and Raman cross section. An alternative approach may be 
to construct the phantom with substances with a varying biochemical similarity, which 
can be measured by the degree of orthogonality.  
 
To mimic the clinical situation, the background would be a substance with similar 
optical properties (less important for mapping phantoms since penetration/sampling 
depth is not really a consideration) and Raman signature to say for example, epithelial 
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tissue, Barrett’s or stroma (or in the most simple of cases intralipid or intralipid/gelatine 
mixture), whilst the focal region may be a small region of cancer. It would be important 
to mimic the biochemical signature of the focal region for the phantom, or use a material 
with comparable orthogonality to the background tissue type chosen. Detecting HGD 
and LGD would require more subtle biochemical differences in the phantom which can 
be represented by a reduced concentration of a substance or more similar biochemical 
signature.  Interpreting the results would become especially complex since multivariate 
techniques are often used to interpret Raman images.   
 
Figure 7-4 shows some initial phantom designs which could potentially be used for 
quantifying spatial resolution and image contrast in Raman images. This could also be 
extended to depth and lateral spatial resolution for Raman probe and surface offset 
Raman spectroscopy.66  
 
 
Figure 7-4: Initial phantom designs which can incorporate materials of varying concentration 
and volume to overcome limitations with current assessment of spatial resolution 
7.3 The combination of chemometric analysis and Raman 
spectroscopy for pathology diagnosis – data quality versus data 
quantity 
As touched upon in both the Raman probe for targeted biopsy and Raman mapping for 
automated histology studies, signal to noise ratio and dataset size are key parameters of 
multivariate tissue classification models. For Raman probe studies, spectra datasets sizes 
are relatively small, compared to Raman mapping studies, and whilst the SNR of the 
probe spectra is relatively good, spectral peaks are masked by probe backgrounds. 
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Considering Raman mapping experiments, to obtain Raman images in clinically 
practicable time frames, the SNR must be sacrificed 
 
It was demonstrated previously (Figure 6-14), that the quality of the PC loads increases 
with dataset size. It has also been shown that fewer numbers of good quality probe 
spectra (albeit with few spectral peaks) can separate out three pathology groups.  
 
Consensus pathology has also been shown to improve tissue classification by improving 
the training of the model.  
 
A further consideration for automated histopathology and targeted biopsy techniques is 
how specifically the spectrum relates to the pathology, which is in effect a problem of 
spatial resolution since it relates to spectral mixing. To investigate this, the classification 
performance of different models was assessed from a perspective of practical clinical 
implementation, with the aim of determining optimum parameters for future clinical 
implementation studies. The number of pathology groups included, dataset size and 
spectral quality were considered. The overall experimental time and analysis time was 
also considered. The results are summarised in Table 7-2. 
 
The quality and quantity of the data required will depend on the diagnostic requirements. 
For example if the ultimate aim is only to separate out normal from abnormal tissues 
then relatively crude spatial averaging and poor signal to noise spectra could be used 
however if the aim is to separate out tissue types, pre-cancers, cancers and even predict 
prognosis then more subtle biochemical features may need to be resolved. It will also 
depend on whether the histopathologist is confident in spectroscopic diagnosis without 
the additional morphological information represented in the form of a pseudocolour 
histology image. If not then crude step size maps could potentially provide a rapid and 
automated method of pathology diagnosis. Taking this idea to the extreme, it may be 
sufficient simply to use an ex vivo probe or collect a spectrum with a low magnification 
objective, averaged over a large area of tissue, although work will need to be carried out 
to verify the minimum level of signal mixing required to detect pathology changes. A 
combination of modalities may be advantageous, for example FTIR for mapping the 
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entire sample, followed by high lateral spatial resolution Raman mapping of regions of 
interest. The complementary nature of FTIR and Raman is being explored by many 
groups including ours.137,190  
 
Table 7-2: Summary of training model performance for Raman probe and Raman mapping 
studies 
Model summary 
Samples/ 
spectra 
Model parameters 
Acq. time, stepsize, 
pathology groups,   
Training 
performance 
% 
Novel probe – Limited dataset size, prelim.  model 30/30 4s&60s,3gp(consensus) 86, 90 
Visionex probe model – reasonable dataset size 184/184 4s, 3gp (consensus) 82 
Raman map B – low SNR, large dataset 1/9000 0.5s, 25.3, N/A N/A(PCA) 
Sample 1 – LDA, poorly define dataset, low spatial res. 1/9592 15s, 8.4, 6gp 70.1 
Sample 2 – LDA, poorly defined dataset, high spatial res. 1/156220 15s, 2.1, 6gp 64.9 
Sample 1 – LDA, well defined dataset, high spatial res. 1/9592 15s, 8.4, 5gp 94.4 
Sample 1 – LDA, well defined dataset, low spatial res. 1/156220 15s, 2.1, 5gp 93.7 
Sample 2 – very well defined dataset, low spatial res. 1/500 15s, 8.4, 3gp 100 
Sample1&2 – LDA, very well defined dataset, low spatial res. 2/1292 15s, 8.4, 5gp 97.5 
    
 
These two points have considerable impact on the implementation of Raman 
spectroscopy as a clinical tool. It can be inferred that if small datasets are used (such as 
Raman probe studies, relatively good SNR spectra will be required until adequately 
large datasets are acquired. This implies that for future model generation, Raman spectra 
with a poorer SNR than initially conceived should be acquired in tandem with better 
quality spectra with the prospect of larger datasets in the future. The number of 
pathology groups which can be separated will be low until larger spectral datasets are 
acquired. In the future, it may become apparent that the limited spectral information 
within Raman probe spectra with high background and poor spectral resolution. 
However, the development of novel probe designs should improve Raman spectra.   
 
The extent to which we attempt to separate out pathology information is a question of 
clinical need which, ultimately, will need to be answered by the histopathologist. 
 
It is evident from the results of this thesis that there is promise for future clinical 
implementation of Raman spectroscopy for both targeted biopsy and automated 
histopathology. For the probe studies, the next step is to take the probe to the next phase 
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of development, dealing with issues such as sterilization and retesting in a clinical 
environment, whilst for the mapping studies, large pre-clinical trials are now required 
which will involve mapping many more samples to verify inter-compare patients and 
pathologies. The following sections summarise potential protocols for these studies 
based on lessons learned from this thesis.  
7.3.1 Optimum parameters for future Raman probe for targeted biopsy 
studies 
One factor which has arisen from these studies is the limits of SNR which can be pushed 
when used in combination with multivariate techniques. In any future study, SNR of 
measured spectra should be taken below what is thought feasible in the anticipation of 
measuring spectral datasets large enough to deal with limited SNR data. Acquiring both 
good and poor quality spectra from each sample enables robust training classification 
models to be generated.  
 
A proposed protocol for ex vivo probe validation is to measure clinical samples in 
theatre, prior to clinical throughput for histology. Once samples have been formalin 
fixed and archived, samples can be extracted and reanalysed for consensus pathology. 
This will maximise sample numbers. This method may not be suitable for the probes 
with large sampling volumes, but for the novel probe this is not an issue. The acquisition 
times determined were 2x15 s, 1 s, and 0.1 s. The latter would feasibly allow large areas 
to be sampled or even imaged, with the clinician effectively able to sweep the probe 
over larger areas to survey for potential disease, however, spectrometer design may be 
needed to reduce dead time in CCD readout as with rapid Raman mapping. The 
proposed protocol is schematically described in Figure 7-5. 
 
For probe studies with larger sampling volumes, the in vivo set up must be mimicked 
more closely, for example measuring EMRs or resected samples. Measuring in a theatre 
environment would maximise sample numbers. 
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Figure 7-5: Proposed protocol for large scale ex vivo Raman probe study for targeted biopsy 
7.3.2 Optimum parameters for future Raman mapping studies for 
automated histopathology 
In order to determine optimum parameters, the method in which potential automated 
histopathology will be carried out needs to be considered. There are two possible ways 
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in which it could be utilised which require different approaches. The first approach is the 
use of relatively crude spatial resolution Raman mapping for filtering out non-relevant 
tissue samples (i.e. normal or low risk samples). The second would be to provide the 
histopathologst with a more detailed histology breakdown, and image.  
 
Any potential future study would ideally encompass both eventualities. This would be 
easy to achieve since bulk discrimination of tissue types would likely to be carried out 
using crude spatial resolution with short acquisition times to minimise overall mapping 
times. For more detailed information, these maps can then be followed by longer 
acquisition time and/or high spatial resolution maps.  
 
It appears that high spatial resolution is not necessarily required for bulk tissue 
classification which implies that mid-IR imaging may be a more suitable mapping 
technique, since it is more reliable and has greater SNR data. However, it is also implied 
that higher spatial resolution may have advantages, but until a larger scale trial is carried 
out, this cannot be ruled out. Furthermore, Raman has advantages over mid-IR 
techniques since sample preparation is simple (mid-IR absorption mapping is very 
sensitive to saturations caused by thick tissue samples). Continuity with in vivo studies 
would also be advantageous since this would enable biochemical validation of both 
techniques in tandem.  
 
Considering Raman mapping technology is advancing it can be assumed that Raman 
mapping times will reduce further still in the future. Based on this, future large scale 
Raman mapping studies should be carried out, potentially in tandem with mid-IR 
imaging. Similar SNR factors apply to Raman mapping experiments as well as mid-IR 
imaging, and reducing the SNR of mid-IR spectra should also be investigated.  
 
It is envisaged that the Raman spectrometer system will eventually be situated in the 
histology department. It has been shown that frozen sections can be stained on the 
substrate which enables comparison with contiguous sections (Figure 6-17). However, 
CaF2 substrates (~£25) are not reusable once stained and coverslipped which implies 
that a cheaper alternative is required. Polished aluminium slides have been used in the 
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group for cell mapping studies which are cheaper than CaF2, however they will need to 
be evaluated fully for tissue measurements and histopathology.   
 
Raman mapping could be carried out in parallel with current clinical practice. A 
selection of biopsies will be snap frozen rather than formalin fixed and frozen sections 
and contiguous H&E sections taken. The remainder of the sample could then either be 
retained as a frozen sample, or formalin fixed and archived according to current clinical 
procedure.  
 
Raman mapping would be used in a similar manner to traditional microscopy. A low 
magnification global image would be assessed, followed by higher magnification 
regions of interest. The initial aim would be to filter out non-relevant tissue samples (i.e. 
filter out normal samples), and for this only bulk tissue pathology discrimination would 
be required.  
 
To mimic this process, a Raman mapping protocol should be adopted similar to that 
described in Section 4.6.4, additional rapid scans should be carried out in anticipation of 
larger datasets improving tissue classification. The proposed study would consist of 
several rapid pre-scan (0.1s, 25, 8 and 1-4µm), followed by and a longer acquisition time 
maps of regions of interest (5-15s, 8 and 1-4µm). For developing the training model, 
mapping the entire sample is not necessarily essential, as long each of the pathologies is 
well represented. However, this will be required for clinical implementation.  
 
Investigating the effects of projecting poor quality spectra onto classification models 
with good SNR data may be an alternative to long mapping times in clinic since spectral 
libraries can be built in advance of clinical implementation.  
 
It is likely that main-frame computing may be required for the analysis stage to handle 
large datasets until computer technology improves sufficiently.  
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Chapter 8 Future work 
8.1 Multi-centre study of calibration standards and tissue equivalent 
phantoms  
The previous section described potential protocols for large scale clinical trials for both 
Raman probes for targeted biopsy and Raman mapping for automated histopathology. 
Moving towards inter-departmental trials is another key step, but in order to achieve this, 
it is important to ensure system standardisation and transferability.  This problem has 
been addressed within our laboratories between microscopy systems, using green glass 
intensity calibration. However, problems were experienced in this study for the Raman 
probe system. Further work is required to identify sources of these discrepancies and 
similar investigations carried out using novel probe designs. 
 
Objective: To develop methods of transferring data and classification models between 
microscopy and laboratory Raman systems. This will enable probe data to be compared 
to previously developed classification models (from the Raman microscopy systems) 
and furthermore allow development of large scale spectral databases from different 
hospitals. If a reliable method can be developed, it will enable probe data to be 
compared to previously validated and published results.  
 
It is anticipated that this should be carried out using test phantoms and calibration 
standards since measurements will need to be carried out internationally and 
reproducibly to obtain data to represent different instrumentation under different setups. 
 
It is also proposed that a simple and homogeneous tissue sample is used to obtain 
multiple consecutive sections (with H&E sections in between) to enable more realistic 
comparison of different instrumentation.  Obtaining a large tissue sample from an 
oesophagectomy may be one way of obtaining such a sample since regions of normal, or 
potentially Barrett’s mucosa can be harvested away from the disease site.  
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8.2 Investigate and compare alternative pre-processing and 
multivariate analytical techniques 
It has been discussed previously that there is a need for investigating pre-processing and 
calibration methods to ensure transferability of spectral data between systems. A 
comparison of multivariate techniques such as artificial neural network (ANN), support 
vector machines (SVM) and hierarchal cluster analysis (HCA) with LDA is also 
required.  
8.3 Develop the prognostic model 
The prognostic model investigates correlations between Raman signature and high risk 
patients with HGD, i.e. which high risk patients which are likely to progress to cancer.  
A poster presented at SPEC, Heidelberg (2006) which resulted from some data analysis 
carried out on behalf of Mr. Simon Dwerryhouse (formerly Biophotonics Research 
Group) can be seen in Appendix K.  Following up patients from previous classification 
models, and those within this thesis may enable correlation with progression to cancer.  
8.4 Biochemical fitting of rapid Raman mapping and a comparison 
with immunohistochemistry staining  
One of the next steps towards automated Raman histopathology is fitting biochemical 
constituents to the rapid Raman maps. This so called biochemical mapping has been 
used by our groups and others to elucidate biochemical changes associated with 
carcinogenesis.214,123,175 A further extension of this is to correlate the results with 
immunohistochemistry to identify the presence of mucins and other subtle biochemical 
changes with Raman mapping results and genetic mutation studies.  
 
A collaborative project has already been established with Prof. Sir. N. Wright at CRUK, 
London and preliminary measurements have already commenced to identify different 
phenotypes in Barrett’s crypts.  
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Chapter 9 Conclusions 
9.1 Aim 1 – Classification model conclusions 
The Visionex probe was shown to discriminate three different pathology groups with a 
good overall accuracy in a cross validated multivariate model. Promising results were 
obtained in a preliminary study of a novel single collection fibre probe. Although this 
model was small, it can be inferred that a similar and potentially improved performance 
as the Visionex probe will be achieved with a larger spectral dataset since raw spectra 
(and background spectra) can be seen to contain equivalent spectral information. It was 
also demonstrated that an acquisition time of as low as 4s could be used.  
 
Sampling depth is considered to be an important parameter for probe design and as a 
result, the Emvision probe was ruled out as a potential in vivo probe for endoscopic use 
for early diagnosis of oesophageal premalignancies, however this probe may have other 
applications for probing deeper structures/resection margins.  
 
In summary, both the Visionex and single collection fibre Raman probes have been 
shown to have potential for in vivo applications, and further efforts should now be 
committed to developing large tissue classification models and overcoming 
instrumentation issues prior to in vivo trials.  
9.2 Aim 2 – Evaluation of rapid Raman mapping for potential 
automated histology 
This study has demonstrated the advent of rapid Raman mapping technology in 
combination with multivariate techniques, has enabled mapping times to be reduced to a 
clinically practicable time scale.204,205 
 
A further question of whether or not high spatial resolution mapping is required for 
automated histopathology was addressed. It was concluded that high spatial resolution 
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was not necessarily required and that a step size of 8µm was sufficient for separating 
bulk tissue pathologies. High spatial resolution imaging, does however, have visual 
advantages for the histopathologist since morphological structures can be identified 
more easily. Furthermore, there is the potential for separating out more pathology groups 
by reducing spectral mixing effects. Maps with different spatial resolutions were 
compared using linear discriminant analysis imaging of multiple maps demonstrating 
that technique could be applied between different samples. Rapid Raman mapping has 
been shown to be a useful research tool for elucidating biochemical changes associated 
with pathology.   
 
This thesis and subsequent publications has served to improve the results within the 
literature which will hopefully enable scientists to make an informed choice when 
selecting a Raman imaging technique for biomedical and wider applications.  
9.3 Aim 3 – Factors limiting translation of Raman optical diagnostic 
techniques into the clinical environment 
Practical considerations for implementing Raman spectroscopy for both in vivo and ex 
vivo diagnostic applications were investigated. Ambient light sources such as LCD 
computer screens were found to be a significant problem, which can easily be overcome 
using shielding, switching off the screen or using alternative computer screens. LEDs 
can also provide an alternative light source. However, further work is required to 
investigate theatre lights and those used during endoscopy.   
 
A variation in peak position with ambient temperature was also detected which 
highlights the importance of temperature stabilisation and calibration procedures. Peak 
shifts appear to be less of an issue for the probe based spectrometer. 
 
Consideration of practical issues also led to the development of protocols for future large 
scale clinical studies. One conclusion was that the effectiveness of noise reduction using 
PCA should not be underestimated and it was recommended that this should be taken 
into account when devising study protocols.  
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The potential benefits of optical biopsy/automated histopathology are well known, 
namely that the technique is objective reproducible and in the case of in vivo diagnosis, 
can provide an immediate diagnosis. These factors will have patient outcome and cost 
benefits. This study has addressed some of the important issues which have previously 
limited the translation of Raman spectroscopy into the clinical environment for potential 
in vivo and ex vivo diagnosis of pathology.   
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Appendix A Raman peak assignments in oesophageal 
tissue 
Table A1: Characteristic Raman shift (δ=deformation, νstretch vibration, νs=symmetric vibration, 
νas=asymmetric vibration, adapted from Stone,110 Kendall123 and  Shetty126 
 Assignment Tissue/Substance 
207 Calcium carbonate Cholesterol 
275 τCCC
 
Lactic acid 
350 Ribose, cytosine  
370 δCCC
 
Lactic acid 
385 Cytosine  
400 Silica Fibre probe on cervix 
424 δCCC Human strateum corneum 
425 δCCO
 
Lactic acid 
429 Calcium hydroxyapatite  
430 Cholesterol  
430 δ(OPO) Human tooth 
435 Ribose  
451 O-P-O symmetric bend Chicken leg bone 
481 Glycogen Sigma Aldrich G0885 
492 νs (SiOSi) silicone gel 
500 Cytosine, guanine & disulphide  
500-550 Disulphide (S-S) stretch Protein 
505 ν (S-S) Bovine serum albumin 
507 Disulphide Nails 
509 Disulphide (S-S)  
510 Disulphide (C-S-S-C gauche-gauche-
gauche) 
Protein 
518 Glucose  
525 Disulphide (C-S-S-C gauche-gauche-
trans) 
Protein 
526 ν (S-S) Strateum corneum 
526 ν (S-S) Human strateum corneum 
528 ν (S-S) Protein 
529 Desmosine & isodesmosine (amino 
acids) 
Elastin 
530-1 ν (S-S) Callus, psoriatic plaque 
533 COC deformation (glycosidic ring)  
533 Glucose Blood 
540 Disulphide (C-S-S-C trans-gauche-trans) Protein 
541 νSS AGP (glycoprotein)* 
540 νOCO
 
Lactic acid 
547 Cholesterol Protein 
553 Glucose Blood 
556 ν (S-S)  
574 Tryptophan Eye lens 
575 Cytosine, guanine & disulphide  
576 Glycogen Sigma Aldrich G0885 
576 Glycogen Glycogen (Sigma Aldrich)† 
                                                 
*
 Kopecky, V. et al. (2003). Structure of human a1-acidn glycoprotein. Biochemical and Biophysical 
Research Communications, 300, p. 41-4. 
†
 Hutchings J (Thesis, Section 1.2.3) 
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587 Calcium hydroxyapatite Protein 
591 Apatite Human tooth enamel 
591 δ(OPO) Human tooth 
600 ρ(CH) wagging Human strateum corneum 
607 Cholesterol Protein 
618 Phenylalanine(amino acid) Collagen 
620 Phenylalanine(amino acid) Diseased breast tissue 
620 Phenylalanine  
620-2 ν (C-S) Callus, psoriatic plaque 
620 Phenylalanine (AGP) AGP (glycoprotein)* 
622 Phenylalanine  
623 ν (C-S) Human strateum corneum 
623 ν (C-S) Strateum corneum 
624 Adenine DNA (Z), RNA(Z) 
625 Guanine in the C3' endo/syn form DNA (Z) 
626 Phenylalanine  
626  Cervix tissue 
626 Silica Fibre probe on cervix 
637 Ribose & disulphide Protein 
640 Guanine RNA(Z) 
641 Tyrosine (AGP) AGP (glycoprotein)* 
642 Thymine DNA (A), RNA (A) 
643 ν (C-S), amide IV Strateum corneum, Callus, 
psoriatic plaque 
643 Tyrosine  
644 Tyrosine  
644 ν (C-S), Amide IV Human strateum corneum 
650 δC-COH
 
Lactic acid 
665 Thymine DNA (B) 
668 Guanine in the C3' endo/anti form DNA (A), RNA (A) 
669 ν(C-S) Bovine Serum albumin 
669 ν(C-S)  
669 Thymine  
670 Breathing of aromatic ring of purine 
bases (guanine  & adenine) 
DNA 
670 Guanine DNA (C) 
670 Guanine  
670 Thymine & guanine  
681 Guanine breathing ring  
682 Guanine in the C2' endo/anti form DNA (B) 
692 Creatine (O-C=O) deformation  
704 Calcium carbonate Cholesterol 
709 Glycogen Sigma Aldrich G0885 
700 Cholesterol Brain 
701 Cholesterol  
710 Adenine  
710 νs (Si-C) silicone gel 
710 νCS (AGP) AGP (glycoprotein)* 
717 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
720 Nucleotides Breast cancer in mouse 
720 C-N vibration Phospholipid membrane 
722 Adenine  
724-7 Adenine DNA (A), DNA(B), RNA(A) 
725 C-S Eye lens 
725 CH2 rocking  
727 =C-H in plane bend Breast tissue, lipid 
727 C-C stretch, proline Normal breast tissue 
727 =C-H in plane bend  
728 C-C stretch, proline Oleic acid methyl ester 
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729 Adenine breathing ring  
729 Adenine DNA (Z), RNA(Z) 
730  DL-Lactic acid (C3H6O3) 
742-748 O-P-O DNA (Z), RNA(Z) 
743 in bovine albumin Sigma Aldrich A2153 
746 ρ(CH2) Human strateum corneum 
748 Thymine DNA (B) 
749 Thymine breathing ring  
750 δOCO
 
Lactic acid 
750 Cholesterol Carotid artery 
756 Tryptophan (AGP) AGP (glycoprotein)* 
759 Tryptophan (amino acid)  
759 Tryptophan (amino acid) Human eye lens 
760 Tryptophan (amino acid) Rabbit & human cornea & Rabbit 
aqueous humour 
760 Tryptophan & tyrosine Rabbit lens 
760 Tryptophan (amino acid)  
760 Tryptophan (amino acid)  
760 Tryptophan (amino acid)  
761 Glycogen Sigma Aldrich G0885 
762 Collagen Sigma Aldrich C7774 
770 Breathing of aromatic ring of pyrimidine 
bases (cytosine & thymine) 
DNA 
777 Thymine DNA (A), RNA (A) 
780 Cytosine DNA (A), RNA (A) 
780 Nnucleotides Breast cancer in mouse 
780 Uracil ring  
782 Cytosine ring breathing DNA (B) 
785 O-P-O DNA (C) 
787 Cytosine & uracil  
788 Thymine, cytosine, O-P-O DNA 
790 νs O-P-O DNA 
790 Acetone (C-C-C) stretch  
795 DNA DNA (Sigma Aldrich)† 
800  pyruvate 
806-813 (809) νs O-P-O DNA (A) 
811 Nucleotides Breast cancer in mouse 
814 νs O-P-O DNA 
814 νs O-P-O RNA (A) 
814 C-C stretch, backbone Type I collagen (human placenta) 
814 C-C stretch, backbone Collagen 
814 C-C stretch, backbone in collagen Sigma Aldrich C7774 
815 Phosphate  
816 C-C Proline ring Collagen type I, normal skin 
dermis 
817 C-C stretch, backbone Infiltrating ductal carcinoma 
817 C-C stretch, backbone Diseased breast tissue 
818 Haemoglobin  
818  Cervix tissue 
818 Silica Fibre probe on cervix 
819 Tyrosine  
820 Structural protein Breast 
825-830 Tyrosine (amino acid) Histones 
825-842 O-P-O DNA (B) 
826 in bovine albumin Sigma Aldrich A2153 
827 δ(CCH) aliphatic Human strateum corneum 
828 Tyrosine (amino acid) Sigma Aldrich T8909 
830 C-COOH stretch Lactate 
830 C-COOH stretch DL-Lactic acid (C3H6O3) CH3-
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CHOH-COOH 
830 C-COOH stretch Lactate 
830 Tyrosine (amino acid) Human eye lens 
830 Tyrosine (amino acid)  
830 Tyrosine (amino acid)  
830 Tyrosine (amino acid)  
830 νC-COOH
 
Lactic acid 
832 Tryptophan & tyrosine Rabbit lens 
832 Tyrosine  
832 Tyrosine  
833 νas O-P-O DNA 
833 Ribose phosphate 
 
 
834 (832-834) Tyrosine (AGP) AGP (glycoprotein)* 
835 νas O-P-O DNA (B) 
840 Tyrosine (amino acid)  
840 Glucose  
840-860 Polysaccharides  
840-860 Polysaccharides  
840-880 Glucose Blood 
846 Tyrosine (amino acid) Sigma Aldrich T8909 
847 Glucose Sigma 
849  Breast 
850 Proline  
850 Tyrosine (amino acid)  
850 Tyrosine (amino acid)  
850  Bovine albumin Sigma Aldrich 
A2153 
850 δ(CCH) aromatic Human strateum corneum 
850-3 δ(CCH) aromatic Strateum corneum, Callus, 
psoriatic plaque 
852 Tyrosine (AGP) AGP (glycoprotein)* 
853 Tyrosine (amino acid) Human eye lens 
853 Tyrosine (amino acid) DNA 
853 Glycogen Sigma Aldrich G0885 
854-6 Tyrosine (amino acid) Histones 
855 Tyrosine  
855 C-C stretch Proline ring Collagen 
855 C-C stretch, proline Type I collagen (human placenta) 
856 Glycogen Glycogen (Sigma Aldrich) † 
856 Proline Chicken leg bone 
856  Polysaccharides in glioma grade 
III (human brain tissue) 
856 CC strectch, COC stretch, 1,4 glycosidic 
link 
 
856 C-C stretch collagen backbone & Proline 
ring 
Diseased breast tissue 
856 collagen Collagen IV (Sigma Aldrich)† 
856 C-C stretch, proline Infiltrating ductal carcinoma 
(breast) 
856 ν(CC) skeletal vibrations, keratotic Healthy human skin dermis 
856 C-C stretch collagen backbone & Proline 
ring 
 
856 Tryptophan & tyrosine Rabbit lens 
856 C-C stretch Proline ring in collagen Sigma Aldrich C7774 
857 Tyrosine  
858 C-C stretch in elastin Sigma Aldrich E1625 
859 C-C Proline ring Collagen type I, normal skin 
dermis 
860 Collagen Fibrocystic human breast tissue 
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860 Lactate Human aqueous humour 
865 Ribose, Tryptophan (amino acid) Protein 
866 Lactic acid DL-Lactic acid (C3H6O3) CH3-
CHOH-COOH 
868 C-C stretch, hydroxyproline Oleic acid methyl ester 
870 C-C stretch, hydroxyproline Normal breast tissue 
870 Proline (amino acid) Malignant breast tissue 
870  Breast 
872 C-C stretch of 4-hydroxyproline in 
collagen 
Sigma Aldrich C7774 
873 hydroxyproline Chicken leg bone 
873 Glycerol fragment vibration (Sialic acid)  AGP (glycoprotein) ‡ 
874 C-C stretch, hydroxyproline Type I collagen (human placenta) 
874 C-C stretch of 4-hydroxyproline Collagen 
876 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
876 C-C stretch, hydroxyproline Infiltrating ductal carcinoma 
(breast) 
876 C-C stretch of 4-hydroxyproline Diseased breast tissue 
878 Tryptophan (AGP) AGP (glycoprotein)* 
879 Tryptophan (amino acid) Human eye lens 
880 Tryptophan (amino acid)  
880 Tryptophan (amino acid)  
880 Tryptophan (amino acid)  
880 Tryptophan (amino acid) Rabbit & human cornea 
880 Tryptophan & tyrosine Rabbit lens 
880 Tryptophan (amino acid) Rabbit aqueous humour 
880 Sialic acid (Sia) (AGP) AGP (glycoprotein)‡ 
883 CH2 rocking, Strateum corneum, 
883 ρ(CH2) Human strateum corneum 
885 Ribose, Tryptophan (amino acid) Protein 
890 Structural protein Breast 
890  Breast 
890-1 CH2 rocking, Callus, psoriatic plaque 
892 CH2 rocking,  collagen hydroxyproline Skin 
893  Bovine albumin Sigma Aldrich 
A2153 
895 DNA backbone DNA 
896 Proline Sigma Aldrich T8449 
915 Ribose Protein 
917 Deoxyribose (CH2 deformation) DNA (B) 
920 Glucose Sigma 
920 C-C stretch in elastin Sigma Aldrich E1625 
920 Lactic acid DL-Lactic acid (C3H6O3) 
920 C-C stretch Proline ring Diseased breast tissue, collagen 
920 C-C Proline ring Type I collagen (human placenta) 
& infiltrating ductal carcinoma 
(breast) 
920 C-C stretch Proline ring in collagen Sigma Aldrich C7774 
921 C-C Proline ring Collagen type I, normal skin 
dermis 
921 C-C stretch Proline ring Collagen 
925 DNA backbone DNA 
                                                 
‡
 Oleinikov, V., Kryukov, E., Kovner, K., Ermishov, M., Tuzikov, A., Shiyan, S., Bovin, N. and Nabiev, 
I. (1999). Sialylation sensitive bands in the Raman spectra of oligosaccharides and glycoproteins. Journal 
of Molecular Structure, 480-481, p. 475-480 
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928 DNA backbone, α helix Protein 
928-940 C-C Proline, valine  
930 Tryptophan (amino acid) Protein 
930 rCH3 Lactic acid 
931 CH3 rocking,  collagen proline Skin 
931 ρ(CH3), ρ(C-C) α-helix Human strateum corneum 
932 Skeletal C-C, α helix DNA 
932-5 CH3 rocking,  C-C stretch α helix keratin Strateum corneum, Callus, 
psoriatic plaque 
934 C-C stretch, backbone Collagen 
934 C-C Proline ring Type I collagen (human placenta) 
935-945 (C-C) skeletal vibrations, α helix α-helix protein secondary 
structure 
935 Collagen Fibrocystic human breast tissue 
936 C-C stretch backbone, hydroxyproline & 
collagen 
Skin 
936 C-C stretch, backbone in collagen Sigma Aldrich C7774 
937 C-C stretch collagen Collagen IV (Sigma Aldrich)† 
937 Glycogen Sigma Aldrich G0885 
937 Glycogen Glycogen (Sigma Aldrich) † 
937 C-C stretch, backbone Diseased breast tissue 
937 C-C Proline ring Infiltrating ductal carcinoma 
(breast) 
937 α-helix nails 
938 ν(C-C) skeletal vibrations, 
keratotic 
Healthy human skin dermis 
938 Peptide backbone stretch  
938 C-C backbone Collagen 
939 C-C-N stretching Bovine Serum albumin 
940 C-C-N stretching in bovine albumin Sigma Aldrich A2153 
940 ν(C-C) of proline and valine Normal human skin 
940 Triple helix vibrations Collagen type I, normal skin 
dermis 
941 C-C stretch Protein 
944 ν(C-C) (AGP) AGP (glycoprotein)* 
944 ν(C-C) Asian skin 
950 4-hydroxyproline Malignant breast tissue 
955 Hydroxyapatite  
956 Carotenoids Human brain tissue, acoustic 
neuroma 
956 ρ(CH3), δ(CCH) olefinic Human strateum corneum 
960 Calcification - hydroxyapatite Human brain tissue, central 
neurocytoma 
960 Calcification - hydroxyapatite Aortic valve leaflets & coronary 
artery segments 
960 P-O symmetric stretch Chicken leg bone 
960 P-O symmetric stretch Atherosclerotic plaque calcified 
salts 
960 Hydroxyapatite, P-O symmetric stretch Calcified plaque 
960 Cholesterol  
961 Apatite Human tooth enamel 
961 Υs(PO) of PO43-in apatite Human tooth 
961 Phosphate groups Calcified atherosclerotic plaque 
966 Hydroxyapatite Calcified plaque 
966 Desmosine & isodesmosine (amino 
acids) 
Elastin 
966 Triple helix vibrations Collagen type I, normal skin 
dermis 
968 C-OH  
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972 =C-H out of plane deformation Breast tissue 
972 C-C Proline ring Normal breast tissue, Oleic acid 
methyl ester 
972 =C-H out of plane deformation Breast 
975 Ribose Protein 
975 Deoxyribose (CH2 deformation) DNA (B) 
978 Symmetric phosphate ion stretching Phospholipids, glucose-1-
phosphate 
978 Symmetric phosphate ion stretching Human cervix 
978 Phosphorylated proteins and nucleic 
acids 
Human cervical biopsies 
982 CH2 rocking Strateum corneum 
1000-1100 Glucose Blood 
1000-1150 C-C skeletal vibrations Phospholipid membrane, 
hydrophobic chains 
1000-1250 Phosphate groups DMPC 
(dimyristoylphosphatidycholine), 
a typical lipid, brain 
1000-1200 C-C stretch – lipids Healthy human skin 
1000 Phenylalanine in bovine Albumin Sigma Aldrich A2153 
1001 Phenylalanine(amino acid) Sigma Aldrich T8324 
1001 Phenylalanine(amino acid) Malignant breast tissue 
1001 Phenylalanine(AGP) AGP (glycoprotein)* 
1001  Ovary 
1001-1004 Phenyl ring breathing mode  
1002 υ(C-C) aromatic ring Strateum corneum, Callus, 
psoriatic plaque 
1002 (C-C) skeletal vibrations, β sheet β-sheet protein secondary 
structure 
1002 Phenylalanine(amino acid)  
1002 Phenylalanine(amino acid)  
1002 Phenylalanine(amino acid) Collagen 
1002 collagen Collagen IV (Sigma Aldrich)† 
1002 Hydroxyproline, tyrosine Type I collagen (human placenta) 
1002 ν(CC) aromatic ring Human strateum corneum 
1003 ν(CC) aromatic ring stretch of 
phenylalanine residue in keratin 
Healthy human skin 
1003 Phenylalanine(amino acid) breathing 
mode 
Human brain tissue, protein 
1003 C-N stretch Urea 
1003 C-N stretch of urea Urea 
1003 C-N stretch of urea  
1004 Phenylalanine(amino acid) Rabbit lens, aqueous humour, 
cornea & human cornea 
1004 Aromatic ring (breathing mode) Normal human skin 
1004 Phenylalanine(amino acid)  
1004 Phenylalanine(amino acid)  
1004 Phenylalanine(amino acid)  
1004 Phenylalanine(amino acid) Diseased breast tissue 
1004 Phenylalanine(amino acid) Infiltrating ductal carcinoma 
(breast) 
1004 Phenylalanine(amino acid) + Trp 
aromatic ring 
Bovine Serum albumin 
1004 Carotenoid Beta carotene, Human breast 
carcinoma 
1004 Phenylalanine in collagen Sigma Aldrich C7774 
1004 P-O symmetric stretch Chicken leg bone 
1005 Carotenoid Normal human breast tissue 
1005 Beta carotene Breast 
1005 Carotenoid Human breast tissue 
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Renal cell carcinoma (1003) 
1005 Phenylalanine(amino acid) Protein 
1006 C-N stretch of urea Urea, rabbit aqueous humour 
1006 Phenylalanine, amino acid Collagen, histones 
1006 Phenylalanine, amino acid Protein 
1006 Carotenoids Human brain tissue, acoustic 
neuroma 
1008 C-N stretch Urea NH2-CO-NH2 
1008 Carotenoids Carotenoids in normal colon 
1010 C-N stretch Human aqueous humour 
1013 Urea N-C-N stretch  
1014 Tryptophan (amino acid)  
1015 Tryptophan (amino acid) Protein 
1016 Tryptophan – amino acid DNA in water 
1017 DNA backbone C-O stretch  
1029 Phenylalanine(AGP) AGP (glycoprotein)* 
1030 Collagen Sigma Aldrich C7774 
1031 Proline  
1031 ν(CC) skeletal cis conformation Human strateum corneum 
1031-32 υ(C-C) keratin Strateum corneum, Callus, 
psoriatic plaque 
1032 Phenylalanine(amino acid) Rabbit & human cornea Rabbit 
lens Rabbit aqueous humour 
1032 Phenylalanine(amino acid)  
1032 proline Type I collagen (human placenta) 
1034  Ovary 
1035 Ribose, Phenylalanine(amino acid) Protein 
1035 C-C skeletal cis  
1043 Proline Infiltrating ductal carcinoma 
(breast) 
1043 Formalin artefact breast tissue 
1046 C-O stretch carbohydrate§ 
1046 Lactic acid  DL-Lactic acid (C3H6O3) CH3-
CHOH-COOH 
1046 Glycogen Glycogen (Sigma Aldrich) † 
1048 Glycogen Sigma Aldrich G0885 
1050 νC-CH3 Lactic acid 
1050 CO stretch, CCC trans skeletal stretch Healthy human skin dermis 
1057 DNA backbone C-O stretch  
1060 δOD Methyl lactate 
1061 Lipid Strateum corneum 
1061 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
1062 υ(C-C) skeletal trans conformation lipid Strateum corneum 
1062 ν(CC) skeletal trans conformation Human strateum corneum 
1064 C-C stretch  
1065 C-O stretch & C-O-C sym. stretch - 
phospholipids 
Human brain tissue 
1066 C-C stretch Breast 
1066 C-C stretch breast tissue 
1066 Proline Normal breast tissue 
1066 C-O, C-O-C stretch Phospholipids 
1066 Lipid  
                                                 
§
 Kast, R. E., Serhatkulu, G. K., Cao, A., Pandya, A. K., Dai, H., Thakur, J. S., Naik, V. M., Naik, R., 
Klein, M. D., Auner, G., W. and Rabah, R. (2008). Raman Spectroscopy Can Differentiate Malignant 
Tumors from Normal Breast Tissue and Detect Early Neoplastic Changes in a Mouse Model.  
Biopolymers, 89(3), p. 235-241. 
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1066  Ovary 
1067 Proline Oleic acid methyl ester 
1069 Hydroxyapatite shifted due to 
environment 
Human cervix 
1070 Symmetric phosphate ion stretching Glucose -1-phosphate, collagen 
1070 Symmetric phosphate ion stretching Human cervix 
1070 Collagen/elastin  
1070  Cervix 
1070 Phosphate / carbonate Atherosclerotic plaque 
1070 Phosphate / carbonate  
1071 apatite Human tooth enamel 
1071 Υas(PO) Human tooth 
1072 P-O asymmetric stretch Chicken leg bone 
1074  Adipose tissue 
1074 Triglycerides Adipose tissue from human aorta 
1078 C-N stretch Benign breast tissue 
1078-1090 C-C, C-O stretch in lipids. C-C, PO2 
stretch in nucleic acids 
 
1079 C-C stretch Breast tissue 
1079  Normal breast tissue 
1079 C-C stretch Breast 
1080 C-C stretch & PO2- sym. stretch - 
phospholipids 
Human brain tissue 
1082 υ(C-C) skeletal random conformation 
lipid 
Strateum corneum 
1082  Oleic acid methyl ester 
1082 PO2- vibration in phospholipids and 
nucleic acids 
Normal human skin 
1082 Lipid Normal human breast tissue, 
Lipid (TPE) 
1082 Lipid Human breast tissue 
1082 Lipid  
1082  Protein 
1082 ν(CC) skeletal random conformation Human strateum corneum 
1083 Glycogen Sigma Aldrich G0885 
1084 Lactic acid DL-Lactic acid (C3H6O3) CH3-
CHOH-COOH 
1084-90 ν(CC), ν(CN) (AGP) AGP (glycoprotein)* 
1085 Calcium carbonate Cholesterol 
1085 C-C stretch Lipid 
1085 Phenylalanine(amino acid) Protein 
1085 Phosopholipids Malignant breast tissue 
1086 C-C stretch, PO2 stretch Phospholipids 
1087 Symmetric stretching of phosphate 
groups of the polynucleotide chain 
DNA 
1090 νCO
 
Lactic acid 
1090 PO-2 DNA (C) 
1091 PO-2 DNA (B) 
1092 Glycogen Glycogen (Sigma Aldrich) † 
1094 DNA O-P-O  
1094 DNA O-P-O  
1095 νs of two ionised phosphate oxygens in 
the diphosphate ester 
DNA (B) 
1095 DNA DNA (Sigma Aldrich)† 
1095 PO-2 DNA (Z), RNA(Z) 
1095 CC stretch, COC deformation 1-4 
glycosidic link 
 
1097 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
1099 PO-2 DNA (A), RNA(A) 
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1100 Formalin Formalin 
1100 PO2 stretch Protein 
1100 νs of two ionised phosphate oxygens in 
the diphosphate ester 
DNA (A) 
1100 Lipid disorganised  
1100-1110 (C-C) skeletal vibrations Unordered protein secondary 
structure 
1104 C-C stretch lipid  
1108 Desmosine & isodesmosine (amino 
acids) 
Elastin 
1118  Normal breast tissue 
1119  Oleic acid methyl ester 
1119 C-C stretch Breast tissue 
1119 C-C stretch Breast 
1122 C-C stretch lipid  
1123 Glycogen Sigma Aldrich G0885 
1123 Glucose Sigma 
1125   
1125  Infiltrating ductal carcinoma 
(breast) 
1126 C-N stretch Protein 
1126 C-C stretch - phospholipids Human brain tissue 
1126 ν(CC) skeletal trans conformation Human strateum corneum 
1127 υ(C-C) skeletal trans conformation lipid 
& keratin 
Strateum corneum, Callus, 
psoriatic plaque 
1127 Lipids Strateum corneum 
1127  Type I collagen (human placenta) 
1128 C-C stretch  
1128 Heme vibrational mode  
1129 C-C stretch, lipid Healthy human skin strateum 
corneum & epidermal membrane 
1130 Trans C-C stretch – phospholipids Human brain tissue, glioma grade 
III 
1130 Lipid Healthy human skin strateum 
corneum & epidermal membrane 
1130 C-C stretch, lipid  
1130 C-O stretch glucose  
1130 Low density lipoproteins  
1131 Lactic acid DL-Lactic acid (C3H6O3) 
1135 νCO, rCH3 Lactic acid 
1150 Carotenoid Human artery 
1150 C=C Carotenoid Food 
1150 Cholesterol Carotid artery 
1155 C-C stretch, δ(COH)  
1155 ν(CC), δ(COH) Human strateum corneum 
1156 CN stretch Bovine Serum albumin 
1156 Carotenoid  
1156 Carotenoid Human breast carcinoma, Beta 
carotene 
1157 Carotenoid Normal human breast tissue 
1157 Carotenoid Human breast tissue 
Renal cell carcinoma (1155) 
1157 Carotenoid Human brain tissue, acoustic 
neurinoma, beta carotene 
1158 Carotenoid Carotid artery 
1158 Carotenoid Carotenoids in normal colon 
1158 NH2 rocking vibration Urea 
1159 C-N Protein in eye lens 
1160 Carotenoid Blood plasma 
1162 Ribose  
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1166  Type I collagen (human placenta) 
1167  Infiltrating ductal carcinoma 
(breast) 
1172 ν(CC) Human strateum corneum 
1174 Tyrosine (AGP) AGP (glycoprotein)* 
1175 C-O stretching Human cervical biopsies 
1176 Tyrosine, Phenylalanine Protein 
1180  Cervix 
1180 Tyrosine Breast 
1180 Tyrosine  
1180 Cytosine, guanine, adenine  
1197 Carotenoid  
1200-1700 Collagen Dentine 
1205 Tyrosine + Phenylalanine Bovine albumin, Sigma Aldrich 
A2153 
1206 4-hydroxyproline (amino acid), tyrosine Diseased breast tissue 
1206 4-hydroxyproline (amino acid) Collagen 
1206 Hydroxyproline, tyrosine Type I collagen (human placenta) 
& infiltrating ductal carcinoma 
(breast) 
1207 Tyrosine Human eye lens 
1207 Tyrosine (AGP) AGP (glycoprotein)* 
1207 Tyrosine + Phenylalanine (amino acid) Bovine Serum albumin 
1207  Ovary 
1208 Thymine DNA (B) 
1210 hydroxyproline Chicken leg bone 
1210  Cervix 
1210 Tryptophan, phenylalanine  
1211 Tyrosine, Phenylalanine, Thymine Protein 
1226-1243 Amide III - ν(C-N) β pleated sheet protein secondary 
structure in β-Poly-L-alanine 
1227 Heme vibrational mode  
1227-1247 Amide III (C-N stretch, N-H in plane 
bending) β-sheet 
β-sheet protein secondary 
structure 
1230 Uracil in RNA Cultured breast cells 
1230-1240 Amide III β-sheet  
1230-1245 Amide III - ν(C-N) β pleated sheet protein secondary 
structure in β-Poly-L-glutamate 
1234 Antisymmetric stretching of phosphate 
groups of the polynucleotide chain 
DNA 
1235-1270 Amide III (C-N stretch, N-H in plane 
bending) unordered 
 
1237 Amide III Human eye lens 
1238 Amide III, random coil Rabbit & human cornea 
1238 Amide III in elastin Sigma Aldrich E1625 
1238 Cytosine, uracil, Amide III  
1239 Thymine DNA (A), RNA (A) 
1240 Amide III - ν(C-N) β pleated sheet protein secondary 
structure in β-Poly-L-lysine 
1240 Vibration of pyrimidine bases (cytosine 
& thymine) 
DNA 
1240 Amide III ν(C-N) Benign breast tumour 
1240 Amide III  
1240 Amide III in collagen Sigma Aldrich C7774 
1240 Amide III - ν(C-N) Uterus cancer 
1240 Amide III Caractous lens 
1240 Thymine Protein 
1240-1260 Amide III unordered  
1243 Amide III Liver - collagen 
1243 Amide III Chicken leg bone 
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1243 Amide III Rabbit lens 
1243-48 Amide III - ν(C-N) irregular protein secondary 
structure in β-Poly-L-lysine pH4 
1244 δ(CH2) wagging, ν(CN) amide III 
disordered 
Human strateum corneum 
1245 νCO, δOH Lactic acid 
1245 Amide III, random coil Human brain tissue, glioma grade 
III 
1245 Keratotic Healthy human skin dermis 
1245  Cervix 
1245 Amide III: keratin, disordered collagen  
1245-1305 Amide III (C-N stretch, N-H in plane 
bending) 
Histones 
1246 Amide III Bovine Serum albumin 
1246 Amide III ν(C-N) Collagen & DNA 
1246 Amide III ν(C-N) Human cervix precancer 
1246 Amide III (C-N stretching vibrations) Human cervical biopsies 
1246 Amide III (C-N stretching vibrations)  
1246 Amide III (C-N stretching vibrations) Protein 
1247 Amide III Type I collagen (human placenta) 
& infiltrating ductal carcinoma 
(breast) 
1247 Amide III Diseased breast tissue 
1247  Neutrogena sarcoma (brain) - 
collagen 
1247 Amide III Collagen 
1247 Amide III - ν(C-N) Endometrium cancer 
1247 Collagen Fibrocystic human breast tissue 
 
1248 Amide III Breast 
1248 PO2- vibration in phospholipids and 
nucleic acids 
Normal human skin 
1248 Amide III (C-N stretch, N-H in plane 
bending) 
Collagen 
1249 Amide III - ν(C-N) irregular protein secondary 
structure in β-Poly-L-glutamate 
pH 11 
1250 Cytosine, uracil, Amide III  
1250 Amide III Human artery 
1250 Amide III  
1250 Cytosine DNA (B) 
1250 DNA DNA (Sigma Aldrich)† 
1250 Amide III Collagen type I, normal skin 
dermis 
1252 Amide III Aorta 
1253 Amide III random coil protein Breast cancer in mouse 
1254 Adenine Protein 
1254 Amide III (C-N stretch, N-H in plane 
bending) 
Elastin 
1255 Cytosine Protein 
1256 Glycogen Sigma Aldrich G0885 
1258-1304 Amide III (C-N stretch, N-H in plane 
bending) 
α-helix protein secondary 
structure 
1260-1310 Amide III (C-N stretch, N-H in plane 
bending) 
α-helix protein secondary 
structure 
1259 Amide III Silicone gel 
1260 Tyrosine Unordered protein secondary 
structure 
1260 Structural protein Breast 
1260 Symmetric CH3 deformation Silicone gel 
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1260 Amide III Chicken leg bone 
1260 Amide III Malignant breast tissue 
1260-1280 Amide III Bovine Serum albumin 
1261 Lipid  
1262 Amide III - ν(C-N) Benign or normal cervix 
1262 Amide III - ν(C-N) Benign or normal uterus 
1262 Amide III - ν(C-N) Benign or normal endometrium 
1262 Amide III - ν(C-N) Benign or normal ovary 
1264 Amide III in collagen Sigma Aldrich C7774 
1265-1300 Amide III (C-N stretch, N-H in plane 
bending) 
α-helix protein secondary 
structure 
1265-1348 Amide III - ν(C-N) α-helix protein secondary 
structure in α-Poly-L-alanine 
1265 =C-H in plane deformation Breast 
1265 =C-H in plane deformation breast tissue 
1265 Amide III Normal breast tissue 
1267 =C-H in plane deformation  
1267 Amide III Infiltrating ductal carcinoma 
(breast) 
1267 δ (=C-H) Phospholipid membrane 
1267 δ (=C-H) Coronary Artery, unsaturated 
fatty acids 
1267 Amide III Lymph node 
1267 Amide III Diseased breast tissue 
1267 Amide III Collagen 
1268 Amide III Oleic acid methyl ester 
1268 Amide III - ν(C-N)  and δ(NH) in bovine 
albumin 
Sigma Aldrich A2153 
1269 Amide III Type I collagen (human placenta) 
1269 Amide III α-helix Human brain tissue 
1270  Cervix 
1270 Amide III - ν(C-N) Endometrium cancer 
1271 Amide III - ν(C-N)  and δ(NH) Normal human skin 
1271 Amide III (C-N stretch, N-H in plane 
bending) 
Collagen 
1273 Amide III Collagen type I, normal skin 
dermis 
1274 δ(NH) wagging, ν(CN) amide III α-helix Human strateum corneum 
1280 Amide III Phospholipid membrane 
1290 Amide III - ν(C-N) α-helix protein secondary 
structure in α-Poly-L-glutamate 
1295 Amide III - ν(C-N) α-helix protein secondary 
structure in α-Poly-L-lysine 
1296 δ(CH2) Human strateum corneum 
1296 Keratotic Healthy human skin dermis 
1296 δ(CH2) Strateum corneum 
1297 Lipid Healthy human skin strateum 
corneum & epidermal membrane 
1300 ν(C-C) ν(C-N) Benign breast tissue 
1300 Amide III Bovine insulin 
1300 C-H bending Lipid 
1300 Phospholipids - CH2 twist and wagging Human brain tissue 
1300 Lipids – fatty acids Breast 
1300 δCH Lactic acid 
1300 Adenine , cytosine  
1300 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
1302 Lipid Lipid (TPE) 
1302 Lipid Human breast tissue 
1302 Lipid Normal human breast tissue 
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1302 Lipid Human breast tissue 
1303 CH2 twisting Breast 
1303 Triglycerides Adipose tissue from human aorta 
1303 Adenine  
1303 δ CH2 Phospholipid membrane 
1303 CH2 twisting Normal breast tissue 
1303 CH3CH2 twisting Diseased breast tissue 
1303 CH3CH2 twisting Normal breast tissue & 
infiltrating ductal carcinoma 
1304 CH3CH2 twisting Oleic acid methyl ester 
1306 Lipid Human colon 
1309 CH2 twisting & wagging in lipids Normal human skin 
1310-16 ∆(CH2) Callus, psoriatic plaque 
1316 Histidine Sigma Aldrich T8776 
1316 Guanine DNA (Z), RNA(Z) 
1317 CH2 twisting Skin 
1318 Guanine DNA (A), RNA (A) 
1319 CH3CH2 twisting Type I collagen (human placenta) 
1319 CH3CH2 twisting Collagen 
1320 Guanine  
1321 in bovine albumin Sigma Aldrich A2153 
1322 C-H  
1325 Tryptophan (amino acid) ring vibrations  
1325 Nucleic acid ring vibrations  
1330 Tryptophan (amino acid) ν(C-C) Cervix cancer 
1330 Tryptophan (amino acid) ν(C-C) Uterus cancer 
1330 Tryptophan (amino acid) ν(C-C) Ovary cancer 
1330 C-H Nucleic acid bases & DNA, 
phospholipids 
1330 C-H Human cervix precancer 
1330  Cervix 
1330 DNA Cultured breast cells 
1330 δCH Lactic acid 
1332 DNA DNA (Sigma Aldrich)† 
1333 Glycogen Sigma Aldrich G0885 
1333 Guanine DNA (B) 
1334 CH deformation  
1335 Nucleic acids Colon 
1335 Adenine DNA (A), RNA (A) 
1337 Nucleic acid, purine bases (adenine, 
guanine) 
Colon 
1337 Nucleic acid, purine bases (adenine, 
guanine) 
 
1337 Purine bases (adenine, guanine) DNA in water 
1337 Adenylates Colon mucosa 
1338 Glycogen Glycogen (Sigma Aldrich)† 
1338 Tryptophan, amino acid  
1339 Adenine DNA (B) 
1339-41  Strateum corneum, Callus, 
psoriatic plaque 
1340 Tryptophan (amino acid) Rabbit & human cornea 
1340 Tryptophan (amino acid) Rabbit aqueous humour 
1340 Nucleic acid Colon  adenocarcinoma 
1343 CH3CH2 wagging Diseased breast tissue 
1343 CH3CH2 wagging Collagen 
1343 CH3CH2 wag Type I collagen (human placenta) 
& infiltrating ductal carcinoma 
(breast) 
1343  Rabbit aqueous humour 
1343 Adenine  
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1350 Glucose Sigma 
1358  Normal renal parenchyma & renal 
cell carcinoma 
1359  Hepatocellular carcinoma 
1360  Normal hepatic parenchyma 
1360  Myoglobin 
1360  Human aqueous humour 
1361 Tryptophan  
1365 Guanine, tryptophan  
1372 Lipid Human colon 
1375  Myoglobin 
1376 Thymine, guanine, adenine  
1377 Glycogen Sigma Aldrich G0885 
1380 δCH3 δOH Lactic acid 
1382 Glycogen Glycogen (Sigma Aldrich)† 
1385 δ(CH3) symm Human strateum corneum 
1400 Uracil, adenine  
1400  Cervix 
1400 vCOO- AGP (glycoprotein)* 
1401 Symmetric CH3 bending in proteins  
1410 δOH Methyl lactate 
1412 Antisymmetric CH3 deformation Silicone gel 
1420 δOH, νCO
 
Lactic acid 
1421 δ(CH3) Human strateum corneum 
1421 Guanine, adenine  
1438 δ(CH2) scissoring Human strateum corneum 
1438 CH2 deformation  
1439 CH2 scissoring deformation breast tissue 
1439 CH3, CH2 deformation Normal breast tissue 
1439 CH2 deformation Human breast biopsy 
1439 CH2 deformation due to lipids and 
proteins 
Human brain tissue 
1439 CH2 scissoring deformation Breast 
1440 Lipid  
1441 CH2 bending Fibrous atherosclerotic plaque 
1441 Lipid Liver 
1441 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
1442 CH3, CH2 deformation Oleic acid methyl ester 
1442 Lipid Human breast tissue 
Colon tissue 
1442 Lipid Normal human breast tissue 
1442 Lipids – fatty acids Normal breast tissue 
1443 elastin Sigma Aldrich E1625 
1444 Lipid Lipid (TPE) 
1444 Triglycerides Adipose tissue from human aorta 
1445 δ(CH2) or δ(CH3) Cervix cancer 
1445 δ(CH2) or δ(CH3) Uterus cancer 
1445 δ(CH2) or δ(CH3) Benign or normal cervix 
1445 δ(CH2) or δ(CH3) Benign or normal endometrium 
1445 δ(CH2) or δ(CH3) Benign or normal ovary 
1445 δ(CH2) or δ(CH3) Human breast tissue. Benign and 
Malignant tumours 
1445 CH2 deformation breast tissue 
1445 CH2 bending mode Normal breast tissue 
1445 CH3CH2 deformation in collagen Sigma Aldrich C7774 
1447 δ(CH2)  (AGP) AGP (glycoprotein)* 
1447 CH3CH2  bending modes in bovine 
albumin 
Sigma Aldrich A2153 
1448 CH2 deformation Chicken leg bone 
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1448 Deoxyribose DNA (B) 
1448-9 ∆(CH2) scissoring Strateum corneum, Callus, 
psoriatic plaque 
1449 CH2 deformation Lymph node 
1450 Glucose Blood 
1450 CH bending Rabbit & human cornea 
1450 CH bending Rabbit aqueous humour 
1449 CH3CH2  bending modes Bovine Serum albumin 
1450 CH3CH2 deformation Diseased breast tissue 
1450 CH2 bending Human artery 
1450 CH2 bending mode Diseased breast tissue 
1450 δ(CH2) or δ(CH3) Endometrium cancer 
1450  Elastin & collagen 
1450 CH3, CH2 deformation Infiltrating ductal carcinoma 
1451 C-H bend Normal human aorta 
1451 CH3, CH2 deformation Type I collagen (human placenta) 
1451 CH3CH2 deformation Collagen 
1451 CH2 bending  
1451-1454 CH2 bending Histones 
1452 Structural protein Breast 
1452 δ(CH2) scissoring in lipids & δ(CH2) 
δ(CH3) in proteins 
Normal human skin 
1452 CH2 bending Malignant breast tissue 
1452 CH2 in plane bending Normal aorta 
1453 δ(CH2) or δ(CH3) Ovary cancer 
1453 δ(CH2) or δ(CH3) Benign or normal uterus 
1453 C-H bending modes Aorta 
1454 CH3 bending CH2 scissors Elastin & collagen & 
phospholipids 
1454 CH3 bending CH2 scissors Human cervix 
1454 CH3 asymmetric bending of proteins  
1454  Cervix 
1455 δCH3 Lactic acid 
1455 Glycogen Sigma Aldrich G0885 
1455 CH2 deformation Breast 
1456 CH3 bending in elastin Sigma Aldrich E1625 
1456  Ovary 
1457  DL-Lactic acid (C3H6O3) CH3-
CHOH-COOH 
1458 Nucleic acid Colon  adenocarcinoma 
1460 Pentose sugar vibration due to δ CH2 DNA 
1462 Deoxyribose DNA (B) 
1475 δCH3 Lactic acid 
1475 DNA DNA (Sigma Aldrich)† 
1480 Vibration of purine bases (adenine & 
guanine) 
DNA 
1480 DNA Cultured breast cells 
1485 Nucleic acids Colon 
1485 Purine bases DNA in water 
1485 Nucleic acid, purine bases (adenine, 
guanine) 
Colon 
1485 Nucleic acid, purine bases (adenine, 
guanine) 
 
1487 Nucleic acid Colon 
1491 Formalin  
1500-1650 Heme  
1509 Phenylalanine Bovine Serum albumin 
1510 Adenine, guanine  
1512  Ovary 
                                                                  A 17 
1517 Carotenoid  
1520-1670 Tryptophan & tyrosine Cultured breast cells 
1520 C=C Carotenoid Food 
1520 Carotenoid Blood plasma 
1522 Carotenoid Carotid artery 
1523 Carotenoid Human breast tissue 
Renal cell carcinoma 
1523 Carotenoid Normal human breast tissue 
1524 Carotenoid Human brain tissue, acoustic 
neuroma 
1525 Carotenoid Beta carotene 
1525 Carotenoid Human breast carcinoma 
1525 Carotenoid Human breast carcinoma 
1528 Carotenoid Carotenoids in normal colon 
1529 Carotenoid Carotenoids in normal colon 
1540 Amide II Bovine insulin 
1541 Tyrosine  
1547 Tryptophan Human eye lens 
1550 Tryptophan  
1552 Tryptophan (AGP) AGP (glycoprotein)* 
1552 δ(NH), ν(CN) Amide II Human strateum corneum 
1553 Tryptophan  
1554  Type I collagen (human placenta) 
& infiltrating ductal carcinoma 
(breast) 
1555 Tryptophan DNA in water 
1556 Tryptophan Bovine Serum albumin 
1570 Vibration of purine bases (adenine & 
guanine) 
DNA 
1570 nucleotides Breast cancer in mouse 
1575 Guanine, adenine tryptophan  
1576 Nucleic acid Colon  adenocarcinoma 
1577 Guanine, adenine  
1577 DNA DNA (Sigma Aldrich)† 
1580 nucleotides Breast cancer in mouse 
1580 DNA Cultured breast cells 
1580  Cervix 
1585 Nucleic acid, purine bases (adenine, 
guanine) 
Colon 
1585 Nucleic acid, purine bases (adenine, 
guanine) 
 
1585 υ(C-O) olefinic Strateum corneum, Callus, 
psoriatic plaque 
1585 ν(C=C) olefinic Human strateum corneum 
1593 Purine bases DNA in water 
1600   
1602 Phenylalanine  
1602 Tyrosine Tyrosine, colon adenocarcinoma 
1606 Phenylalanine Bovine Serum albumin 
1607 Phenylalanine in bovine albumin Sigma Aldrich A2153 
1610 Tyrosine Colon mucosa 
1610 Tyrosine Protein bands 
1612 C=C stretching Benzene 
 
1615 Tyrosine (AGP) AGP (glycoprotein)* 
1616 Tyrosine Bovine Serum albumin 
1617 Tyrosine, phenylalanine  
1620 Tryptophan, tyrosine, phenylalanine, 
uracil 
 
1620 Tryptophan Colon mucosa 
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1620 Tryptophan Protein bands 
1622 Tryptophan DNA in water 
1637 Amide I ν(C=O) Diseased breast tissue 
1637 Amide I ν(C=O) Collagen 
1640 OH bending Water 
1642 Amide I ν(C=O) Collagen 
1648-1661 Amide I ν(C=O) Histones 
1645 Bending mode Water 
1645 Amide I (C=O stretch) α-helix protein secondary 
structure in α-Poly-L-lysine 
1645-1660 Amide I (C=O stretch) α-helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) β-sheet protein secondary 
structure 
1660-1670 Amide I (C=O stretch) Unordered protein secondary 
structure 
1645-1655 Amide I (C=O stretch) α-helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) β-sheet protein secondary 
structure 
1655-1665 Amide I (C=O stretch) Unordered protein secondary 
structure 
1654-1662 Amide I (C=O stretch) α-helix α-helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) β-sheet protein secondary 
structure 
1654-1685 Amide I (C=O stretch) Unordered protein secondary 
structure 
1650 Amide I Normal human aorta 
1650 lipid Colon mucosa 
1650 Pyrimidine bases (cytidine, thymidine) ?  DNA in water  
1650 C=C lipid bands Colon 
1650 Amide I ν(C=O) 
 
Bovine insulin 
1650  Ascorbate 
1650  Rabbit aqueous humour 
1650 Amide I (C=O stretch) ν(C=O) Human artery 
1650-1666 C=C vibration cis-isomer in fatty acid 
chain 
Phospholipid membrane 
1651 Amide I, ν(C=O) Benign breast tissue and 
malignant tumours 
1651-1664 Amide I, ν(C=O) Healthy human skin 
1651 Amide I, ν(C=O) in collagen Sigma Aldrich C7774 
1651 Amide I, (C=O stretch) Ovarian cancer 
1651-4 υ(C-O) Amide I, α helix Strateum corneum, Callus, 
psoriatic plaque 
1652 Lipid Lipid (TPE) 
1652 Lipid Human breast tissue 
1652 Amide I α-helix protein secondary 
structure in α-Poly-L-glutamate 
1652 ν(C=O) Amide I α-helix Human strateum corneum 
1653 Lipid Human breast tissue 
Human colon 
1653 Lipid Normal human breast tissue 
1653 Amide I protein  
1653 Amide I (C=O stretch) in bovine 
albumin 
Sigma Aldrich A2153 
1654 α-helix nails 
1654 C=C stretch Olefinic Breast biopsy tissue 
1654 C=C stretch Breast tissue 
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1654 Amide I Normal breast tissue 
1654 C=C stretch Breast 
1655 C=C stretch of unsaturated fatty acid 
chains 
Aorta 
1655 Amide I Oleic acid methyl ester 
1655 Amide I protein (C=O stretch) Coronary Artery 
1655 Amide I (C=O stretch) Lymph node 
1655 Amide I (C=O stretch) Endometrial cancer 
1655 Amide I (C=O stretch) α-helix protein secondary 
structure in α-Poly-L-alanine 
1656 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
1656 Amide I (C=O stretch) Collagen 
1656 Amide I (C=O stretch) Human cervix 
1656 Amide I (C=O stretch)  
1656  Cervix 
1656 Amide I (C=O stretch) Benign or normal endometrium 
1656 Amide I (C=O stretch) irregular protein secondary 
structure in β-Poly-L-glutamate 
pH 11 
1657 Amide I (C=O stretch) Cervical cancer 
1657 Lipids – fatty acids Breast 
1657 Lipids Colon 
1657 Amide I (C=O stretch) Malignant breast tissue 
1657 Amide I Infiltrating ductal carcinoma 
(breast) 
1657 Amide I (C=O stretch) Diseased breast tissue 
1658 Amide I (C=O stretch)  
1658 Amide I Aorta 
1659 Amide I, ν(C=O) Benign breast tumours 
1659 Amide I (C=O stretch) Benign or normal ovary 
1659 Amide I (C=O stretch) Benign or normal cervix 
1659 Amide I (C=O stretch) Benign or normal uterus 
1659 Amide I (C=O stretch) Uterus cancer 
1659 Amide I (C=O stretch) ά helical Human brain tissue 
1659 Amide I (C=O stretch) Bovine Serum albumin 
1659 Amide I (C=O stretch)  
1661 Amide I ν(C=O) in elastin Sigma Aldrich E1625 
1661 Amide I ν(C=O) Normal human skin 
1662 Nucleic acid Colon  adenocarcinoma 
1662 Triglycerides Adipose tissue from human aorta 
1662 Nucleic acids Colon 
1662 Amide I (AGP) AGP (glycoprotein)* 
1664 Amide I (C=O stretch) Healthy human skin 
1664  Ovary 
1665 Amide I (C=O stretch) irregular protein secondary 
structure in β-Poly-L-lysine pH 4 
1665 Amide I (C=O stretch) Collagen 
1665 Amide I Type I collagen (human placenta) 
1665 Amide I (C=O stretch) Liver - collagen 
1665 Carbonyl vibration mode Fibrous atherosclerotic plaque 
1666 C=O stretching modes of pyrimidine 
bases 
DNA 
1667 Structural protein Malignant breast 
1668 Amide I (C=O stretch) Elastin 
1669 Amide I (C=O stretch) Human eye lens 
1669 Protein Breast cancer in mouse 
1669 Amide I (C=O stretch) β pleated sheet protein secondary 
structure in β-Poly-L-alanine 
1669 Amide I (C=O stretch) Normal aorta 
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1670-1680 C=C vibration trans-isomer in fatty acid 
chain 
Phospholipid membrane 
1670 Amide I Chicken leg bone 
1670 Amide I (C=O stretch) Pure protein - β pleated sheet 
1670 Amide I (C=O stretch) Collagen 
1670 Amide I (C=O stretch)  
1670 Amide I (C=O stretch) Rabbit lens 
1670 Amide I (C=O stretch) β pleated sheet protein secondary 
structure in β-Poly-lysine 
1672 Amide I (C=O stretch) β pleated sheet protein secondary 
structure in β-Poly-L-glutamate 
1683 Amide I (C=O stretch) Bound protein - regular 
uncharacterised secondary 
structure 
1717 C=O stretching modes of purine bases DNA 
1725  Lactate 
1725 νC=0 Lactic acid 
1726 Lactate  
1736 ester stretching mode C=O DMPC 
(dimyristoylphosphatidycholine), 
a typical lipid 
1740 ν(C=O) -lipid Food, coronary artery 
1742 phosphotidylcholine Phosphotidylcholine(Sigma 
Aldrich)† 
1743  Oleic acid methyl ester, normal 
human breast tissue 
1743 C=O stretch Breast tissue 
1743 C=O stretch Breast 
1743 ν(C=O) lipid Human strateum corneum 
1747 C=0 stretch Aorta 
1750 C=O Normal skin dermis 
1752 Triglycerides Adipose tissue from human aorta 
1768 ν(COO) Human strateum corneum 
2579 S-H stretch Rabbit lens 
2700-2880 Collagen C-H stretch Dentine 
2717-23 υ(CH) aliphatic Strateum corneum, Callus, 
psoriatic plaque 
2723 ν(CH) aliphatic Human strateum corneum 
2730  Breast 
2800-3000 CH stretch – lipids Healthy human skin 
2850-2960 CH3, CH2 stretching in alkyl/ acyl chains DMPC 
(dimyristoylphosphatidycholine), 
a typical lipid 
2850 νs(C-H) in (Ethylene CH2=CH2) Phospholipid membrane 
(constant with temperature) 
2850 C-H stretching vibration Normal skin dermis 
2852 υ(CH2) symmetric Strateum corneum 
2852 νs(CH2) in lipids & proteins Normal human skin 
2852 νs(CH3) - lipid Healthy human skin 
2852 ν(CH2) symm Human strateum corneum 
2857 C-H stretch (-CH3 sym.) Breast tissue 
2857 C-H stretch (-CH2 sym.) Breast 
2872 υ(CH2) asymmetric Callus, psoriatic plaque 
2875 C-H stretch (-CH3 asym.) Breast tissue 
2875 C-H stretch (-CH2 asym.) Breast 
2880 νas(C-H) Phospholipid membrane 
2880 C-H stretch Human tooth enamel 
2882 C-H stretch Chicken leg bone 
2883 υ(CH2) asymmetric Strateum corneum 
2883 ν(CH2) sym.- lipid Healthy human skin 
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2883 ν(CH2) symm, ν(CH2) asymm Human strateum corneum 
2885 CH3 stretch Lactate 
2886 C-H stretching vibration Normal skin dermis 
2898 C-H stretch (-CH3 sym.) Breast 
2890 νas(C-H) in (Ethylene CH2=CH2) Phospholipid membrane 
 
2890 CH2 symmetric stretch Glucose 
2890 CH2 stretch Rabbit & human cornea 
2890 CH2 stretch Glucose 
2890 CH stretch Rabbit & human aqueous humour 
2893 Glucose & lactate Rabbit aqueous humour 
2894-5 Lactate & glucose  
2898 C-H stretch (-CH3 sym.) Breast tissue 
2918 C-H stretch Chicken leg bone 
2929 C-H stretch (-CH3 sym.) Breast tissue 
2929 C-H stretch (-CH3 sym.) Breast 
2930 ν(CH2) – lipid Coronary Artery 
2931 υ(CH3) symmetric Strateum corneum, Callus, 
psoriatic plaque 
2931 ν(CH3) symm, ν(CH2) asymm Human strateum corneum 
2932 C-H stretch Human tooth enamel 
2935 ν(CH2) sym.- lipid Healthy human skin 
2935 C-H stretch Rabbit lens 
2939 Glucose & lactate Rabbit aqueous humour 
2942 C-H  
2942 νas(CH3) – lipids and proteins Normal human skin 
2943 Glucose  
2945 CH stretch Rabbit & human cornea 
2945 CH3 stretch Lactate 
2945 CH stretch Rabbit & human aqueous humour 
2945 Lactate  
2950 CH2 anti-symmetric stretch Glucose 
2950 CH2 stretch Glucose 
2958 ν(CH3) asymm Human strateum corneum 
2960 C-H stretch (-CH3 asym.) Breast tissue 
2960 C-H stretch (-CH3 asym.) Breast 
2975 C-H stretch  
2982 Glucose & lactate Rabbit aqueous humour 
2983 υ(CH3) symmetric Strateum corneum, Callus, 
psoriatic plaque 
2990 CH3 stretch Lactate 
2995 Lactate  
3006 =C-H stretch Breast tissue 
3006 C-H stretch Breast 
3059-60 υ(CH) olefinic Strateum corneum, Callus, 
psoriatic plaque 
3060 ν(CH) olefinic Human strateum corneum 
3063 C-H stretch Rabbit lens 
3245 νOH Methyl lactate 
3390 OH mode Rabbit lens 
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Appendix B Investigation of sample state using PCA 
Following the Raman probe tissue classification, PCA analysis of the sample state 
(fresh and frozen) was investigated. It was found that no separation of the fresh and 
frozen samples was evident as shown below.  PCA was carried out, and plots 
constructed colour coded for sample state – fresh (black), frozen once (green) and 
frozen twice (pink). There was no correlation/clustering for different sample state. The 
plot of PC1vPC3 shown in the figure, exhibited 5 outliers, which upon further 
investigation were found to be gastric samples exhibiting strong lipid peaks confirming 
that these samples should be removed from the model. No evidence was visible in the 
other PCs. There was no evidence in other PC plots.  
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Figure C: PC1 vs PC3 (colour coded for sample state fresh (black), frozen once (green) and frozen twice 
(pink) 
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Appendix C Preliminary study of rapid Raman mapping 
 
Rapid Raman maps were acquired using the prototype 785nm rapid mapping system at 
Renishaw. The sample contained a normal squamous island in Barrett’s (with query 
LGD) as shown in Figure D1. PCA (using the Wire 3.0 Renishaw software), 
demonstrates that NSq is easily detectable with PC loads indicating presence of 
glycogen.  
 
 
Figure C1: H&E of an oesophageal EMR section containing normal squamous, Barrett’s (IM) and query 
low grade dyplasia (non conclusive).  
 
Figure C2: Rapid Raman maps (78x228=17784 total spectra) acquired with a step size 27.5 µm and 
acquisition times of 5, 0.5 and 0.1s. The 6th PC load (5th for the 0.1s map since the 6th PC was dominated 
by noise) are shown which exhibit peaks which can be attributed to glycogen (green bands) in normal tissue. 
The overall mapping time and relative standard deviation (RSD) is shown for comparison purposes. 
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Appendix D Previous mapping of oesophageal tissue 
(Shetty et al.**) 
 
Figure D1: Examples Raman point maps of oesophageal two biopsy sections taken from Shetty et al. 
“Normal squamous and HGD sample (H&E stained section Figure 1A). (A) Third principal component 
score map with selected regions marked. 
(B) Mean Raman spectra from selected regions. (C) Relative concentration of selected biochemical 
constituents calculated with mean spectra from selected 
regions. Normal squamous and adenocarcinoma sample (H&E stained section Figure 1B). (D) Third 
principal component score map with selected regions 
marked. (E) Mean Raman spectra from selected regions. (F) Relative concentration of selected biochemical 
constituents calculated with mean spectra from 
selected regions.” 
 
                                                 
**
 Shetty, G., Kendall, C., Shepherd, N., Stone, N. and Barr, H. (2006). Raman spectroscopy: elucidation 
of biochemical changes in carcinogenesis of oesophagus. British Journal of Cancer, 94(10), p. 1460-
1464. 
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Appendix E Raman mapping objective comparison (PCs 5-
8) 
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Figure E1: PCs 5-8 for comparison of maps acquired with the Nplan x50, 5 s, 27.5 µm step size (left) and 
Leica x50 long working distance, 5 s, 11 µm step size (right) objectives. Note that PC6 and PC8 for the Leica 
x50 obejctive, the colour bar is inverted and thus the PC load is also inverted. 
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Appendix F Raman Vs FTIR imaging 
A comparison of Raman and FTIR mapping was carried out on a sample of NSq 
epithelium.  
 
 
Figure F1: A comparison of Raman and FTIR maps acquired with the same mapped area, and similar 
signal to noise 
 
Less data processing (cosmic rays etc) 
Higher SNR 
Quicker mapping times 
More spectra peaks 
Potential for higher spatial resolution 
PE Spotlight 300 - 1.4h 15h 
With upgraded Spotlight 400 - 0.7h ~0.2-1h with optimised parameters 
 
The conclusion of this study was that FTIR also has potential for automated 
histpathology, but it is limited by sample preparation, and furthermore, increasing the 
spatial resolution is not an option. However, reduced mapping times are extremely 
beneficial. Raman mapping would also provide continuity with in vivo studies.  
 
• 6.6µm step size 
• 141x111=15651 spectra 
• acquisition time 30s 
• 6.25µm step size 
• Cropped to 15651 spectra 
• 16 scans per pixel 
 
                                                               G 1 
Appendix G Hutchings et al. Journal of Biophotonics, 2(1-
2), p. 91-103 
(BLANK PAGE) 
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Appendix H PCs 1-8 for the rapid Raman map D 
 
 
Figure H1: PC loads 1-8 for Map D 
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Appendix I      Manuscript submitted to the Analyst (Nov 2008) 
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Appendix J Ambient temperature poster 
2. Method
5. References
4. Conclusions
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Hutchings J1,2, Kendall C1,2, Barr H1,2 and Stone N1,2
1. Biophotonics Research Group, Gloucester Royal Hospital, Gloucester, GL1 3NN
2. Cranfield Health, Cranfield University, Silsoe, Bedfordshire, MK45 4DT
• Raman spectroscopy has been used to successfully    
identify and classify precancerous changes in the 
oesophagus1
• Ambient temperature has been shown to affect Raman 
spectra2 which is a possible limitation on the use of 
Raman spectroscopy in a clinical environment
1. Introduction
a) Peak shift investigation
3. Results
1. Kendall C, Stone N, Shepherd, Geboes K, Warren B, Bennett and Barr H Raman Spectroscopy, a 
potential tool for the objective identification and classification of neoplasia in Barrett’s 
oesophagus. Journal of Pathology; 2003; 200: 602-609
2. Fukura S, Mizukami T, Odake S and Kagi H. Factors Determining the Stability, Resolution, and 
Precision of a Conventional Raman Spectrometer. Applied Spectroscopy. 2006; 60 (8): 946-950 
2006
The effect of ambient temperature on a Raman classification model 
for the diagnosis of precancerous changes in the oesophagus
• The air conditioning unit setting was altered in 
2ºC intervals ranging from 19 to 31ºC (the actual 
room temperature was also measured)
• Polymer spectra were acquired using two 
Renishaw System 1000 spectrometers (830nm, 
5s, x50objective) and a Visionex probe system in 
combination with a Renishaw System 100 
spectrometer (830nm, 30s 
• Spectra were also acquired from a neon argon 
lamp (1s)
• At each aircon setting, the systems were 
allowed to reach temperature equilibrium for 
2hours
• Peak positions were plotted against actual 
room temperature
b) The effect of peak shifts on a multivariate tissue classification model
• A multivariate tissue classification model was tested by projecting  spectral 
data with an artificial peak shift to illustrate the effect of ambient 
temperature on the model performance
a) Peak shift investigation
• Peak shifts were noted in both System 1000 spectrometers for both the 
polymer standard and neon argon lamp
• A Raman map of the polymer standard was also acquired whilst ramping the 
temperature up from 19-28ºC using S1000(1).
• An 2mm square was mapped with a step size of 2µm, with acquisition time 
of 2s.  
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3. Results cont…
Aim
To investigate spectral artefacts caused by variation in ambient temperature 
and to demonstrate the effect on a multivariate tissue classification model
• Peak shifts can have significant effect on Raman spectra
• Shifts occurred in both the polymer standard and neon argon spectra 
suggesting that shifts were caused by expansion or contraction of 
spectrometer components with temperature as well as a potentially 
significant contribution from the laser source
• The apparent linear shift across the entire wavelength range would make 
correction easier than for example if a breathing artefact was apparent
• Initial results suggest that the effect is less pronounced when using the 
compact S100 spectrometer which may be due to the simplicity of the 
spectrometer, or due to the lower resolution spectra, although further work 
is required to investigate this. This could potentially ease the transition to 
clinical application, in theatre for example. 
• The detrimental effect of temperature induced peak shifts on a tissue 
classification model is demonstrated highlighting the importance of 
temperature stabilisation over short and long time periods
a) The effect of peak shifts on a multivariate tissue classification model
• A classification model was generated using spectra acquired from S1000(1) 
at 23ºC 
• An test set consisting of the original data set with an artificial peak shift of 
5cm-1 was projected onto the original classification model
Normal
Barrett’s
Dysplasia 
& cancer
• The figure shows a psuedocolour score 
map of the 1st principle component
• The region of increasing temperature is 
clearly evident as a region of low scores 
(blue-purple)
• A repetitive stripe pattern is also evident 
once the temperature has stabilised and 
this is attributed to temperature oscillation 
as the air-conditioning maintains a 
constant temperature, consistent with that 
noted by Fukura et al2
• The region of oscillation is consistent with 
a peak shift of approx 0.5cm-1
• The training set and test set 
centroids are illustrated in the figure 
with a square and triangle 
respectively
• The percentage correctly classified 
drops from 94% to 75%
• Note that the most significant shift 
is the misclassification of Barrett’s 
as cancer with the shifted spectra
• This temperature shift would also 
have a detrimental effect on Raman 
maps of tissue sections
• The loading for 
the 1st PC 
exhibits 
discontinuities 
characteristic of 
peak shifts
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• It is evident that there is potentially a contribution to the ambient temperature 
artefacts from both the spectrometer and laser
• For the S100 probe system, a linear peak shift with temperature was not 
evident with the polymer standard so the range is stated
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Appendix K Prognostic model poster 
Can Raman Spectroscopy be used to predict the prognosis 
of cancer in patients with high grade dysplasia (HGD)? 
Joanne Hutchings1, Simon Dwerryhouse2, Nicholas Stone1, Catherine Kendall1, Hugh Barr1
1. Biophotonics Research Group, Gloucester Royal Hospital, Gloucester, GL1 3NN
2. Department of Surgery, Addenbrooke’s Hospital, Cambridge, CB2 2QQ
email: Johutchings@hotmail.com
1. Introduction
2. Method
5. References
4. Conclusions
Currently, patients with Barrett’s oesophagus undergo routine endoscopic 
surveillance. Biopsy samples are taken and analysed in histopathology to 
detect cancerous cells and premalignant changes such as dysplasia. 
Oesophageal Cancer
Oesophageal cancer is the 9th most common cancer 
in UK [1]. Over 7,500 people diagnosed per year in the 
UK [1]. 5-year survival 2 to 25%[2]. In most cases 
patients do not present until the disease is advanced 
at which point it is difficult to treat. The earlier we 
diagnose the cancer the easier to treat.
Barrett’s Oesophagus
Barrett’s oesophagus is a precursor condition to oesophageal cancer. 
Acid reflux causes normal stratified squamous epithelium that lines the 
stomach adapts over time to become columnar epithelium, similar to 
that found in the stomach. Patients with Barrett’s oesophagus have a 
30 fold chance of developing adencarcinoma[3].  
1. Cancer Research UK 2005
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002 CA Cancer J Clin 2005; 55:74-108
3. Spechler SJ Managing Barrett’s Oesophagus, BMJ 2003;326:892-894
Barrett’s 
oesophagus
Normal 
stratified 
squamous 
epithelium
Columnar 
epithelium
Dysplastic cells 
have ‘malignant 
potential’
Precede cancer 
but do not 
always result in 
cancer
LGD HGD
dysplasia In situ 
cancer
Invasive 
cancer
cell 
alteration metaplasia
More difficult to treat
•25 biopsies were obtained from 14 patients with Barrett’s oesophagus
•Acquired using customised Renishaw system 1000 
•10-40 spectra measured on 1st biopsy diagnosed HGD (total 576)
•Excitation 830nm
•x80 objective 
•Acquisition time of 30s
Aim
To determine whether or not Raman spectroscopy can be used to detect 
those dysplastic cells with a higher probability of progressing to cancer.
What is Raman Spectroscopy?
Raman Spectroscopy is based on the inelastic scattering of 
monochromatic light. Energy changes in the scattered light can be 
detected and used to characterise tissue samples. 
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3. Data Analysis and Results
Multivariate Analysis
•A prognostic model was created 
using Matlab. 
•Principal component analysis 
(PCA) was carried out and the first 
15 components were fed into a 
linear discriminant model.
•The linear discriminant loads 
were used to create a scatter plot 
of the four different groups. 
Performance of the Model
•The performance of the model 
can be seen in the bar chart which 
plots spectral prediction against 
actual outcome.  
•The training performance, 
sensitivity and specificity are 
tabulated below. 
92-99%Specificity
81-97%Sensitivity
81.6%Training performance
•This was a pilot study. More patients and samples (including LGD) are 
required to improve the reliability of the model. Cross validation will also 
be carried out. Other areas will also investigated such as the location of 
the cancer compared to the initial biopsy. 
•Although further work is required, this pilot study demonstrates the 
potential for Raman spectroscopy to correctly predict the future
development of cancer in patients with HGD. Hopefully in the future this 
will lead to the in vivo diagnosis and prognosis of patients with HGD and 
Barrett’s oesophagus. 
Correlate pathology results with Raman spectra
Monitor patients over 2yrs
Identify those who develop cancer
Develop model that predicts if a patient will develop cancer
Raman on 1st biopsy
•Patients were grouped into one 
of four categories. The spectral 
prediction was compared to the 
histopathological results and the 
mean spectra determined. 
1) never developed cancer              
2) cancer at first biopsy 
3) cancer within 1 year
4) cancer after 1 year
Patient Groups
Endoscopic image of 
advanced oesophageal cancer
Raman Shift (cm-1) 
a.u
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Appendix L Grants, awards, publications and presentations 
Grants 
• Institute of Physics and Engineering in Medicine (IPEM) Research Training 
Fellowship – September 2006 
 
Awards 
• Barrett’s Oesophagus Foundation National Meeting Scientific Poster Prize – 
London, March 2008 
• PROBE Lay Persons Presentation Prize – London, March 2008 
• BMLA Scientific Presentation Prize – Manchester, June 2007 
• 3 Counties Cancer Research Network Scientific Poster Award – Cheltenham 
June 2006 
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• 2009 Hutchings, J., Kendall, C., Shepherd, N., Ludeman, L., Barr, H., Stone, N. 
‘A Raman mapping study of high grade dysplasia in oesophageal tissue using 
linear discriminant analysis to evaluate the importance of spatial resolution for 
histopathology’ Submitted to Analyst 
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Rapid Raman mapping was carried out on 20 mm sec-
tions of oesophageal biopsy samples. Contiguous 7 mm
sections were stained with haematoxylin and eosin
(H&E) with histopathology provided by an expert
pathologist. The step size and acquisition times were
varied and the resulting spectra, principal component
(PC) score maps and loads were compared. Overall
mapping times were also compared to traditional Ra-
man point mapping. The principal component loads for
each of the maps were seen to be similar despite varying
the acquisition time and number of spectra. Gross bio-
chemical information was extracted showing good corre-
lation with the H&E sections even for short overall
mapping times (30–90 minutes for a 2 mm biopsy, 0.5 s
acquisition time per 25.3 mm Raman pixel). This demon-
strates that low signal to noise spectral maps are suffi-
cient for the identification of histologically relevant bio-
chemistry using principal component analysis as long as
the spectral dataset is large enough.
5th PC score map and corresponding load for a rapid
Raman map (1.7 s acquisition, 10.6 mm step size, 5 104
total spectra, overall map time 4 h)
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1. Introduction
1.1. Oesophageal cancer
Barrett’s oesophagus is a condition caused by long
term gastro-oesophageal reflux. Patients with
Barrett’s oesophagus have an increased risk of de-
veloping adenocarcinoma [1]. As a result, patients
undergo routine endoscopic surveillance during
which biopsies are taken, formalin fixed, sectioned
and stained with haematoxylin and eosin (H&E) for
histopathological diagnosis. Approximately 90% of
biopsies taken during routine endoscopic sur-
veillance are not of clinical relevance resulting in
unnecessary removal of tissue and stretched his-
topathological resources. A further problem is that
histological diagnosis is subjective since the process
of carcinogenesis is a continuum, and morphologi-
cally based classification can not reliably predict can-
cer risk [2]. An objective and reliable method of
identifying non-relevant tissue samples would poten-
tially relieve the huge burden of biopsy numbers on
the histopathologist.
1.2. Raman Spectroscopy
Raman spectroscopy is an inelastic scattering techni-
que that has been shown to be a promising method
for distinguishing tissue pathologies based on a spec-
trum (effectively a biochemical fingerprint) not only
in oesophageal disease [3], but also in other organ
systems such as cervix [4, 5], stomach [6], breast
[7, 8] colon [9] and parathyroid [10]. This technique
could potentially be used as an aid to the his-
topathologist to classify more subtle biochemical
changes occurring within the transition from Bar-
rett’s oesophagus, through dysplasia, to adenocarci-
noma. Furthermore, it may be possible to detect mo-
lecular changes occurring before macroscopic
morphological changes are evident at histopathologi-
cal analysis.
Raman scatter is a relatively weak process com-
pared to elastic scatter with as little as one in a mil-
lion photons undergoing Raman scattering. As time
has progressed technological advances have enabled
the acquisition of Raman point tissue spectra in rela-
tively short acquisition times. Imaging applications
of Raman have generally relied on point mapping,
which is widely regarded as a slow technique. How-
ever, there has been some use of flat field illumina-
tion coupled with liquid crystal tunable filters and ar-
ray detection (ChemImage) [11].
In previous studies we have shown that Raman
spectroscopy is capable of detecting and classifying
pre-cancerous and cancerous changes with a high
sensitivity and specificity [3]. Further studies have
gone on to elucidate biochemical changes occurring
during the progression to cancer in the oesophagus
[12–14]. The first demonstration of Raman for the
biochemical analysis of the bladder was made by
Stone et al. [15]. Other groups have used Raman
mapping to investigate cells [16, 17] and biological
tissues in the bronchus [18], breast [19] and brain
[20]. Raman mapping has also been used for phar-
maceutical [21–23], materials [24, 25] and geological
applications [26]. However, the long overall mapping
times have limited the size of the datasets which can
be acquired and consequently the biochemical infor-
mation which can be gleaned using multivariate ana-
lysis. Furthermore, long overall mapping times have
hindered the progression of the technique into the
clinical environment.
1.3. Raman mapping
Details of Raman mapping techniques can be found
in the following reference [27]. A brief overview of
point and line mapping techniques is provided to il-
lustrate the rapid mapping technique in context.
During point spectral mapping (Figure 1a), a
point spectrum is acquired using effectively the en-
tire length (actually the edges are removed to reduce
noise) of the charged couple device detector (CCD)
with the collection pixels region spanning the width
of the laser line to maximise the collected signal.
The rest of the CCD is not read out to minimise
dark current readout noise and readout time. The
sample is stepped along to the next position using an
XY translational stage and the next spectrum is ac-
quired and so on until a grid of spectra is obtained,
often referred to as a spectral data cube. The overall
mapping time is often limited by the acquisition time
(per spectrum) when measuring tissue samples since
they are not strong scatterers. The acquisition time
may be of the order of 1–30 s depending on the tis-
sue type and even as long as 120 s when measuring
single cells [16]. Typically the total mapping time is
roughly equal to the total number of spectra multi-
plied by the acquisition time. Additionally, there is a
stage translation delay and CCD readout time delay
for each of the spectra. This is of the order of 1.6 s
(combined CCD readout and stage translation, cal-
culated from a 0.1 s acquisition point map using a
Renishaw system 1000 – see methods section for de-
tails). For shorter acquisition times, the speed of the
XY translational stage and, often most significantly,
the readout time of the CCD can significantly limit
the rate at which spectra can be acquired. Further-
more, factors such as extended scanning and auto-fo-
cusing reduce the rate of spectral acquisition. In one
study, Krafft et al. reported an acquisition rate of
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only 30 spectra per hour based on an acquisition
time of 30 s whilst using autofocus during the map-
ping of brain tissue [28].
A development of point mapping was the intro-
duction of a cylindrical lens to create a line-focused
laser, often referred to as line mapping. A line
focused laser can be used in two different ways as il-
lustrated in Figure 1b and c. First, line mapping can
achieve spatial separation of the laser line using the
CCD pixels, resulting in an increased spatial resolu-
tion as illustrated in Figure 1b. This is achieved by
reading out each CCD line separately creating multi-
ple spectra, the trade off being a reduction in the sig-
nal of each spectrum since only a portion of the laser
light is used to illuminate the area of the tissue im-
aged by that CCD pixel. A further drawback is that
since the power varies along the length (50 mm for
the 50 objective used in this study) of the laser line
(approximately Gaussian) this method of line map-
ping results in a variation in the intensity of the spec-
tra along the laser line as illustrated in Figure 2a and
c. Consequently, there is a variation in the signal to
noise ratio (SNR) as illustrated in Figure 2b. A cor-
rection can be performed, but this can be unreliable
for inhomogeneous samples such as biological tissue.
One further consequence of this correction process is
that noise will be magnified at the edges of the line
focused laser. As shown in Figure 2b, the SNR at the
edges of the line-focused laser is less, therefore cor-
rection would result in the non-uniform magnification
of the noise along the laser profile.
The second method for line mapping is to utilise
the expanded laser line to sample the mapped region
in fewer steps (Figure 1c). In this case, an increased
signal to noise is achieved compared to the high re-
solution line-focused mapping (since the entire laser
line is used to generate each spectrum), but the
trade off is reduced spatial resolution.
Figure 1 a) Illustration of tradi-
tional point Raman mapping in
which a spectrum is acquired at
each position on a grid, b) High
spatial resolution line mapping
using a barrel lens to produce a
line focused laser. Many spectra
are acquired simultaneously by se-
parating out the lines on the CCD,
c) Low spatial resolution line map-
ping in which the entire laser line
is used to sample a large area of
the sample utilising vertical binning
of the CCD pixels and d) Illustra-
tion of rapid Raman mapping in
which the CCD readout is synchro-
nized with the movement of the
stage to allow constant readout of
Raman spectra thus reducing dead
time between spectra. Note that re-
lative intensity/power colour cod-
ing is for demonstrative purposes
only and is not quantitative.
J. Biophoton. (2009) 3
FULL
ARTICLE
# 2009 by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwww.biophotonics-journal.org
Line mapping is still limited by CCD readout
(especially for short acquisition times), although this
is reduced when portions of the laser line read out
independently for higher spatial resolution since the
readout time is spread over multiple spectra. These
two techniques were rigorously compared, along
with wide field imaging concluding that depending
on the application, line mapping was faster that
point mapping [29].
Rapid mapping systems have been developed by
several manufacturers including WITec (Ulm, Ger-
many) and Renishaw. This paper focuses on Re-
nishaw StreamLine, although the concepts discussed
can potentially be applied to any imaging system
capable of rapidly acquiring large Raman datasets.
Considering StreamLine technology (Figure 1d), the
sample is stepped along the laser line and the posi-
tion of the stage is synchronised with the readout of
the CCD (as illustrated in Figure 1b). Each spectrum
is effectively made up of an accumulation of spectra
as the entire laser line passes over each part of the
sample. There is a short delay at the beginning of
each column in the grid as the laser line passes over
the first pixel and then following spectra are ac-
quired at an increased rate. This enables high spatial
resolution mapping without the Gaussian profile in-
tensity trade off (associated with line mapping) and
consequently eliminates the variation in SNR due to
the laser profile, as illustrated in Figure 2d. There is
still however a reduction in signal intensity and SNR
compared to point mapping using the entire laser
line. A further advantage is that constant readout
(i.e. reduced dead time between sequential data
points compared to point mapping) of spectral data
results in the acquisition of spectra and maps at an
increased rate. This uses the multichannel advantage
of the CCD in two dimensions simultaneously. These
advances have facilitated the acquisition of thou-
sands of spectra within a matter of minutes com-
pared to previous mapping techniques which took
hours and even days. A previous study by our group
evaluated rapid Raman mapping for spectroscopic
analysis of oesophageal tissue by varying mapping
parameters [30]. Bernard et al. have also investi-
gated the use of rapid Raman mapping (referred to
as advanced line-scanning) for geological applica-
Figure 2 a) (online colour at: www.biophotonics-journal.org) Variation in intensity along laser line of a line focused
laser beam (left axis is 1 mm step size along the sample and right axis is Raman shift 450–1850 cm1) measured on
oesophageal tissue, b) Example oesophageal tissue spectra from the line focused line map illustrating the variation in
SNR along the laser line (CCD pixels), c) Variation in signal intensity (at 520 cm1 peak) along the line focused laser
line (for line mapping) measured on a piece of silicon, d) Example spectra at 1.1 mm step size acquired using the rapid
Raman mapping system on the same region of tissue as plots a and b, with the spectra number equivalent to one pixel
in plots a–c.
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tions, including a comparison with line mapping (sta-
tic line scanning) [26].
1.4. Data analysis
Principal component analysis (PCA) has been ap-
plied by many groups as a spectroscopic image pro-
cessing technique for both Raman and FT-IR appli-
cations [14, 16, 31]. Other techniques for vibrational
imaging such as k-means [19, 28, 32], hierarchal clus-
ter analysis (HCA) [17], and artificial neural net-
works (ANN) [33] have been applied to biological
tissue. For further details on multivariate techniques
for image analysis of Raman datasets, the reader is
referred to the following references [34, 35].
Hayden et al. investigated the effects of sampling
parameters for Raman line images using PCA, de-
monstrating that improved results were obtained
using the higher magnification, concluding that this
was due to an increased dataset size [31]. Work has
also been carried out elsewhere to investigate the
effects of reducing the acquisition time (from 30 s
to 3 s) with Raman mapping of pharmaceutical
beads analysed using principal component analysis
as a pre-processing noise reduction method [21]. In
this and a previous study [22], Sasic et al. used the re-
lative standard deviation (RSD) to compare maps
with varying degrees of noise within the raw spectra,
but the effect of varying the size of the dataset was
not considered. Since the performance of multivari-
ate techniques improves with increased dataset size,
the number of spectra within a map is an important
variable to consider and this is the first paper to in-
vestigate the effects of this with Raman mapping.
Krafft et al. also demonstrated that PCA could be
used to evaluate low SNR data acquired from map-
ping single cells [16]. However, the focus of this paper
was on the recovery of biochemical information
rather than the implications of reducing the total
mapping time. To date, little work has been carried
out to investigate the effect of reducing the total map-
ping time on the data obtained from biological tissue
samples.
It is well known that larger datasets improve the
performance of multivariate techniques, and in parti-
cular PCA can be used to remove noise from large
Raman datasets [35]. Subsequently it was hypothe-
sised that using PCA sufficient diagnostic informa-
tion, for screening out non-relevant samples, could
be extracted from low SNR spectra providing that
the dataset was sufficiently large. Therefore the SNR
was monitored for a range of maps methodically ac-
quired with various combinations of acquisition time
and spatial resolution parameters (step size). This
paper presents the results of this investigation and
attempts to demonstrate that the total mapping time
for oesophageal biopsies can potentially be reduced
to a clinically practicable timescale.
This is the first paper reporting rapid Raman map-
ping of biological tissue. Raman maps containing lar-
ger numbers of spectra (100000þ spectra) of biologi-
cal tissue are presented. There is only one paper in
the literature reporting Raman mapping of oesopha-
geal tissue [14], in which maps contained approxi-
mately 2000 spectra, therefore, this paper presents a
significant improvement over map size and image
quality (total number of spectra and spatial resolu-
tion) due to an increase in the size of the spectral da-
taset. In combination with principal component ana-
lysis, this enables the elucidation of pathology
dependent biochemical information. This is also the
first paper to demonstrate that Raman mapping times
for biopsies has reduced sufficiently to enable the
technique to be used as a histological screening tool.
2. Experimental
2.1. Sample collection and preparation
Informed consent was obtained from patients under-
going routine upper gastrointestinal endoscopic sur-
veillance of Barrett’s oesophagus. Ethical approval
for this study was obtained from Gloucestershire Lo-
cal Ethics Committee. In this study, three samples
from three different patients have been mapped.
Tissue samples were snap frozen in liquid nitro-
gen. A 20 mm frozen section was cut onto a calcium
fluoride substrate for Raman spectral mapping. The
thickness of the mapping section was chosen to max-
imise Raman scattered photons from the tissue sec-
tion. A contiguous 7 mm section was obtained and
stained with H&E for diagnosis by an expert gastro-
intestinal registry pathologist (Prof. Neil Shepherd).
Due to the heterogeneous nature of the samples the
pathologist annotated each sample with the various
pathologies, classifying the regions as normal squa-
mous, Barrett’s, low grade dysplasia (LGD), high
grade dysplasia (HGD) and adenocarcinoma. In-
flammation, connective tissue (smooth muscle and fi-
brous tissue), oesophageal glands and ducts were
also identified. Biopsy samples are typically 1–2 mm
in diameter.
2.2. Raman spectral measurement
Typically, the core of the StreamLine instrument is
a Renishaw inVia Raman microscope, although in
these experiments the maps were acquired using a
customised Renishaw Raman System 1000 spec-
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trometer coupled to a microscope fitted with a Leica
50 long working distance objective (NA 0.5). A
diode laser with a wavelength of 830 nm was used
with 70 mW at the sample (270 mW at source). A
grating with 300 lines/mm was used to disperse the
scattered light which was measured with a deep de-
pletion charged couple device (CCD) detector.
Repeated maps were carried out on tissue sec-
tions, methodically varying the spectral acquisition
time and step size. There are several variables to
take into consideration – for a constant area map, a
higher resolution map (i.e. smaller step size) results
in a larger number of spectra compared to a lower
resolution map (i.e. larger step size) of the same
area. The total number of spectra is an important
consideration since the size of the dataset has an im-
pact on the reliability of any multivariate analysis
used. However, for a lower spatial resolution map
the total number of spectra is reduced, thus the ac-
quisition time can be increased to obtain higher
quality spectra in the same overall time scale. The
quality of the spectral dataset is also an important
factor when attempting to identify subtle biochem-
ical changes using multivariate techniques.
Acquisition times ranged from 0.1–20 s as sum-
marised in Table 1. For each acquisition time, the
step size was also varied between 7.4–25.3 mm. The
total mapping time was limited to a maximum of
24 h since longer maps were not practicable. The to-
tal number of spectra in each map varied between
0.9  104 and 10  104. The approximate mapping
time using standard point mapping (using the Ren-
sishaw system) was calculated based on a CCD read-
out and XY translation delay of 1.65 s per spectrum
(1.2 s per step reported by Schlucker et al. [29]). This
value was determined by running a map (traditional
point map mode) with an acquisition time of 0.1 s,
step size of 6 mm and calculating the delay according
to actual map time minus the best case scenario map
time (i.e. number of spectra multiplied by the acqui-
sition time) and dividing this by the total number of
spectra in the map. To account for the difference in
Raman signal intensity for the rapid Raman spectra
compared to point mapping (which varies with step
size, in a similar manner to line mapping), the acqui-
sition time used in the estimate of the overall point
mapping time was scaled by a factor equal to the
step-size divided by the length of the laser line. In-
Table 1 Summary of mapping parameters for repeated maps. Maps A–D are for a constant step size of 25.3 mm, maps
E–H are for a constant step size of 7.4 mm, maps C, I, J and F are for a constant acquisition time of 1.7 s. Overall
mapping times are shown along with estimated mapping times for traditional point mapping (only applicable to the
Renishaw system).
Map ID Step size (mm) Acquisition time (s) Total number of spectra Total mapping time (h)
Rapid mapping Point mapping
(actual) (estimated)
A 25.3 0.1 0.9  104 0.1 4.2
B 25.3 0.5 0.9  104 0.5 4.7
C 25.3 1.7 0.9  104 1.5 6.5
D 25.3 20 0.9  104 17 29.0
E 7.4 0.5 10  104 2.0 49.6
F 7.4 1.7 10  104 6.3 55.2
G 7.4 3.0 10  104 11 60.4
H 7.4 5.0 10  104 19 70.8
C 25.3 1.7 0.9  104 1.5 6.5
I 15.8 1.7 2  104 2.8 13.9
J 10.6 1.7 5  104 4.0 27.3
F 7.4 1.7 10  104 6.3 55.2
Figure 3 (online colour at: www.biophotonics-journal.org)
Annotated H&E (restained) section of the contiguous sec-
tion to the frozen section used in the repeated mapping
studies a) Maps A–J – sample containing areas of smooth
muscle (SM) and fibrous connective tissue (FT) are identi-
fied and b) Maps I–V – sample containing circumferential
normal squamous epithelium (Nsq) and fibrous connective
tissue (FT).
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cluding this scaling factor ensured that the advantage
of rapid Raman mapping was not overestimated.
Signal to noise (SNR) measurements were car-
ried out on spectra measured on a relatively homo-
geneous tissue sample containing connective tissue
and smooth muscle as diagnosed by an expert
pathologist (Figure 3). Further SNR and relative
standard deviation (RSD) measurements were made
using a sample containing circumferential normal
squamous epithelium. To determine the optimum
mapping parameters, the step size (and thus total
number of spectra) was varied from 9.5–31.7 mm
whilst optimizing the acquisition time to maintain a
constant total mapping time of 4.5 h (as detailed in
Table 2).
2.3. Data analysis
Data analysis was carried out using Matlab and the
PLS toolbox (Eigenvector Technologies, Manson,
Washington, USA). Saturated spectra and cosmic
rays were removed by replacement with the nearest
neighbour. Principal components (PCs) were calcu-
lated and pseudocolour PC score maps were gener-
ated. Any remaining cosmic rays appearing in the
score maps were blanked out and the PCs recalcu-
lated so as not to distort the loads. The relative stand-
ard deviation (RSD) (the ratio between the stand-
ard deviation and the mean at a given peak position
[21]) measured at the 1000 cm1 phenylalanine peak,
expressed as a percentage, was used as a measure of
the SNR to enable comparison between the different
maps. This technique was adopted since the SNR of
the raw spectra was low making it difficult to deter-
mine accurately. The focus of the laser causes varia-
tion in the spectral intensity and SNR at the edge of
the sample and in areas where the calcium fluoride
substrate has been measured. To overcome this, a re-
gion 1/16th of the total map area was selected over
the region of connective tissue for the RSD measure-
ments. The area was kept constant for all maps to en-
able direct comparison. The RSD calculations were
performed on normalised data to give an indication
of SNR variation only. Spectra with saturations and
cosmic rays were not included in the RSD calcula-
tions. Although not directly attributable to the ac-
quired spectra, the ‘signal to noise ratio’ (‘SNR’) of
the principal component loads was also calculated at
the 932 cm1 peak (the strongest peak in the 5th PC
load) to provide a relative comparison between the
loadings for the different mapping parameters. This
was done for the fifth principal component only. The
fifth PC was chosen since the pseudocolour score
map provided good correlation with the morphology
of the H&E sections which was underpinned by good
correlation biochemically with the PC load.
3. Results and discussion
Figure 3 shows the H&E stained section, contiguous
to the sample used in maps A–J, illustrating regions of
fibrous connective tissue (FT) and smooth muscle
(SM). The contiguous section to the sample used in
maps I–V is also shown illustrating circumferential
normal squamous (NSq) and fibrous connective tis-
sue.
3.1. Signal to noise variation in repeated
maps
Figure 4 shows pseudocolour score maps (PC5 for
maps B–D, F–H and PC9 for maps A and E). Maps
A–D were measured with varying acquisition time
whilst maintaining a constant mapped area and step
size of 25.3 mm. Maps E–H show each of the various
acquisition times whilst maintaining a constant
mapped area and a step size of 7.4 mm. Maps C, I, J
and F (Figure 5) show maps acquired with a constant
acquisition time of 1.7 s with various step sizes. The
fifth PC load (PC9 for map A and E) exhibits oppos-
ing positive and negative peaks consistent with the
difference between actin and collagen spectra, which
is consistent with the biochemical signatures of
smooth muscle and connective tissue respectively,
Table 2 Maps I–V are repeated maps of the sample with parameters adjusted to maintain a constant total mapping time
of 4.5 h. Overall mapping times are shown along with estimated mapping time for traditional point mapping.
Map ID Step size (mm) Acquisition time (s) Total number of spectra Total mapping time (h)
Rapid mapping Point mapping
I 9.5 2.4 4  104 4.5 23.6
II 12.7 3.0 2  104 4.5 15.7
III 19.0 4.7 1  104 4.5 9.6
IV 25.3 8.2 0.6  104 4.5 9.1
V 31.7 9.0 0.4  104 4.5 7.4
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which is consistent with pathology identified in the
H&E sections (see online supporting evidence S1).
For maps A and E, PC 9 exhibited the same mor-
phological appearance and similar loads and as a
consequence were used instead of PC 5. PCs 1–4
(scores and loads not shown, but available online
with the supporting evidence S2) describe the differ-
ence between tissue and calcium fluoride substrate,
small regions of luminescence, and protein distribu-
tion. Fibrous connective tissue and smooth muscle
are in fact very similar biochemically and as a result
this was a good test of detecting very subtle bio-
chemical changes. Further biochemical analysis will
be published elsewhere but it is evident that it is
possible to detect gross biochemical changes.
Figure 6 shows typical raw spectra from maps
with acquisition times of 0.5 s, 1.7 s and 20 s exhibit-
ing the quality of the raw spectra within the maps.
The values for the RSD of the raw spectra calculated
at the peak at 1000 cm1 are shown in Table 3. They
clearly demonstrate that the RSD reduces with in-
creasing acquisition time as expected. For Map D, an
RSD value of 2 was considered as a benchmark
since the 20 s acquisition time provided a reasonable
Figure 4 (online colour at:
www.biophotonics-journal.org)
Fifth principal component pseudo-
colour score map and corresponding
principal component load (Maps A
and E display ninth PC). Maps A–D
are for a constant step size of
25.3 mm with increasing acquisition
time from left to right of 0.1, 0.5, 1.7
and 20.0 s. The total mapping time is
shown in brackets for comparison.
Maps E-H are repeated maps using
a step size of 7.4 mm with increasing
acquisition time from left to right of
0.5, 1.7, 3 and 5 s.
Figure 5 (online colour at:
www.biophotonics-journal.org)
Fifth principal component pseudo-
colour score map and correspond-
ing principal component load for
maps C, I, J and Fall with a constant
acquisition time of 1.7 s with de-
creasing step size (thus increasing
total number of spectra) from left to
right of 25.3, 15.8, 10.6 and 7.4 mm.
Figure 6 Typical raw spectra with
an acquisition time of a) 0.5 s, b)
1.7 s and c) 20.0 s taken from map
B, C and D respectively.
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SNR of the raw spectra. The relative ‘SNR’ values
measured at the 932 cm1 peak of the principal com-
ponent loads are also shown in Table 3. The corre-
sponding ‘SNR’ for PC 5 load of map D was also
high (>50) as expected. Similarly high ‘SNR’ values
for the loads were achieved with shorter acquisition
times provided the total number of spectra was large
enough. As expected the relative ‘SNR’ of the load-
ings also increased with increasing number of total
spectra with maps C, I, J and F. with the ‘SNR’ in-
creasing from 12 to 44.
Figure 7 shows maps acquired with a constant
mapping time of 4.5 h. From left to right, maps I–V
were acquired with increasing acquisition time and
step size detailed in Table 2. There is good correla-
tion with the pathology indicated on the H&E sec-
tion with circumferential normal squamous identified
by the negative peaks of the 5th PC load. Visually,
the degradation in the spatial resolution is evident
whilst there is little difference between the PC loads.
The RSD and ‘SNR’ results are shown in Table 3,
which demonstrates a slight decrease in the RSD as
the acquisition time and step size are increased. This
was mirrored for the previous set of maps (C, I, J
and F), all acquired with an acquisition time of 1.7 s,
illustrating that this increase in RSD is not linked to
the reduction in spectral acquisition time, but more
likely due to the number of spectra contained in the
area sampled for the RSD calculation. The ‘SNR’ of
the loads remains approximately constant. It should
be noted that the ‘SNR’ values are not directly com-
parable with maps A–J since they have been meas-
ured on different samples obtained from two pa-
tients.
3.2. Comparison with point mapping
The ratio of the estimated point map time and over-
all mapping time for the rapid Raman maps, for var-
ious mapping parameters, is shown in Table 4. This
illustrates the large reduction in mapping time
achievable with rapid Raman mapping when com-
pared to point mapping using a standard Renishaw
Raman spectrometer.
3.3. Discussion
There is a clear advantage of increasing the number
of spectra within the map in terms of the perfor-
mance of multivariate techniques. In this study, lar-
ger datasets were achieved by increasing the spatial
resolution but this would also be achieved by map-
ping a larger sample at lower spatial resolution. Fac-
Table 3 Summary of the RSD for normalised spectra (one
16th of the total mapped area) within each map measured
at the 1000 cm1 peak and ‘SNR’ for the fifth principal
component loading (PC9 for maps A and E) measured at
the 932 cm1 peak. Total mapping time (in hours) is
shown in brackets next to the map ID for comparison.
Map ID RSD
(normalised data)
PC (5th)
load ‘SNR’
A (0.1 h) 16 <2
B (0.5 h) 7 4
C (1.5 h) 4 12
D (17 h) 2 >50
E (2 h) 11 8
F (6.3 h) 6 44
G (11 h) 5 >50
H (19 h) 4 >50
C (1.5 h) 4 12
I (2.8 h) 4 14
J (4 h) 5 28
F (6.3 h) 6 44
I (4.5 h) 6 8
II (4.5 h) 5 10
III (4.5 h) 4 10
IV (4.5 h) 4 8
V (4.5 h) 4 11
SNR and RSD results are not comparable between maps
A–J and I–V due to different samples and corresponding
PC loads.
Figure 7 (online colour at:
www.biophotonics-journal.org)
Fifth principal component pseudo-
colour score map and correspond-
ing principal component load for
maps I–V (left to right) all ac-
quired with parameters adjusted to
give a total mapping time of 4.5 h.
See Table 2 for parameter details.
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tors limiting the size of the dataset include the 32-bit
operating system addressable memory restriction
and Matlab’s requirement for the entire matrix to be
held in a contiguous block. In the case of this study,
memory restrictions limited the spatial resolution
achievable for mapping the entire biopsy sample
since smaller step sizes would have generated exces-
sively large datasets (mapping the sample shown in
Figures 3, 4 with 1.1 mm step size would result in ex-
cess of 5  106 spectra).
3.4. Relative standard deviation (RSD)
and signal to noise ratio (SNR) variation
From Figures 4 and 5, for all maps shown except A
and E, it is evident that the fifth PC load represents
similar tissue features (in this example tentatively
attributed to collagen which is abundant in fibrous
connective tissue and actin which is abundant in
smooth muscle – see supporting evidence S1) in
each of the repeated maps despite the variation in
the number of spectra and acquisition time. For
map A, noise dominated the ninth principal compo-
nent load, although tissue peaks can be approxi-
mated. Considering map E, these spectral features
appeared further down the PC loads at the 9th PC
component.
For all maps except for D, for which an acquisi-
tion time of 20 s was used, the SNR of the raw
spectra was very low (results not tabulated). There-
fore the RSD measure was used to allow compari-
son. Ideally a high SNR would be desirable to en-
sure that subtle biochemical changes are detected
but from these results it is evident that PCA is
powerful enough to extract gross biochemical infor-
mation even with a very low SNR. The RSD calcu-
lations on the normalised data (Table 3) illustrate
the reduction in noise with increased acquisition
time. The lowest RSD, as expected, was for the
longest acquisition time of 20 s for map D. In gener-
al, this was mirrored on the raw data without nor-
malisation (results not shown), although RSD va-
lues tended to be higher than expected for larger
maps indicating a larger variance, likely to be
caused by the presence of luminescent spectra and
cosmic rays highlighting the difficulty in ‘cleaning
up’ large datasets. This could also be caused by fo-
cusing issues across the sample area.
The relative ‘SNR’ values calculated for the PC
loadings showed improved performance with longer
acquisition times, in particular in the case of maps D
and H for which the apparent noise was negligible
with respect to the 932 cm1 peak within the load.
As expected, the relative ‘SNR’ of the loadings
also increased with increasing number of total spec-
tra with maps C, I, J and F. An additional advantage
of improved resolution is improved recognition of
morphological features, which will make this techni-
que more acceptable to the histopathologist.
When considering the maps acquired with a con-
stant mapping time of 4.5 h (Maps I–V) it is evident
that there is little difference regarding the loads but
increased spatial resolution would be beneficial. The
advantage afforded by rapid Raman mapping is also
greater for higher resolution maps. Increased spatial
resolution would also reduce the effects of under-
sampling and the possibility of missing crucial bio-
chemical information. This would have little conse-
quence for the samples in this study, but may be-
come clinically significant for a sample containing a
focus of disease.
The section shown in Figure 3 was initially
thought to contain a region of inflammation or possi-
bly adenocarcinoma to the bottom left, but this was
inconclusive due to very poor uptake of the H&E
stain with the frozen section. Following rapid Raman
mapping, in which there was no evidence of a region
of adenocarcinoma, this section was re-stained to ob-
tain definitive diagnosis and found to only contain
smooth muscle and fibrous tissue. This highlights a
Table 4 Summary of mapping parameters and comparison
of total mapping times with traditional point mapping
times indicated by the ratio of the estimated total map
time using the point mapping technique (Renishaw sys-
tem) and the total map time using the rapid mapping
technique.
Map ID Acquisition time Ratio
(s) (estimated point map time/
actual rapid map time)
A 0.1 37.1
B 0.5 10.4
C 1.7 4.2
D 20.0 1.7
E 0.5 25.0
F 1.7 8.8
G 3.0 5.4
H 5.0 3.7
Map ID Step size Ratio
(mm) (estimated point map time/
actual rapid map time)
C 25.3 4.2
I 15.8 5.0
J 10.6 6.9
F 7.4 8.8
I 9.5 5.1
II 12.7 3.5
III 19.0 2.1
IV 25.3 2.0
V 31.7 1.6
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further potential advantage of spectroscopic diagno-
sis which could enable diagnosis of inconclusive sec-
tions based on distinguishing biochemical features.
3.5. Comparison with point mapping
From Table 4 it is evident that rapid Raman map-
ping is significantly faster than traditional point map-
ping (from the same manufacturer). As expected
there is a correlation between the step size and the
speed of the map acquisition and thus the total map-
ping time. For a step size of 25.3 mm (maps A to D)
rapid Raman mapping was approximately 3 times
faster than point mapping for long acquisition times
and up to 37 times faster for short acquisition times.
Data published previously [30] was based on best
case scenario point mapping times which signifi-
cantly underestimated overall mapping times for
short acquisition times. With a step size of 7.4 mm
(maps E to H) rapid Raman mapping was of the or-
der of 4 times faster than point mapping for longer
acquisition times (5 s) and 25 times faster for short
acquisition times (0.5 s). Due to the large number of
spectra within the dataset the advantage of rapid ac-
quisition of spectra is accentuated. Bernard et al. re-
ported a similar reduction in overall mapping time
(13 times faster, although maps were not acquired
with the same acquisition times or step size) com-
pared to traditional line mapping [26].
3.6. Future work
One option, not considered in this paper, is the po-
tential to mismatch x and y step sizes to prevent un-
der-sampling when using step sizes greater than the
width of the laser line (7 mm for the 50 objective
used in these experiments). This is an area which
will need further investigation before optimum map-
ping protocols can be determined. Further work
must also be carried out to investigate the potential
problems associated with undersampling with
regards to missing diagnostically significant informa-
tion. The step size in this study has not be reduced
beyond that of the width of the laser line (7 mm for
the 50 objective used in this study) due to size lim-
itations on the datasets and also to prevent over-
sampling but this is also an area for further investi-
gation since this may provide further benefits with
regards to increased spatial resolution and even lar-
ger datasets. This may be of particular interest when
mapping cells at high resolution and leads to the
possibility that biochemical changes within the tissue
can now be investigated at the cellular level across
larger areas of tissue. One consequence of this
would be the need for improvement in computa-
tional facilities. The use of 64-bit computers has in-
creased the datasets that can be managed since this
work was undertaken.
There is also potential to investigate noise reduc-
tion techniques and smoothing of the spectral data
such as those described by Sasic et al. [21].
Potential sample degradation has previously lim-
ited the maximum laser power that can be used with
biological tissue samples. However with reduced ac-
quisition times there is the potential to increase the
laser power and thus improve the signal to noise.
Before an automated screening technique can be
developed, further work is also required to develop
automated algorithms capable of identifying ‘non-re-
levant’ samples so that only diseased samples are
forwarded for diagnosis by an expert histopatholo-
gist. It will also be beneficial to reduce the thickness
of the mapped tissue sections towards the thickness
used for H&E histopathology (7 mm), although po-
tentially longer acquisition times may be required to
counteract the reduction in Raman scattered
photons with the thinner tissue section.
Each map contains a vast amount of biochemical
detail and work is ongoing to explore information
regarding the carcinogenesis process.
4. Conclusion
Rapid Raman mapping has enabled frozen tissue
sections to be mapped on a clinically practicable
timescale. The combination of large spectral datasets
(generated by rapid Raman mapping) with multi-
variate analysis provides a powerful method of ana-
lysing tissue sections. The frozen tissue samples do
not require preparation with histological stains, pro-
viding a significant advantage over current techni-
ques. Frozen samples can be stored and subse-
quently stained if required. Furthermore, the process
lends itself to automation using computed algorithms
which removes the subjective element of histological
diagnosis. Potentially a rapid pre-scan could be car-
ried out at relatively low resolution with low SNR.
Subsequent detailed high quality maps can then be
acquired on regions of interest. In combination with
multivariate classification models, there is the poten-
tial for the automated screening out of non-relevant
samples, with those deemed as abnormal going on
for diagnosis by an expert histopathologist. Conse-
quently this would reduce the burden of ‘non-rele-
vant’ samples which currently swamp the system and
allow more time for analysis of the critically diseased
samples.
A large amount of work will be needed to de-
velop a comprehensive database of biochemical in-
formation before Raman mapping can be used in
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the clinical environment. Also the progression to
supervised multivariate classification may require
further evaluation and Bhargava has demonstrated
that there was a relation between the SNR of IR
absorption spectra and classification accuracy,
although a combination of univariate and multivari-
ate techniques were used as an alternative to PCA
[36]. Rapid Raman mapping provides a method of
acquiring such data which will enable verification of
this technique on a timescale that was previously
not possible. Raman spectral mapping has histori-
cally been significantly slower than the complimen-
tary technique of IR absorption spectroscopy and a
rigorous comparison of the two techniques is now
required.
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Surveillance programs to detect pre-cancers in the oesophagus generate large numbers of tissue 
samples. Rapid Raman mapping has the potential application for automated histopathology, by 10 
providing an adjunct to the histopathologist by screening out normal samples. Linear discriminant 
analysis (LDA) is suggested as a potential chemometric technique for automated classification of 
Raman tissue maps. This paper investigates the effect of tissue classification based on Raman maps 
acquired with different lateral spatial resolution using LDA as a means of comparison. Model 
performances of 94.4% (79.4-99.0% sensitivity  and 95.0-99.8% specificity and 93.7% (87.3-15 
99.9% sensitivity  and 95.2-100% specificity ) were obtained for LDA models generated using 8.4 
µm and 2.1 µm step sizes respectively. Initial results suggest that high lateral spatial resolution is 
not necessarily required for classifying tissue pathologies but the advantage of additional 
morphological information is advantageous and could facilitate separation of sub tissue groups in 
the future. 20 
Introduction 
Clinical motivation 
The current gold standard for diagnosing oesophageal pre-
cancers and cancers is endoscopic biopsy followed by 
histological staining with Haematoxylin and Eosin (H&E). 25 
Surveillance programs to detect pre-cancers in the oesophagus 
generate large numbers of tissues samples which places a 
strain on histology resources. There are also inadequacies 
associated with the histopathology diagnosis, namely that the 
technique is subjective and morphologically based.1 30 
 Raman spectroscopy is an inelastic scattering technique 
which effectively provides a biochemical fingerprint that 
allows the classification of different tissue types and 
pathologies. Consequently, the technique has the potential to 
provide automated, objective and reproducible diagnosis of 35 
tissue pathologies. Our group and others have shown that the 
technique is a promising method to distinguish normal, 
precancerous and cancerous changes in unstained oesophageal 
tissue using a laboratory based Raman system.2,3  Applications 
in other tissues have been reported including the cervix,4 40 
bronchus,5 colon,6 breast,7 and brain.8  The technique also has 
the potential to be used in vivo.9The main text of the article 
should appear here. Headings and subheadings should be 
formatted using the relevant button from the “Styles” toolbar. 
Raman spectral mapping 45 
Raman has been shown previously to separate out 9 
pathologies based on multivariate classification models.2 This 
paper develops the idea of using the combination of 
multivariate analytical techniques and rapid Raman spectral 
mapping as a potential technique for automated 50 
histopathology. In previous publications, we have shown that 
technological advances have reduced Raman mapping times to 
a level which has made implementation in a clinical 
environment a future possibility and Raman spectroscopic 
mapping could potentially be used as an aid to the 55 
histopathologist.10,11 One question which remained 
unanswered was whether or not the potential additional 
information gained from high (lateral) spatial resolution 
Raman mapping would be a useful adjunct for the 
histopathologist.   60 
 Raman has the potential for high lateral spatial resolution 
mapping (micrometer to sub micron level).12 However, 
applications on biological tissue sections have been limited 
due to the size of these spectral datasets (and mapped areas) 
due to lengthy overall mapping times.  65 
 FT-IR imaging has provided an alternative with 
biochemical information provided by many studies of 
biological tissue.13,14 Other studies have used both Raman and 
FR-IR as complimentary techniques.15,16 The spatial 
resolution of laboratory based FT-IR systems however is 70 
difraction limited,17 and at mid-IR wavelengths this can cause 
problems with signal to noise in the low wavenumber region 
of the spectrum with apertures smaller than 10-15µm. Higher 
lateral spatial resolutions can be achieved with synchrotron 
sources,18 and attenuated total reflection (ATR), whereby a 75 
high refractive index crystal enables light to contact the 
sample at relatively smaller spot size. However, there are still 
issues due to the fact that contact is required between the ATR 
crystal and the sample over the whole field of interest.  
 Spatial resolution is considered to be one of the most 80 
critical measurement parameters in spectroscopic imaging.17 
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However, an in depth quantification of the lateral spatial 
resolution is beyond the scope of this paper, but for the 
purposes of this study it is sufficient to use the step size as a 
rough indication of the relative lateral spatial resolution that 
can be achieved. For further information, the reader is referred 5 
to the aforementioned publications.  
 In previous studies by the authors using rapid Raman 
mapping, the step size was not reduced beyond 7.4µm 
(approximately the width of the line focused laser line using 
the x50 objective), due to limitations caused by the dataset 10 
size and also to prevent over-sampling. Improvements in 
programming, software and computer power have since 
enabled larger datasets to be handled. From one perspective 
this has increased the total areas which can be mapped and 
also increased the spatial resolution which could be utilised. 15 
The detrimental effects of under-sampling are clear with the 
possibility of missing an area of focal disease. This paper 
explores this and demonstrates the potential for mapping with 
high lateral spatial resolution. The limitation of the system is 
a 1.1 µm step size using a x50 objective, and since the 20 
advantage of StreamLine™ (outlined elsewhere11) is greater 
for smaller step sizes, large datasets (of the order of hundreds 
of thousands of spectra) can be generated in a practicable time 
frame.  
 Many studies have reported the use of principal component 25 
analysis (PCA) for Raman imaging purposes. This paper 
extends the multivariate analysis to include PC fed linear 
discriminant analysis (LDA), which is not only proposed as a 
potential multivariate technique for future automation of 
Raman histopathology, but it is also used as a tool for 30 
comparing maps acquired with different mapping parameters. 
Other multivariate techniques have been used for Raman and 
IR imaging such as cluster analysis and but the drawback of 
this  is the high computational requirements.13 Artificial 
neural networks (ANN) has also been used as a supervised 35 
classification method,19 but comparison of these with LDA is 
beyond the scope of this paper.    
Materials and Methods 
Sample collection and preparation  
Informed consent was obtained from patients undergoing 40 
routine upper gastrointestinal endoscopy and surgical 
resection. Gloucestershire Local Ethics committee granted 
ethical approval for this study.  
 Fresh tissue samples were immediately snap frozen in 
liquid nitrogen and stored in a -80°C freezer until 45 
measurements were carried out. For each sample, a 15 µm 
frozen section was cut onto a calcium fluoride substrate for 
Raman spectral mapping. The thickness of the mapping 
section was chosen to maximise Raman scattered photons 
from the tissue section (whilst not taking the section beyond 50 
1-2 cells thick). A contiguous 7 µm section was obtained and 
stained with H&E for diagnosis by an expert gastrointestinal 
registry pathologist. The diagnosis was verified on the 
mapped section H&E (on CaF) by a second histopathologist. 
Regions of connective tissue (smooth muscle (SM) and 55 
fibrous connective tissue (FCT)), normal squamous (NSq), 
Barrett’s (BO), low grade dysplasia (LGD), high grade 
dysplasia (HGD) and adenocarcinoma (Ad) were identified.  
Biopsy samples are typically 1-2 mm in diameter.  
 Mapped samples were also stained with H&E following 60 
Raman mapping to enable better correlation with 
morphological features. 
 Two samples from two different patients have been mapped 
in this study.  
Raman spectral measurement 65 
Raman maps were acquired using a customised Renishaw 
Raman System 1000 spectrometer with StreamLine 
technology (Renishaw Plc. Wotton-under-Edge, 
Gloucestershire, UK). In brief, the system comprises an NIR 
diode laser (830nm), a Leica microscope with a Leica x50 70 
(NA 0.5) long working distance objective was used to focus 
(line focussed) and collect the Raman scattered photons. A 
metal oxide edge filter was used to remove the elastically 
scattered light and a grating with 300 lines/mm was used to 
disperse the inelastically scattered light which was measured 75 
with a deep depletion charged coupled device (CCD) detector.   
 An initial rapid pre-scan was carried out using a crude step 
size (26.4µm) and short acquisition time (0.5s). Further maps 
were acquired with step size of 8.4, 4.2 and 2.1µm with a 15 s 
acquisition time (to achieve spectra with good signal to noise 80 
ratio). It was decided that it was optimum to generate the 
tissue classification model using good quality spectra. 
Data Analysis 
Cosmic rays were removed by interpolating between the data 
points either side of the cosmic ray peak. Saturated spectra 85 
were also removed. Subsequently each map dataset was 
normalised and mean-centred. Principal component analysis 
(PCA) was carried out in Matlab using the PLS toolbox 
(Eigenvector Technologies, Manson, Washington, USA). Any 
remaining cosmic rays which were still evident were in the PC 90 
loads were blanked out, removed the calculation and PCs re-
generated. Pseudocolour PC score maps were then plotted. 
The pixels of the Raman map were colour coded with the 
upper and lower extremes of the PC scores and those pixels 
falling into the central range of the scores were left 95 
transparent to enable the images to be overlaid. This 
represented the pixels/spectra with the most significant 
contributions from the positive and negative aspects of the PC 
loads, respectively. The corresponding PC loads were colour 
coded accordingly to enable correlation of biochemical 100 
constituents from peaks within the PC loads with 
morphological information from the pseudocolour PC score 
image.  
 To compare the different step size maps, PC fed LDA was 
carried out (using the first 10 PCs). Spectra were classified as 105 
either calcium fluoride (CaF2), tissue border (TB), high grade 
dysplasia (HGD), fibrous connective tissue (FCT) and 
luminescence (Lum). For the remaining spectra, for which 
their grouping was ambiguous (either due to the fact that there  
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Fig. 1 Sample 1 a) White light image and mapped area b) mapped tissue section stained with H&E (on CaF2) c) contiguous 7µm H&E stained section 
 
 
Fig. 2 Example of how PC images are overlaid. (psuedocolour PC 2 scores image and corresponding PC load for the 2.1 µm map) 5 
is not a distinct boundary between tissue or the spectra found 
to have overlapping PC load contributions) were classed as 
unknown.  
 Two PC fed LDA models were generated for each map. The 
first with the unknown group included as a separate group to 10 
investigate misclassifications within the LDA. For the second 
model, the unknown group was excluded from the model and 
subsequently projected onto the classification model as an 
independent test set.   
 As a first step toward automated histopathology, bulk tissue 15 
discrimination was tested i.e. discrimination between 
connective tissue and glandular (HGD) tissue. In the future 
separation of further sub tissue types may be possible. 
Results 
Principal component imaging 20 
The results from one sample (Sample 1) is presented in detail, 
with the results from a second (Sample 2) sample added to 
demonstrate the technique can be used to identify other 
pathology groups. Figure 1 shows the white light montage 
image of Sample 1, acquired using a x2.5 objective. The small 25 
box indicates the region containing high grade dysplasia  
(HGD) and fibrous connective tissue (FCT) which was 
mapped repeatedly. It was noted that the regions between the 
HGD glands were also FCT. The H&E stained CaF2 image 
(i.e. the mapped tissue section) and contiguous section stained 30 
with H&E for histology purposes are also shown.  
 Figure 2 shows PC2 as an example of a psuedocolour PC 
score images and corresponding PC load. The extremes of the 
colour bar represented by a single colour, with the central 
portion remaining transparent. This allows the PC images to 35 
be overlaid, as shown in Figure 3, in which PCs 1-5 are shown 
overlaid with corresponding PC loads colour coded 
accordingly. 
 The biochemical information contained within the PC loads 
is shown to be similar (for the two maps acquired with 8.4 and 40 
2.1 µm). Although the two different regions of tissue can be 
identified in both maps, it is much easier to identify 
morphological structure in the smaller step size map as 
glandular features and this further supports the presence of 
HGD. 45 
Linear discriminant analysis (LDA) 
Initially, six group LDA models were generated (see Table 1 
for detailed). For the 8.4 µm map, the overall training 
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Fig.3 Pseudocolour PC score images overlaid for the 8.4 µm and the 2.1 µm step size map. PC loads are shown with corresponding colour coding 
 
Table 1 Classification performance of the training (including the ‘unknown’ group) dataset of the LDA model (8.4 µm and 2.1 µm step sizes, 15s 
acquisition time) 5 
  CaF2 TB FCT HGD Lum Unknown % correctly classified 
CaF2 354 27 0 0 0 0 94.4 
TB 62 111 3 0 0 13 82.7 
FCT 0 0 920 1 0 79 99.3 
HGD 1 67 234 2608 0 752 88.0 
Lum 0 1 13 0 140 13 96.3 
8.4 µm 
Unknown 7 185 796 544 6 2655 71.7 
         
CaF2 5713 371 0 0 0 0 93.9 
TB 150 1386 13 0 0 1 89.4 
FCT 0 3 5145 0 0 252 95.3 
HGD 0 41 2952 52864 424 14322 74.9 
Lum 0 3 0 0 4070 0 99.9 
2.1 µm 
Unknown 2100 1528 13533 14152 5046 32151 46.9 
 
performance of the LDA model was 70.1% although the 
overall performance is degraded by the large number of 
misclassifications in the ‘unknown’ group (see data analysis 
for explanation) and also the CaF2 group. Sensitivity and 10 
specificity were 58.7–92.9% and 88.1–99.9% respectively. 
The number of spectra within each group and the percentage 
correctly classified by the LDA model is summarised in Table 
1. 
 For the 2.1 µm map, the overall training performance of the 15 
LDA model was 64.9%. As with the 8.4 µm  model, the 
majority of the misclassified samples are from the ‘unknown’ 
group (as expected) which consequently skews the overall 
performance value. There are also misclassification of FCT 
spectra (predicted as ‘unknown’s) and some discrepancies 20 
with CaF2 and tissue border. Table 1 shows the number of 
spectra within each LDA classification group. Sensitivity and 
specificity were 46.9 - 99.9% and 83.4 - 98.9% respectively, 
but again, these values are skewed by the large number of 
misclassifications within the ‘unknown’ group. 25 
 Figure 4 illustrates the model performance spatially to 
provide further insight. Figures 4a and 4c identify spectra 
(pixels) which are misclassified by the LDA model for the 8.4 
µm and 2.1 µm maps respectively.  In Figures 4b and 4d, these 
misclassified spectra (pixels) are colour coded according to 30 
the group in which the LDA model classifies them for the 8.4 
µm and 2.1 µm maps respectively. This additional spatial 
information provides an insight into whether or not the LDA 
prediction is sensible which can potentially provide useful 
information regarding initial group. 35 
 In the 2.1 µm map PC image (Figure 3), the FCT appears to 
extend into regions between HGD glands. In the LDA 
pathology classification, although over 25000 spectra are  
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Fig. 4 Pseudocolour LDA pathology images for the  8.4 µm (a-b) and 2.1 µm (c-d) maps colour coded with pathology. Figures 4a) and 4c) show the 
locations of the misclassified spectra/pixels, whilst Figures 4b) and 4d) show the predicted pathology according to the LDA model for each of the 
misclassified spectra. 
misclassified as FCT, this is not within the inter glandular 5 
regions which appear to remain as “unknown” (white) and 
luminescence. This is likely to be due to initial choice of LDA 
groups for which the LDA process would try to separate the 
groups, but it could possibly be due to a biochemical 
difference in the FCT depending on the location of the tissue. 10 
This issue is addressed in the next section in which the 
‘unknown’ group is extracted from the model and used as an 
independent test set. There is also the possibility there is 
spatial and spectral averaging of nearby HGD and further 
work is required to verify the actual spatial resolution 15 
achieved with rapid Raman mapping systems.  
 The central portions of the glands appear to be 
misclassified as FCT, but again it is likely that a separate 
group would be required to account for these gland lumens 
which are likely to contain glandular mucin secretions etc. 20 
from the goblet cells. This may be an important classification 
for diagnosis, but further work is required.  
 Luminescence also appears to be very structural within the 
tissue. Mostly, within the regions of FCT. The location of the 
luminescence within the FCT is more evident with the small 25 
step size map, highlighting the potential importance of high 
lateral spatial resolution mapping.  
 Including spectra acquired from calcium fluoride in the 
mean centring process is possibly not the optimum method, 
but it was concluded that calcium fluoride/other substrate 30 
would be an important constituent with any model since any 
discrepancy with substrate impurities may lead to 
misclassifications. This may also be important for regions of 
thin tissue which may contain contributions from both 
substrate and tissue. Further work will be needed to 35 
investigate this. 
 Projecting the ‘unknown’ group as an independent test set 
Figure 5 shows the pseudocolour LDA image for the model 
generated excluding the ‘unknown’ group as a separate test set 
and later projecting these onto the model. Both the 8.4 µm and  40 
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Fig. 5 Projection of the test set onto the LDA model (generated excluding the ‘unknown’ group which was kept aside as a test set) for the 8.4 µm (a-c) and 
2.1 µm (d-f) maps. Figures a) and d) illustrate tissue classification of the training set by the LDA model according to tissue pathology colour code with 
misclassifications as black pixels and the test set identified as white pixels. Figures b) and e) illustrate the predicted classification group of the 
misclassified spectra within the training set according to the LDA model and figure c) and f) show the projected test set results according to the 5 
classification by the LDA model. Caption 
 
 
Fig. 6 Projection of the larger test set (to account for tissue margins) onto the LDA model (generated excluding the test set) for the 8.4 µm (a-c) and 2.1 
µm (d-f) maps. Figures  a) and d) illustrate tissue classification by the LDA model according to tissue pathology colour code with misclassifications as 10 
black pixels with the test set identified as white pixels. Figures b) and e) illustrate the predicted classification group of the misclassified spectra according 
to the LDA model and figure c) and f) show the projected test set results according to the classification by the LDA model.  
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Fig. 7 LDA model trained with a small region of normal squamous (green) fibrous connective tissue (yellow) and CaF2  (grey). 
 
 5 
Fig. 8 Classification model generated based on a training set taken from two samples (Sample 1 and 2 combined to one map) Sample 1 is the sample 
containing HGD and FCT and sample 2 contains FCT and NSq. a) shows the training set performance with correctly classified spectra classified according 
to pathology colour code with misclassified spectra highlighted as black pixels, b) illustrates the groups into which the misclassified spectra are predicted 
and c) illustrate the predicted classification for the test dataset (previously white pixels)   
the 2.1 µm maps are comparable, with spectral predictions 10 
consistent with morphological features and location in the 
image. 
 The overall performance of the training set models 
improved from 70.1% to 94.4% (79.4-99.0% sensitivity  and 
95.0-99.8% specificity ) for the 8.4 µm step size model and 15 
from 64.9% to 93.7%  (87.3-99.9% sensitivity  and 95.2-100% 
specificity ) when the unknown group was excluded as the test 
dataset. 
 As with previous LDA models which included the 
‘unknown’ group, FCT appears to extend in between the 20 
glandular features of the HGD. Previously, this was only 
2.1µm map, but using in Figure 5 this is also evident in the 8.4 
µm map. The centre of some of the glandular HGD structures 
are classified as FCT (especially evident in the small step size 
map). This is likely to be incorrect, and as discussed 25 
previously, a further group, tentatively attributed to mucin, 
may need to be added to the model to account for such 
regions. However, there is also the possibility that FCT, which 
is relatively transparent, is misclassified as tissue border since 
it comprises a lesser contribution from tissue spectral features 30 
and more CaF2 due to spectral mixing with substrate spectra. 
Further work is needed to investigate the origins of these 
misclassifications.  
 The projection model also suggests that regions of 
luminescence are within FCT surrounds the regions of 35 
luminescence.  
 To further investigate the projection of test dataset (and the 
presence of luminescence within the FCT), the LDA model 
was recalculated with fewer spectra in the training dataset. An 
additional ‘unknown’ margin around each pathology group 40 
was defined and allocated to the test dataset i.e. each region of 
luminescence was surrounded by a region of test set 
pixels/spectra. Similarly, the region between HGD and FCT 
was blocked out and allocated to the test set. Results indicate 
more strongly that luminescence is structural within the FCT. 45 
Pixels at the edge of the tissue and also the gland centres are 
also projected to be FCT, reiterating the need for an additional 
group within the model. The results are shown in Figure 6. 
 It is evident that reducing the training dataset does not 
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impact on the ability to project the test set onto the 
classification model.  
An example of normal squamous epithelium 
The above process was repeated on a map (15s acquisition and 
8,4 µm step size) of Sample 2 (containing NSq and FCT), but 5 
in this case the size of the training dataset was reducted 
further still. 
 Results are shown in brief in Figure 7, which shows the 
white light image and pseudo colour LDA image, the training 
set (defined by relatively small, but distinct regions of Nsq, 10 
FCT and CaF2), H&E of the contigous section and also the 
mapped section stained with H&E (on CaF2). 
Combined maps 
To further test the LDA projection of map data onto the tissue 
classification model, the two maps (15s acquisition time  and 15 
8.4 µm step size), were combined to form a large map 
containing HGD (sample 1), FCT (from samples 1 and 2), 
NSq (sample 2) and CaF2 (from samples 1 and 2). The entire 
map was then reanalysed to investigate the feasibility of 
extending this to multiple tissue maps and tissue types.  20 
 Again, small, distinct regions of each tissue type (NSq, 
FCT and HGD) and also CaF2 were defined as the training 
dataset, with the test set defined as the remainder of the 
dataset (Figure 8a and b). Figure 8c shows the classification 
for each spectra/pixel for the test dataset projected onto the 25 
LDA model generated using the training dataset.  
 The overall accuracy of the training set classification model 
was 97.5% (98.8–100% sensitivity and 95.8 – 100% 
specificity). 
 In general, projection of the test dataset (Figure 8c) agrees 30 
with histology diagnosis (Figure 1 - sample 1, Figure 7 – 
sample 2), however there are discrepancies which occur 
within the basement membrane region of the NSq (i.e the 
border between NSq and FCT) which gets projected as HGD. 
Regions of luminscence, not previosuly identified in Sample 2 35 
are also detected within the FCT.  
 Admittedly this is not a full model containing all pathology 
groups, nor was the region of basement membrane included in 
the training dataset, but conclusions can still be drawn from 
this, since the result indicates that classification could be 40 
occurring based on biochemical signature of cell nuclei which 
are rapidly proliferating and densely packed in both HGD and 
also basement membrane regions. Furthermore, this indicates 
that misclassifications are highly likely if sub tissue classes 
are not included into the training dataset, and perhaps 45 
suggests that spatial averaging may be advantageous to avoid 
such issues. In the future, work is required to determine 
optimum number of pathology groups required for tissue 
diagnosis. 
Discussions 50 
This study has shown that high lateral spatial resolution 
mapping is not necessarily needed for histology diagnosis. 
However, high lateral spatial resolution mapping does have 
advantages. There is the advantage of acquiring a large 
number of spectra which is amplified for reduced step sizes 55 
due to the square relation between step size and number of 
pixels. The additional spatial and spectral biochemical 
information could potentially facilitate the separation of more 
pathology groups.  
 LDA is a well known and accepted technique for spectral 60 
classification, and this paper has shown its potential 
application in Raman imaging for histology diagnosis. Further 
work is still required to investigate the extent to which the 
technique can be exploited with respect to automated imaging 
and also larger sample numbers need to be included in the 65 
model. The projection of an unknown dataset onto the model 
allows validation of the model to a degree but using spatial 
information relating to morphology, but rigorous validation 
and testing will still be required when further samples are 
added to the model. Nevertheless, this is an important step in 70 
the move towards clinical implementation of vibrational 
spectroscopy for automated histopathology.   
 Although LDA model performance provides a relatively 
arbitrary method of comparison, it allows a quick and easy 
method of comparing the maps acquired with different 75 
parameters. PC fed LDA models are also able to cope with 
low signal to noise spectra, where other techniques fail. Since 
it is well known that the initial group choices are an important 
factor with LDA models, the initial grouping may play a large 
part in the model performance, but as the groups were the 80 
same in both the 8.4 and 2.1 µm models, it enabled direct 
comparison of the two maps. The use of this ‘unknown’ group 
as an independent test set to validate the model provided 
confirmation that the classification was reasonable, supported 
further by spatial information relating to morphology.  85 
 There is also the potential, as discussed above that the 
small step size map may identify more subtle biochemical 
features which may account for the larger number of 
misclassified spectra within the small (2.1 µm) step size map. 
As a result, the model performance for the small step size map 90 
could potentially be significantly better if the initial groupings 
are chosen more carefully. However, mapping at even smaller 
step sizes, may also induce greater heterogeneity in the maps, 
even from cells of the same pathology (due to sampling 
different parts of the cell within each image pixel).   95 
It remains a question of how much separation is required 
for a specific pathology application. For example if the 
ultimate aim is only to separate out normal from abnormal 
then relatively crude spatial averaging and poor signal to 
noise spectra could be used however if the aim is to separate 100 
out tissue types, pre-cancers, cancers and even predict 
prognosis then more subtle biochemical features may need to 
be resolved. It will also depend on whether the 
histopathologist is confident in spectroscopic diagnosis 
without the additional morphological information represented 105 
in the form of a pseudocolour histology image. If not then 
crude step size maps could potentially provide a rapid and 
automated method of pathology diagnosis. Taking this idea to 
the extreme, it may be sufficient simply to use an ex vivo 
probe or collect a spectrum with a low magnification 110 
objective, averaged over a large area of tissue, although work 
will need to be carried out to verify the minimum level of 
signal mixing required to detect pathology changes. A 
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combination of modalities may be advantageous, for example 
FTIR for mapping the entire sample, followed by high lateral 
spatial resolution Raman mapping of regions of interest. The 
complementary nature of FTIR and Raman is being explored 
by many groups including ours.16, 17  5 
The extent to which we attempt to separate out pathology 
information is a question of clinical need which, ultimately, 
will need to be answered by the histopathologist.  
Conclusions 
In conclusion, rapid Raman spectral mapping with LDA 10 
discrimination has the potential for automated tissue 
classification in the future. Greater numbers of samples and 
patients, to cover the likely variability in the population of 
interest, with detailed histopathology will need to be included 
into the training model. It also appears from this initial study 15 
that high lateral spatial resolution mapping is not essential for 
clinical diagnosis of bulk tissue types, but may have 
advantages in the future for discriminating further tissue 
types.  
This study has shown that LDA projection imaging process 20 
can be potentially be applied to multiple samples making it a 
suitable technique for automated histopathology in the future. 
Futhermore, spatial information from visually representing 
LDA classification as psuedocolour images can provide 
insightful information which will help to explain 25 
misclassifications based on morphological features which is 
not possible from traditional scatter plot representation.  
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